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ABSTRACT 
CANCER-RELATED DIRECT-TO-CONSUMER ADVERTISING – A STUDY OF ITS 
ANTECEDENTS, INFLUENCE ON PATIENT INFORMATION SEEKING 
BEHAVIORS, AND CONTINGENT EFFECTS  
Andy Soon Leong Tan 
Robert C Hornik 
Direct-to-consumer advertising (DTCA) of prescription medications and 
healthcare facilities has generated much debate over the potential benefits and adverse 
consequences for the public at large, patients, clinician-patient relationships, and the 
overall healthcare system. This dissertation is aimed at contributing to this debate through 
studying the impact of DTCA in the context of cancer treatment. Study 1 assessed the 
reliability and validity of three candidate measures of patient-reported exposure to 
cancer-related DTCA across seven criteria. The study found that all three measures 
performed well in terms of convergent, nomological, discriminant, and face validity. 
Findings from this study offer support for utilizing these survey measures in future 
studies targeting cancer patients. Next, Study 2 examined the prevalence and correlates of 
cancer-related DTCA exposure in a sample of patients in Pennsylvania diagnosed with 
breast, prostate, or colorectal cancers. On average, patients reported modest exposure to 
such DTCA (median exposure was once per week). Significant correlates of exposure 
included cancer type, age, stage of disease, and ethnicity. Study 3 investigated the 
relationships between DTCA exposure and subsequent information seeking behaviors. 
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The analyses detected a significant association between DTCA exposure and cancer 
patients’ subsequent information engagement with their clinicians at one-year follow-up. 
Exposure to DTCA was marginally significant in predicting information seeking from 
non-clinician (lay media and interpersonal) sources. Based on the Integrative Model of 
Behavioral Prediction, a focused analysis showed a significant indirect path between 
DTCA exposure and subsequent information seeking from non-clinician sources, 
mediated through attitudes and intention to seek from these sources. Study 4 was guided 
by the Structural Influence Model of Communication to explore disparities in health 
information seeking behaviors arising from DTCA exposure. The study found that the 
associations between DTCA exposure and active information seeking behaviors were not 
moderated by patients’ age, educational level, race/ethnicity, or cancer type. To conclude, 
these studies would likely inform the ongoing debate and future research regarding the 
impact of cancer-related DTCA exposure on communication outcomes and disparities. 
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Chapter 1 BACKGROUND AND LITERATURE REVIEW 
Introduction 
The practice of direct-to-consumer advertising (DTCA) for prescription 
medications and healthcare services is controversial in the United States and subject to 
much debate involving stakeholders ranging from consumer interest groups, medical 
professionals, the pharmaceutical industry, and regulatory agencies (Bonaccorso & 
Sturchio, 2002; Fox & Ward, 2008; Frosch, Grande, Tarn, & Kravitz, 2010; Hoen, 1998; 
Hollon, 1999, 2005; Holmer, 1999, 2002; E. T. Rosenthal, 2010b). On one side there are 
arguments that DTCA potentially provides educational information for consumers that 
leads to patient empowerment, increases patient adherence to treatment, and subsequently 
improves patient outcomes (Calfee, 2002). Conversely, critics counter that possible 
adverse effects of DTCA include patients being misled with inaccurate information 
intended to sell a product, alteration of patient-physician relationships, inappropriate use 
of prescription drugs, side-effects from over-treatment, and ballooning healthcare costs 
(Lipsky & Taylor, 1997). Thus far, purported benefits and adverse consequences of 
DTCA voiced by both sides of the debate are not convincingly borne out in research over 
the past two decades, underlining the need for more inquiry on the implications of 
DTCA, if any, on physician or patient behaviors and on health outcomes. 
Extending from the broader debate of the overall benefits and risks of DTCA in 
general, more recent research is being conducted to examine the impact of specific kinds 
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of DTCA that targets patients who are diagnosed with certain severe medical conditions. 
Studies that focus on DTCA for treatments of cardiovascular disease and cancer—disease 
conditions requiring complex care—are two such examples of research on specific kinds 
of DTCA. In the case of such “subspecialty DTCA”, the specialized nature of treatments, 
complicated technical information, higher risks of adverse outcomes, and higher costs 
justify greater skepticism about claims of educational benefits of such advertising for 
patients and calls for heightened scrutiny of its impact on patient perceptions, decision-
making processes, and health outcomes (Abel, Burstein, Hevelone, & Weeks, 2009).  
This dissertation research addresses knowledge gaps associated with one specific 
form of “subspecialty DTCA”, that is cancer-related DTCA. For the purpose of this 
present research, cancer-related DTCA is defined as “promotional efforts by a 
pharmaceutical company, healthcare provider, or medical facility to present information 
about medications, medical devices, or medical services for patients diagnosed with 
cancer in the lay media environment” (adapted from Wilkes, Bell, & Kravitz, 2000). In 
the following sections, I outline the purpose of each study in this research, rationale for 
engaging in research specifically on cancer-related DTCA, historical and regulatory 
background of DTCA, and relevant literature on DTCA research underpinning this 
dissertation project. More detailed literature reviews relevant for the research objectives 
of each of the four individual studies are included in the introduction sections of the 
respective studies. 
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Purpose 
The overall purpose of this dissertation project is to study the antecedents of 
patients’ exposure to DTCA, assess the influence of DTCA on patient information 
seeking behaviors, and examine communication disparities associated with DTCA in the 
specific context of cancer treatment. This research includes four distinct but inter-related 
studies. Laying the groundwork for this research is Study 1, which assessed the reliability 
and validity of a set of self-reported survey measures to elicit patients’ frequency of 
exposure to DTCA. Findings from this study provide important validity information on 
the use of measures employed in existing surveys when compared with alternative 
approaches of measuring exposure to DTCA. These validation results further provide 
support for justifying the use of self-reported measures of DTCA exposure in examining 
the research questions in the remaining studies.  
Next, Study 2 is an analysis of survey data from a population-based sample of 
cancer patients to provide information on the correlates of patients’ DTCA exposure. 
This study assessed whether there is differential exposure of DTCA across different 
patient characteristics and the potential for communication disparities. Briefly, this study 
compared the frequency of exposure to DTCA between patients across different cancer 
diagnoses (breast, prostate, or colorectal cancer), race/ethnicity, levels of educational 
attainment, and age groups. Disparities in exposure to DTCA based on individual 
characteristics may have important implications for reinforcing existing health disparities 
in cancer outcomes among socially advantaged and disadvantaged groups. 
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Study 3 investigated the associations between DTCA exposure and cancer 
patients’ subsequent information seeking behaviors. This study offers empirical evidence 
to inform the ongoing debate about the spillover informational benefit of DTCA on 
broader patient information engagement about managing their illness. The study further 
identifies potential psychosocial mechanisms that may account for DTCA motivating 
health information seeking behaviors. 
Guided by the Structural Influence Model of Communication, Study 4 built on 
Studies 2 and 3 to analyze whether the lagged associations between DTCA exposure and 
health information seeking behaviors are contingent upon various patient characteristics. 
This study aims to contribute to the literature in communication inequalities associated 
with public health information in the context of cancer care by assessing whether age, 
educational level, race/ethnicity, and cancer type moderate the above associations. 
Presence of communication disparities may have implications for widened disparities in 
cancer outcomes among certain patient groups. 
Rationale 
There are several reasons for focusing on cancer treatment advertising in this 
dissertation research. From an epidemiological standpoint, cancer is the second leading 
cause of mortality in the U.S., accounting for an estimated 573,855 deaths in 2010, or 
more than 1,500 people a day (Murphy, Xu, & Kochanek, 2012). Cancer survivors 
number approximately 11.7 million Americans (last estimated in 2007) and close to 1.6 
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million new cancer cases are expected to be diagnosed each year (American Cancer 
Society, 2011). Given the sizable proportion of the population for whom cancer-related 
DTCA would be salient, efforts to better understand potential impacts of cancer treatment 
advertising on cancer patients are justifiable. 
As noted earlier, in terms of weighing the risks versus educational benefits of 
subspecialty DTCA, cancer treatment is often specialized in nature, requires multi-
disciplinary care, potentially involves serious adverse effects, and is associated with high 
costs. Such complex information about cancer treatment is arguably less amenable to 
convey using direct advertising to patients when compared to DTCA that are targeted for 
less life-threatening symptoms or conditions where the stakes are not as high (Abel et al., 
2009). In other words, direct educational benefits posited by DTCA advocates appear less 
compelling in the case of cancer treatment, especially given the complexity and urgency 
associated with the disease trajectory of many forms of cancer. It is equally important to 
consider that there may be risks of cancer-related DTCA in encouraging inappropriate 
treatments or over-utilization of healthcare among certain cancer patients with advanced 
stage illnesses when curative treatment options may be limited. Research on the 
informational impact of cancer-related DTCA is important to provide empirical evidence 
to help evaluate the risks and benefits of such DTCA on cancer outcomes.   
Another reason for focusing on DTCA in cancer care is related to mounting 
recognition that cancer patients are actively engaging and navigating through the rapidly 
evolving and potentially confusing public health information environment (Viswanath, 
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2005). DTCA contributes to this relentless profusion of health information on cancer 
treatment available to healthy individuals, those who are at-risk (e.g., individuals with 
strong family history of cancer), or newly diagnosed cancer patients alike. Literature on 
cancer communication suggests cancer patients have a wide variety of information needs 
and engage with various information sources to meet these needs (Rutten, Arora, Bakos, 
Aziz, & Rowland, 2005; Rutten, Squiers, & Hesse, 2006). One qualitative study indicated 
cancer patients frequently report cross-source use of information, moving from traditional 
media sources (e.g., broadcast television or print newspapers and magazines)—where 
DTCA are usually presented—to other sources including their physicians or other health 
professionals, lay interpersonal contacts, and the internet (Nagler, Romantan, et al., 
2010). A survey among cancer patients in Pennsylvania found about one in five patients 
(19%) bring information from traditional media sources (i.e., television, radio, 
newspapers, or magazines) to discuss with their treating doctors (Lewis, Gray, Freres, & 
Hornik, 2009). Some of this information from media sources may conceivably include 
treatment ads although the study did not specify the type of information that patients 
bring to discuss with their physicians. In this dissertation research, one objective is to add 
to the growing literature on cancer communication by examining how DTCA contributes 
to this dynamic process of patients’ active information engagement across varied sources 
for managing their illness.  
A further motivation for focusing on cancer-related DTCA is the concern over the 
impact of DTCA on patient-provider relationships. To address this concern, Abel and 
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colleagues (2009) examined the extent to which cancer patients from one cancer center 
receiving active treatment discuss cancer-related DTCA with their clinicians. Mirroring 
the above research by Nagler et al. (2010) and Lewis et al. ( 2009) on cross-source 
information seeking, Abel and colleagues (2009) also reported that under one in five 
patients (17%) who were aware of DTCA for cancer-related prescription medications had 
been prompted by an ad to talk to their cancer doctor or nurse about a prescription drug in 
the past year. This suggests that DTCA may not be a prominent factor in influencing 
patient-provider discussions about cancer treatment options among cancer patients 
receiving active treatment. The study was limited by the convenience study sample of 
patients within a single cancer center and the emphasis on interactions about drug 
information rather than discussions about treatment more broadly. One objective in this 
dissertation research is to address the above gaps in understanding the role of DTCA in 
relation to the patient-provider interactions surrounding cancer-related treatment 
information.  
Historical and Regulatory Background 
 An exhaustive review of how DTCA became prevalent, development of 
regulations for DTCA, and evolution of stakeholder perspectives about DTCA is beyond 
the scope of this project and is more amply described elsewhere (Donohue, 2006; 
Palumbo & Mullins, 2002; Pines, 1999; Terzian, 1999; J. H. Young, 1961). However, a 
brief account of the growth and regulation of DTCA is necessary to provide a historical 
context for this dissertation project. 
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The advent of promoting medicinal treatments in the U.S. can be traced to 1708 
when Nicholas Boone, an apothecary in Boston, first paid a fee to place a newspaper ad 
for a patent medicine (J. H. Young, 1961, 1967). Leading up to the 20th-century, patent 
medicine ads accounted for a substantial proportion of newspaper publishers’ advertising 
revenues (J. H. Young, 1961, 1967). During this period, it was the norm for patients to 
engage with self-treatment using such advertised products and regulations of patent 
medicines were not yet in place to ensure public safety. This was also an era when 
physicians had not yet achieved the role as professional gatekeepers of potentially 
harmful medicinal substances as they have today (Donohue, 2006). 
Norms of direct consumer access to medicinal products gradually shifted toward 
more restricted access due to increased regulation of the drug industry beginning in the 
turn of the 20th-century. In 1906, President Theodore Roosevelt signed into law the Pure 
Food and Drugs Act to ensure the quality and purity of drugs through the requirement of 
stricter regulation on labeling contents of medicinal products. While the law prohibited 
misleading information about ingredients of a drug as stated on labels, it did not limit 
false therapeutic claims from appearing on such labels that could misinform consumers of 
drug benefits (Donohue, 2006). Subsequent passage of the Food, Drug, and Cosmetic Act 
(FDCA) in 1938 improved drug safety by requiring manufacturers to obtain U.S. Food 
and Drug Administration (FDA) approval of drugs prior to marketing and sale. The 1938 
FDCA included additional stringent requirements for drug labeling and provision of 
consumer instructions on the packaging. Legislative amendments to the FDCA between 
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1938 and 1969 gradually reduced the direct availability of many over-the-counter (OTC) 
medications to consumers. Over time, these legislations increasingly limited patients’ 
access to many drugs through physician prescription only, raised the requirements for 
proving safety and effectiveness of drugs, and introduced various advertising regulations 
for drug manufacturing companies (Donohue, 2006). These regulations progressively 
restricted consumer self-treatment while boosting the role of physicians as gatekeepers to 
substances that are potentially harmful if used without appropriate medical supervision.  
The paradigm shift in increased regulatory oversight of medicines and evolving 
importance of physicians to gain access to medications dramatically reduced direct 
advertising to consumers by drug manufacturers. As a result, in the ensuing decades, 
prescription medication promotional spending remained largely directed at physicians. 
The predominance of marketing to physicians rather than directly to consumers is still the 
case today. Some examples of physician-directed promotions currently in practice 
include paid advertising in medical journals, detailing by sales representatives, and direct 
mailing to physicians (Harris, 1964; Rehder, 1965). 
By the 1980s, a small number of ads for drugs and vaccines began appearing in 
print publications, radio, and television (Donohue, 2006; Kolata, 1983). Following public 
concerns surrounding the risks of misleading drug ads, FDA requested a two-year 
voluntary moratorium on DTCA in 1983, during which the first consumer survey was 
conducted to assess public perceptions and behaviors regarding DTCA. This moratorium 
was lifted in 1985 and FDA announced that standards for ads directed at physicians 
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would be applied to DTCA (Terzian, 1999). The FDA guidance in 1997 spelt out ways 
that drug manufacturers could advertise their products on broadcast media. Subsequent 
amendments to this guidance in 2007 gave FDA the authority to review television ads for 
drugs prior to dissemination (Food and Drug Administration, 2007, p.939). However, in 
practice, the FDA review process has not kept pace with the rapid growth in the volume 
of DTCA. Repeated audits by the General Accounting Office revealed that the FDA did 
not have sufficient resources to effectively monitor and prevent drug companies from 
disseminating DTCA that contained misleading information (United States General 
Accounting Office, 2002, 2006, 2008). Although the guidelines are in place with various 
restrictions, the floodgates have been opened, permitting drug manufacturers to promote 
prescription medications directly to consumers and resulting in a rapid increase in the 
placement of DTCA on broadcast media. 
While the focus has been on DTCA of prescription drugs historically, recent 
developments in promoting medical treatments encompass direct advertising of other 
forms of health-related products and services. Examples of these advertising include 
hospitals or doctors offering medical services in specialized clinics or medical centers or 
ads for innovative types of medical devices. In contrast to regulatory safeguards for 
prescription drugs DTCA, this recent trend of healthcare providers or medical facilities 
advertising treatment services directly to consumers is not under similar federal oversight 
(E. T. Rosenthal, 2010a, 2010b). One study on the frequency and content of promotional 
ads by reputable academic medical centers reported the majority of such ads include 
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emotional appeals and highlight the prestige of institutions in targeting prospective 
patients. These ads often do not undergo any review by the respective institutional review 
boards (Larson, Schwartz, Woloshin, & Welch, 2005). The authors proposed that in the 
interests of patient protection and consistency with FDA guidelines that regulate 
advertising for the purpose of recruiting research participants, there is a need for more 
oversight on such promotional activities conducted by healthcare institutions. 
Promotional Spending on DTCA 
Overall industry promotional spending on prescription drugs through DTCA 
increased dramatically, quadrupling from $985 million in 1996 to $4.2 billion in 2005 
(Donohue, Cevasco, & Rosenthal, 2007). Recent data indicate that DTCA spending 
reached a peak of $5.9 billion in 2006 and stabilized at $4.4 billion by 2010 (Kornfield, 
Donohue, Berndt, & Alexander, 2013). Despite these large sums, DTCA spending to date 
represents only a small proportion of total promotional expenditures by pharmaceutical 
manufacturers; DTCA accounted for about 19% of overall promotional expenses in 2010 
(Kornfield et al., 2013). DTCA spending also accounts for a minor cost to manufacturers 
as a percentage of sales, ranging from 1.4% to 2.0% between 2001 and 2010 (Donohue et 
al., 2007; Kornfield et al., 2013). This is largely because the absolute value of the 
pharmaceuticals market has grown phenomenally. In contrast, promotional spending 
directed at physicians and free samples are still the dominant forms of drug advertising. 
In 2010, manufacturers spent $23.3 billion on promotion to providers, constituting the 
majority of the overall industry promotional spending based on reported expenditure 
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trends and accounting for 7.6% of drug sales (Kornfield et al., 2013). This was almost 
five times the amount spent on DTCA in the same year.  
Nevertheless, the volume of prescription drug DTCA available in the public 
sphere and resultant exposure to consumers are sizeable. This is illustrated in a study by 
Brownfield and colleagues (2004) who reported that 428 prescription medication ads 
appeared over the period of one sampled week on three major television networks in 
Atlanta, Georgia. These ads occupied 311 minutes of airtime, translating to over 16 hours 
of exposure to such ads per year for an average television viewer. The authors contrasted 
this amount of exposure to DTCA of prescription medications with an average American 
spending approximately 15 minutes each year with her primary care physician.  
Promotional spending by healthcare providers and facilities is smaller in 
comparison to prescription drug promotional spending but this is still substantial and 
growing steadily. Between 2001 and 2005, promotional spending by hospitals, clinics, 
and medical centers nearly doubled from $493 million to $810 million (American 
Medical Association, 2006). A more recent report indicated American hospitals increased 
their ad spending from $596 million in the first six months of 2010 to $717 million in the 
same period in 2011, representing a year-on-year increase of 20% (Newman, 2011).   
There is limited data on promotional spending trends aggregated by disease 
condition or on the expenditures for subspecialty advertising such as cancer-related 
DTCA. At present, there is no published source of information on overall promotional 
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spending for cancer-related treatment specifically. One recent study obtained data on 
advertising spending for three select brands of aromatase inhibitors (i.e., anastrozole, 
letrozole, and exemestane for reducing breast cancer recurrence risk in postmenopausal 
women) between 2005 and 2007 and reported that monthly expenditures of DTCA on 
these brands varied considerably between about $120,000 to over $22 million (Abel et 
al., 2013). However, there is some evidence that cancer-related DTCA constitutes only a 
minor component of the overall promotional spending on DTCA for prescription 
medications. Studies reporting the top twenty pharmaceutical drugs in terms of ad 
spending did not find cancer-related medications featuring among these highly advertised 
drugs (Donohue et al., 2007; M. B. Rosenthal, Berndt, Donohue, Frank, & Epstein, 
2002). Based on content analyses of ads in consumer print magazines, cancer-related 
DTCA for prescription drugs occurs less frequently than DTCA related to other health 
conditions including allergies, oral contraceptives, HIV and AIDS, and dermatological 
conditions (Bell, Wilkes, & Kravitz, 2000; Welch Cline & Young, 2004; Wilkes et al., 
2000; Woloshin, Schwartz, Tremmel, & Welch, 2001). One reason may be oncology-
related medications ads tended to appear more frequently in magazines targeted for 
cancer patients (e.g., CURE, Coping with Cancer, and MAMM: Women, Cancer & 
Community) rather than in general interest magazines (Abel, Lee, & Weeks, 2007).  
Similarly, systematic data sources on promotional spending by healthcare 
providers and medical facilities for cancer treatment services are absent. Cancer centers 
are seen as reluctant in revealing their advertising activities to attract patients (E. T. 
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Rosenthal, 2010a, 2010b). A few studies provide some indication of the extent of 
promotion by healthcare providers for cancer treatment. In one recent analysis of 400 
U.S. hospital websites, Jin et al. (2011) reported 41%  of these websites described robotic 
surgery. Of these sites, 32% made claims of improved cancer control with robotic 
surgery. In another content analysis of print ads in local newspapers by 17 nationally 
acclaimed academic medical centers, researchers showed cancer treatment services were 
advertised less frequently compared to other health conditions or healthcare services 
(Larson et al., 2005). The study found that 10 of 122 unique print ads from these medical 
centers promoted cancer treatment services. The study excluded print ads meant for 
patient recruitment into clinical trials or public announcements of community events 
unrelated to promoting hospital services. These findings suggest more research may be 
warranted to document the prevalence and promotional spending of cancer-related DTCA 
among medical centers.  
Consumer Awareness and Opinions of DTCA 
 Several consumer surveys over the past decade consistently found overall public 
awareness of DTCA in general to be high (Aikin, Swasy, & Braman, 2004; Murray, Lo, 
Pollack, Donelan, & Lee, 2004). One survey conducted by the FDA reported 81% of a 
national sample of adults were aware of DTCA in 2002 (Aikin et al., 2004). Another 
survey conducted among adults in Sacramento, California found that awareness of 10 
drugs advertised at the time of the study ranged from 8% to 72%. On average, 
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respondents reported being aware of four drug ads out of the 10 ads that were shown to 
them (Bell, Kravitz, & Wilkes, 1999).  
Public opinion about DTCA was mixed based on the FDA national survey. While 
the majority of respondents agreed DTCA helped make them aware of new drugs (77%) 
and provided enough information to decide whether to visit a physician (58%), a sizable 
proportion agreed DTCA made the drug seem better than it was (58%) and made it seem 
as though a doctor was not needed to make decisions about prescribing the drug (23%) 
(Aikin et al., 2004).  
 Surveys have been conducted on awareness and opinions of specific cancer-
related DTCA of prescription medications among cancer patients. In one study among 
cancer patients who were receiving active treatment for hematologic and breast cancers, 
Abel et al. (2009) found 86% of respondents were aware of DTCA for at least one of 24 
specific medications for cancer treatment or supportive care. The highest awareness 
levels were for DTCA promoting supportive medications during chemotherapy including 
Procrit (erythropoietin alfa) for improving red blood cell count and Neulasta 
(pegfilgrastim) for boosting immune cells. Respondents who were aware of these DTCA 
had mostly favorable opinions concerning such ads. The majority agreed or somewhat 
agreed that DTCA made them aware of treatments they did not know (62%), provided 
information in a balanced manner (65%), and provided information in language they 
could understand (89%). In contrast, a small minority of these patients felt that DTCA 
made them less confident in their provider’s judgment (11%), suggesting that it was 
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unlikely that such ads were harmful to most patients’ relationships with their physicians. 
The study was limited to assessing awareness of DTCA for cancer-related prescription 
medications and the study population was confined to cancer patients diagnosed with 
either breast or hematologic cancers and receiving treatment at a single institution. 
Consumer and Physician Behaviors Associated With DTCA 
 There is evidence that DTCA is associated with certain consumer communication 
behaviors including information seeking behaviors and prescription requests from their 
physicians. In the 2002 FDA survey, 43% of respondents reported that DTCA prompted 
them to look for more information about the advertised drug or health condition from 
their healthcare provider, reference books, interpersonal contacts, and the internet (Aikin 
et al., 2004). In another national survey, about half of the respondents (47%) who 
indicated they had seen a drug ad that was personally relevant in the past year reported 
talking about information in the ad during a visit with their doctor (Murray et al., 2004).  
In addition, studies indicated physician prescription behaviors are altered when 
consumers request certain advertised prescriptions. In the survey by Murray et al. (2004), 
among respondents who discussed information from a drug ad with their physicians, 29% 
reported they were prescribed the medication mentioned in the ad. In a randomized 
controlled trial, Kravitz et al. (2005) found physicians were more likely to prescribe anti-
depressants when standardized patient actors made a general request for medications or a 
brand-specific request than when no such requests were made. These associations were 
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present when standardized patients actors portrayed major depression symptoms (for 
which treatment is indicated) as well as when actors portrayed adjustment disorders with 
depressed mood (for which treatment is not indicated). Based on these findings, the 
authors concluded that patient requests have a profound impact on physician prescribing 
patterns for these mental health conditions in opposing directions—potentially improving 
care by reducing under treatment of major depression while worsening care by overuse of 
antidepressants in adjustment disorders.   
Currently, there is limited research that focuses on patient and physician behavior 
with regards to cancer-related DTCA for medications, healthcare providers, or hospital 
facilities. In the study by Abel et al. (2009) described earlier, only a small proportion of 
cancer patients (17%) who were aware of DTCA reported they discussed an advertised 
treatment with their physicians. Of these patients who discussed DTCA with their 
physicians, about one in five (19%) reported receiving a prescription for the medication 
while 62% were told by their physicians that they did not need the medication. The 
proportion of patients who received the medication was comparatively lower than those 
described above in the national survey by Murray et al. (2004) related to DTCA in 
general and prescription behaviors. Further research is needed in this area to assess 
whether cancer-related DTCA may be associated with patient communication behaviors 
(e.g., information seeking about their condition, requests for prescriptions, or requests for 
referrals to other hospitals) and physician behaviors.  
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Summary 
 This chapter provided a brief introduction to the controversy surrounding the 
practice of DTCA and the rationale for focusing the dissertation research on cancer-
related DTCA. Through a brief outline of historical regulatory events and a review of 
selected literature on patient awareness, opinions, and behaviors associated with DTCA, I 
identified several knowledge gaps in the research on cancer-related DTCA that this 
dissertation aimed to address. The next chapter will outline relevant theoretical 
frameworks that guided the design of this dissertation project. 
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Chapter 2 THEORETICAL FRAMEWORK 
There are many potential positive or adverse effects of DTCA on patient and 
physician behaviors, healthcare utilization and outcomes. The subject of this research is 
an important one among these possible effects—whether DTCA motivates patients to 
engage in additional health information seeking from their healthcare providers or from 
other sources. In this dissertation, the studies are guided by theoretical concepts relevant 
to DTCA effects on health information seeking behavior. These concepts are derived 
from psychosocial theories of predicting behavior including the Integrative Model of 
Behavioral Prediction and Social Cognitive Theory, the framework of patient-centered 
communication in cancer care, and the Structural Influence Model of Communication. 
These key theoretical concepts are briefly outlined below and integrated into the 
subsequent chapters describing each study in this dissertation research.  
Integrative Model of Behavioral Prediction 
The Integrative Model (IM) offers a theoretical framework to situate the present 
research in studying the relationships between cancer-related DTCA exposure and patient 
communication behaviors. Broadly, the IM specifies a causal pathway between one’s 
intention to perform a behavior and the actual engagement in the behavior. The IM 
further theorizes that behavioral intention is influenced by individuals’ underlying 
attitudes toward the specific behavior, perceived normative pressure (PNP) to perform the 
behavior, and perceived behavioral control (PBC) associated with enacting the behavior. 
Intention is operationalized as an individual’s self-reported likelihood of performing a 
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behavior in a future timeframe. Intention is further defined in terms of specific time, 
action, context, and target to be compatible with the behavior of interest. Attitude toward 
the behavior is defined as “degree to which a person has a favorable or unfavorable 
evaluation or appraisal of the behavior in question” (Ajzen, 1991, p.188) (i.e., whether 
performing the behavior would be good or bad for oneself, beneficial or harmful, wise or 
foolish). PNP is a person’s “perceived social pressure to perform or not to perform the 
behavior” (Ajzen, 1991, p.188) or whether important others think one should or should 
not perform the behavior and whether others who are similar are also performing the 
behavior. PBC refers to “people’s perception of the ease or difficulty of performing the 
behavior of interest” (Ajzen, 1991, p183), that is whether someone believes that he or she 
would have the ability to perform the behavior and that it would be under his or her 
control to engage in the behavior. 
Applying the above IM constructs to the dissertation research, Study 3 explores 
the theoretical pathways between exposure to DTCA and patients’ active cancer-related 
health information seeking, mediated through individuals’ attitudes, PNP, and PBC 
associated with actively seeking information behaviors. DTCA exposure is hypothesized 
to influence these IM constructs in a few ways. For instance, spokespersons featured in 
DTCA may serve as models to actively engage with their physicians to talk about their 
health condition. These portrayals of patient-doctor discussions convey positive outcome 
expectations about the information seeking that are associated with positive attitudes 
toward the behavior. They may also influence perceived descriptive norms that other 
patients are likely to consult their doctor for information. DTCA may improve behavioral 
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control through observing spokespersons enacting discussions effectively and 
information aimed at empowering patients’ ability to discuss with their doctor about their 
condition. For instance, in an ad for Detrol LA (indicated for overactive bladder 
symptoms), a spokesperson promoted a website that provided tips on how patients can 
get the discussion started with their physician about their symptoms.   
At present, there is a lack of empirical evidence that is directly relevant for this 
dissertation research regarding the psychosocial mediators of DTCA effects on general 
health information seeking; prior studies focused on specific drug inquiry as the 
behavioral outcome (Deshpande, Menon, Perri III, & Zinkhan, 2004; Herzenstein, Misra, 
& Posavac, 2004; Liu, Doucette, Farris, & Nayakankuppam, 2005; Welch Cline & 
Young, 2004; H. N. Young, Lipowski, & Welch Cline, 2005; H. N. Young & Welch 
Cline, 2005). Despite this, seeking information about an advertised treatment may be 
considered as a subset of general health information seeking. Therefore, findings from 
studies that examined pathways of DTCA effects on drug inquiry behaviors may still 
inform the generation of hypotheses pertaining to similar theoretical mechanisms of 
DTCA effects on general health information seeking. In one study utilizing the Theory of 
Planned Behavior and Self-Efficacy Theory, Liu and colleagues (2005) found that 
attitudes and subjective norms toward seeking drug information from physicians and 
pharmacists predicted intentions to seek from these sources among a sample of patients 
with osteoarthritis who were recently exposed to DTCA for osteoarthritis prescription 
medications. In contrast, only attitudes toward seeking drug information from the internet 
22 
 
predicted intention to seek from the internet. Perceived difficulty was not predictive of 
intentions to seek from all three sources.  
Social Cognitive Theory 
 Social Cognitive Theory (SCT) provides another theoretical framework to 
understand the psychosocial determinants of health behaviors (Bandura, 1986). SCT 
posits that core determinants of behavior include: 1) knowledge of the risks and benefits 
of health behaviors, 2) perceived self-efficacy of one’s control over performance of 
health behaviors, 3) outcome expectancies or beliefs about the likelihood and value of 
enacting certain behaviors, 4) health goals, 5) perceived facilitators, and 6) social and 
structural impediments to behavior change (Bandura, 2004). Other key concepts from 
SCT are reciprocal determinism (defined as a triadic model in which behavior, personal 
factors, and environmental factors interact as determinants of one another) and 
observational learning of new behaviors through exposure in the media or peer modeling 
(McAlister, Perry, & Parcel, 2008). Of these theoretical constructs in SCT, three key 
concepts that are relevant for Study 3 in this dissertation research are observational 
learning, outcome expectancies, and self-efficacy.  
 Observational learning or vicarious learning is a central concept of SCT (Bandura, 
1986) which refers to the process of “learning to perform new behaviors by exposure to 
interpersonal or media displays of them, particularly through peer modeling” (McAlister 
et al., 2008). According to Bandura, there are four key processes underlying 
observational learning: 1) attention to the modeled behavior, 2) retention of an observed 
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behavior, 3) production of the behavior, and 4) motivation to imitate the modeled 
behavior (Bandura, 1986). For DTCA to influence observational learning of the desired 
behavior (e.g., interacting with physicians, requesting the treatment, or finding out more 
information about an advertised treatment), ads must first attract patients’ attention, 
ensure retention of information from the ad, guide patients to produce the desired 
behavior through peer modeling, and motivate them to enact the behavior by generating 
positive outcome expectancies.  
Outcome expectancies are defined as “beliefs about the likelihood of various 
outcomes that might result from the behaviors that a person might choose to perform, and 
the perceived value of those outcomes” (McAlister et al., 2008). The concept of outcome 
expectancy is not unique to SCT and corresponds closely to similar constructs described 
in other influential behavioral theories including the IM in the earlier section (Fishbein & 
Ajzen, 2010) and the Health Belief Model (Champion & Skinner, 2008). The underlying 
premise of the importance of outcome expectancies in predicting behavior is the notion 
that consumers act rationally to maximize benefits and minimize costs. Therefore, 
consumers would be more likely to undertake a specific behavior if they believe doing so 
would provide more rewards or have least amount of costs. Relating this to DTCA, 
beliefs about positive outcomes associated with discussing an advertised treatment with 
physicians or with receiving the treatment may motivate patients to discuss information 
from an ad or request for the advertised treatment. 
 Self-efficacy is another central concept of SCT widely incorporated in behavioral 
change communication and interventions. The concept refers to “people’s judgments of 
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their capabilities to organize and execute courses of action required to attain designated 
types of performances” (Bandura, 1986) and is found to be a predictor of health 
behaviors directly or indirectly across different domains (Gwaltney, Metrik, Kahler, & 
Shiffman, 2009; Holden, 1991; Strecher, McEvoy DeVellis, Becker, & Rosenstock, 
1986). Consistent with the concept of self-efficacy and its impact on health behaviors, 
advocates claim DTCA plays a role in encouraging patient autonomy and participation in 
medical decision making through raising awareness about therapeutic choices, promoting 
information seeking, and reaching autonomous decision choices (Calfee, 2002; Holmer, 
1999; Zachry III & Ginsburg, 2001). It should be noted that self-efficacy as described in 
SCT corresponds closely to perceived behavioral control, which is a core construct in the 
IM.  
In the context of research on DTCA, the above SCT concepts offer meaningful 
theoretical mechanisms for expecting and explaining effects of advertising on cancer 
patients’ cognitions and behaviors. For instance, in a series of content analyses 
employing SCT concepts to examine the visual and textual elements of DTCA in print 
magazines, researchers found DTCA contains various characteristics frequently 
associating positive outcome expectancies with the use of advertised drugs (Welch Cline 
& Young, 2004; H. N. Young & Welch Cline, 2005). These behavioral motivators 
included portraying rewards in terms of identity, relational, or instrumental benefits 
associated with using an advertised drug. Survey research among young female 
consumers suggested positive outcome expectancies of discussing about an advertised 
drug with their physicians were associated with increased intention to communicate with 
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physicians about the drug (H. N. Young et al., 2005). Through the perspective of 
observational learning, one of the studies examined the role of models in DTCA and 
reported the majority of DTCA depicted models who possessed positive characteristics 
(e.g., being healthy, active, and friendly) (Welch Cline & Young, 2004). The authors 
concluded portraying models whom consumers could identify with and desired to 
emulate might facilitate consumers’ observational learning to modify interactions with 
their physicians and to discuss about an advertised drug. 
Framework for Patient-Centered Communication in Cancer Care 
Cancer patients have a wide variety of information needs related to their condition 
and frequently seek information from various sources to meet their needs (Hesse, Arora, 
Burke Beckjord, & Finney Rutten, 2008; Nagler, Gray, et al., 2010; Rutten et al., 2005; 
Squiers, Finney Rutten, Treiman, Bright, & Hesse, 2005). Studies consistently find that 
most cancer patients turn to their clinicians when they are looking for cancer information 
(Hesse et al., 2008; Lewis et al., 2009; Rutten et al., 2005). Accordingly, effective 
patient-clinician communication constitutes an important element of information 
acquisition by cancer patients and plays a critical role in influencing patient health 
outcomes (Epstein & Street Jr., 2007; Street Jr., Makoul, Arora, & Epstein, 2009).  
The framework for patient-centered communication offers a model for 
understanding the pathways through which patient-clinician communication may lead to 
better health outcomes (Street Jr. et al., 2009). First, core communication functions (e.g., 
information exchange, responding to emotions, making decisions, and enabling self-
26 
 
management) may have direct influences on health outcomes including survival, 
emotional well-being, or symptom control. In addition, communication may indirectly 
influence health outcomes through proximal outcomes (e.g., patient knowledge and 
understanding, satisfaction, and trust in clinicians) or intermediate outcomes such as 
access to care, quality medical decisions, and self-care skills. Street and colleagues (2007, 
2009) proposed seven pathways through which communication could contribute to 
improved health: 1) facilitate access to needed care, 2) increase patient knowledge and 
shared understanding, 3) enhance therapeutic alliances (among clinicians, patient, and 
family), 4) enhance emotional self-management, 5) activate social support and advocacy 
resources, 6) increase quality of medical decisions, and 7) enable patient agency (self-
efficacy and empowerment). From the above concepts, I highlight the roles of patient-
clinician information exchange as they pertain to Study 3 in this dissertation research.   
Patient-clinician information exchange is conceptualized as one of the core 
functions of patient-clinician communication that could affect patient outcomes (Epstein 
& Street Jr., 2007). Information exchange refers to the “reciprocal efforts of both 
clinicians and patients to manage information and achieve, even negotiate, a shared 
understanding of the medical and personal issues underlying the patient’s health 
condition” (Street Jr. & Epstein, 2008). For effective information exchange to occur, 
patients should actively engage with their physicians to elicit more and clearer 
information. Physicians should concurrently use partnering and supportive forms of 
communication tailored to the information needs, beliefs, and values of their patients 
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(Street Jr., Gordon, Ward, Krupat, & Kravitz, 2005; Zandbelt, Smets, Oort, Godfried, & 
de Haes, 2007).  
To frame patient-clinician discussions about DTCA within the concept of 
information exchange, one scenario would be an actively engaged patient bringing 
information from a cancer treatment ad to discuss with his or her physician. In the course 
of the discussion, the physician may respond with supportive information and explanation 
about benefits and risks associated with the advertised treatment. This exchange of 
information in turn leads to improved patient understanding and other outcomes. For 
instance, Martinez et al. (Martinez, Schwartz, Freres, Fraze, & Hornik, 2009) found 
patient-clinician information engagement about various cancer-related topics—which 
included discussing information patients had gotten elsewhere—was found to predict 
increased feelings of being informed and treatment decision satisfaction among cancer 
survivors. This was corroborated by another study that found almost all cancer patients 
(96%) who discussed an advertised cancer prescription drug with their physicians were 
satisfied with the discussion even though most of them did not eventually receive a 
prescription for the advertised medication (Abel et al., 2009). The findings suggest 
information exchange about DTCA, in this case initiated by patients, may contribute to 
intermediate outcomes of patient satisfaction about treatment decisions or about their 
interactions with clinicians. 
Patient knowledge and shared understanding are viewed as intermediate outcomes 
that could contribute to improved patient health. In order to make informed treatment 
decisions, patients need to have an understanding of their disease condition as well as 
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effectiveness, risks, and benefits associated with various treatment options (Braddock, 
Edwards, Hasenberg, Laidley, & Levinson, 1999). Both clinicians and patients play 
important roles in this process (Charles, Gafni, & Whelan, 1997). Apart from managing 
the complexity and uncertainty of treatment-related information, clinicians need to 
consider individual values, needs, and preferences of patients and communicate 
effectively to come to a shared understanding of the above issues (Street Jr. et al., 2009). 
Relating the concept of patient knowledge to research on DTCA, patients may obtain—
through discussion and information exchange with their treating doctors—a better 
understanding of whether an advertised treatment is appropriate for their specific 
condition and attendant risks and benefits involved with the treatment. From this process, 
patients may experience increased satisfaction about the discussion or treatment decision 
as described earlier (Abel et al., 2009; Martinez et al., 2009), improved ability to cope 
with the illness (Hagerty, 2005; Roberts, Cox, Reintgen, Baile, & Gibertini, 1994), and 
more commitment to the treatment plan (Zolnierek & Dimatteo, 2009), all of which may 
contribute to improved treatment outcomes and patient health. 
Alternatively, patient-centered communication may lead to improved patient 
health outcomes through enhancing patient empowerment and agency. The concept of 
agency is closely related to PBC described above in the IM and self-efficacy in SCT and 
encompasses patient perceptions and skills across various domains. These skills include 
the ability to engage actively with clinicians in medical encounters, participate in 
treatment decision-making, and to perform self-care for everyday health-related activities 
(O’Hair et al., 2003). Effective patient-clinician communication may facilitate patient 
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involvement in the decision-making process and offer resources for patients to develop 
specific skills for self-care (Van Dam, Van der Horst, Van den Borne, Ryckman, & 
Crebolder, 2003). In terms of the role of DTCA in enhancing patient agency, evidence 
supports the view that these ads may give patients the confidence to talk to their doctors 
about their concerns, improve discussions with their physicians, and increase feelings of 
being in control (Abel et al., 2009; Murray et al., 2004). 
Structural Influence Model of Communication 
The Structural Influence Model of Communication, described by Kontos & 
Viswanath (2011), suggests disparities in health communication have important roles in 
mediating relationships between social determinants (e.g., race, education, and income), 
access to healthcare resources, and more distal health outcomes (e.g., health behaviors, 
adherence, and treatment outcomes). The underlying assumption for this model is the 
notion that “control of communication is power and that whoever has the capacity to 
generate, access, use and distribute information enjoys social power and advantages that 
accrue from it”. According to the model, communication inequalities that may lead to 
health outcomes disparities include differences between social groups in terms of their: 1) 
exposure, 2) attention, 3) external information seeking, and 4) processing of health 
information. Most relevant to this dissertation research are inequalities in DTCA 
exposure (Study 2) and external information seeking following DTCA (Study 4).  
Applying concepts of Structural Influence Model of Communication to the impact 
of cancer-related DTCA, Kontos & Viswanath (2011) suggested communication 
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inequalities associated with DTCA may arise at three distinct but related levels: 1) certain 
groups may be less likely to gain exposure to DTCA, 2) differential attention and 
processing of DTCA may occur, and 3) some groups may not engage in additional 
information seeking after viewing DTCA. If such inequalities exist, DTCA may have 
differential effects between certain social groups. For example, on one hand, if some 
groups were more likely to be exposed to DTCA or attend to such ads, they may be more 
aware of treatment options available for their cancers than others. This may widen health 
outcomes disparities between these groups. On the other hand, detrimental effects of 
DTCA such as inappropriate use of treatments may affect one group more than others due 
to communication inequalities at various levels. For instance, it may be that certain social 
groups are more likely to look for additional information about an advertised treatment 
and are therefore able to weigh benefits and risks of an advertised treatment better than 
other groups. Therefore, research is necessary to assess whether certain groups have 
higher exposure to DTCA than others (Study 2) and whether certain groups are more 
likely to engage in additional information seeking following DTCA (Study 4). 
Summary 
 Relevant theoretical concepts are adapted from psychosocial models of behavioral 
change (IM and SCT), patient-centered communication, and the Structural Influence 
Model of Communication in this dissertation research. Specifically, Study 2 drew on the 
concepts of communication inequalities in exposure and attention to examine 
determinants of cancer survivors’ reported exposures to DTCA. In addition, Study 3 
assessed the impact of patients’ exposure to DTCA on active information seeking based 
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on the concept of information exchange from patient-centered communication framework 
and explored the theoretical pathways of this relationship through psychosocial constructs 
from the IM. Finally, Study 4 explored communication inequalities associated with 
DTCA by comparing its effects on information seeking behaviors across patients with 
different characteristics. 
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Chapter 3 MEASURING EXPOSURE TO DIRECT-TO-CONSUMER 
ADVERTISING—A VALIDATION STUDY IN THE CONTEXT OF CANCER-
RELATED TREATMENT ADVERTISING (STUDY 1) 
Abstract 
Emerging research suggests that direct-to-consumer advertising (DTCA) may be 
associated with patient and physician behaviors pertaining to treatment decision making. 
However, systematic efforts to develop and validate measures of patient exposure to 
DTCA are lacking. This study evaluated three candidate measures (I-III) of patient-
reported exposure to cancer-related DTCA. Using data from two population-based 
surveys, this study assessed the performance of each measure based on seven criteria. 
Results were consistent across both surveys; all three measures performed well in terms 
of convergent, nomological, discriminant, and face validity with a few differences 
between these measures. Measure I—the briefest of the three measures—posed the 
lowest level of survey costs and respondent burden among the three measures and was 
also deployed successfully for mailed and internet-based survey administration. Future 
directions for application and research relevant for cancer-related DTCA as well as 
DTCA for other illnesses are discussed. 
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Introduction 
The practice of direct-to-consumer advertising (DTCA) for prescription 
medications and healthcare services is controversial in the United States and subject to 
much debate (Bonaccorso & Sturchio, 2002; Fox & Ward, 2008; Frosch et al., 2010; 
Hoen, 1998; Hollon, 1999, 2005; Holmer, 1999, 2002; E. T. Rosenthal, 2010b). Cancer-
related DTCA, a form of “subspecialty DTCA” which is targeted at patients with cancer, 
is of further concern because of the limited options of highly effective interventions and 
potentially higher risks associated with specialized treatments (Abel et al., 2007). To 
better understand the extent of cancer patients’ perceptions of cancer-related DTCA—
which is defined as “promotional efforts by a pharmaceutical company, healthcare 
provider, or medical facility to present information about medications, medical devices, 
or medical services for patients diagnosed with cancer in the lay media environment” 
(adapted from Wilkes, Bell, & Kravitz, 2000)—and the potential impact of exposure to 
this advertising on various treatment-related behaviors or outcomes, it is essential to be 
able to measure patients’ exposure to DTCA adequately.  
Prior research that formally assessed the validity of exposure measures of cancer-
related DTCA or DTCA more generally is lacking. This research presents an approach to 
validate candidate measures of patients’ exposure to DTCA. While the present study 
pertains to the specific context of cancer treatment advertising, this approach would also 
benefit research in DTCA associated with other illnesses because of the similarity in the 
conceptual issues faced by measuring DTCA exposures. I first begin with a brief review 
of the rationale for this study and conceptual issues related to measuring cancer-related 
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DTCA exposure. Next, validation criteria and methods are outlined, followed by findings 
from two population-based surveys. Finally, I discuss the implications of the findings and 
recommendations for further research. 
Rationale for study and conceptual issues of measuring cancer-related DTCA 
exposure 
The impetus for this present validation research stemmed from a need to assess 
the reliability and validity of existing survey items of cancer-related DTCA exposure that 
were to be used in the analyses reported in subsequent chapters. These exposure items 
were part of a survey among a sample of cancer patients in Pennsylvania (to be described 
shortly). Participants were asked, “Since your diagnosis, how often have you seen or 
heard advertisements concerning each of the following?” for three categories of ads 
including “treatment alternatives for your cancer”, “dealing with side effects of 
treatment”, and “hospitals or doctors offering services for cancer”. Responses were 
measured along a 5-point scale (1 = Never to 5 = Almost every day). Lower scores 
represented lower frequencies of exposure to these types of ads (see Appendix A). 
These three survey items are conceptually novel compared to exposure measures 
of DTCA described in the literature and encompass a few measurement limitations. First, 
the individual items focus on three broad categories of treatment ads that differ topically 
from measures in previous literature. These prior studies on DTCA exposure 
overwhelmingly focused on measuring exposure to prescription drug ads alone (Abel et 
al., 2009; Aikin et al., 2004; Bell, Kravitz, et al., 1999; Deshpande et al., 2004; Frosch, 
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May, Tietbohl, & Pagán, 2011; Martinez & Lewis, 2009; Murray et al., 2004; Sumpradit, 
Fors, & McCormick, 2002; Weissman et al., 2003; Wilkes et al., 2000). Second, the 
survey items in our study are brief and do not elaborate with examples or define the 
individual categories of ads for the respondents. The concern with this brevity is the 
inherent assumption that respondents could discriminate among the named categories and 
report their exposure to ads according to those categories accurately. For instance, on its 
face, the survey item on the category of “hospitals of doctors offering services for 
cancer” could conceivably trigger recalling different types of ads in different respondents. 
In comparison, Abel and colleagues (2009) provided a list of 24 cancer-related brand 
name medications that appeared in print advertisements to prompt patients’ responses 
about their awareness of ads for each of these medications. Third, the survey items in our 
research asked respondents about the frequency of encountering cancer treatment ads. 
This contrasts with measures from other studies that only asked about awareness (i.e., 
whether respondents had seen or heard prescription drug advertisements (yes/no)) (Aikin 
et al., 2004). Furthermore, the three survey items in our study may be limited by the 
absence of prompts to recall ad exposure from various sources, potentially leading to 
under-reporting exposures. They differ from measures used by studies to assess 
respondents’ exposure to prescription drug ads across a variety of sources including 
television, radio, newspapers or magazines, or on the internet (Aikin et al., 2004; 
Martinez & Lewis, 2009).  
The above conceptual issues motivated a separate survey to assess if modifying 
the existing cancer-related DTCA survey items to address these issues would improve the 
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ability to measure DTCA exposure more accurately. For instance, the brief instructions in 
the existing items for how respondents should think about their exposure to cancer-
related DTCA may appear to reduce the face validity of these items. On the other hand, 
the brevity of these items might be simpler to understand and less confusing among 
respondents. This concern drove the effort to compare various versions of these survey 
items to assess whether brevity was in fact lowering the validity of the existing items and 
to judge the relative usefulness in measuring exposure of different versions across several 
criteria. In one modified version, survey items include longer verbal descriptions of each 
of the ad categories and list media sources to prompt respondents about their recall of 
cancer treatment ads from these sources. For instance, respondents were asked 
“Sometimes hospitals or doctors advertise their services (radiation therapy, 
chemotherapy, or comprehensive treatment) for treating patients with cancer. These 
advertisements may appear in the mass media (e.g., television, radio, newspapers, 
magazines, billboards, or the internet). Since your diagnosis, how often have you seen or 
heard advertisements concerning hospitals or doctors offering services for cancer?” 
(Appendix A). Despite these slightly more detailed descriptions, respondents may still 
not understand the named categories uniformly or distinguish between the categories. In a 
second set of alternative survey items, I incorporate longer descriptions of each ad 
category, list various media sources, and further provide two exemplars of ads that are 
representative of each category to illustrate what the ad categories mean for respondents 
(Appendices A and B). This separate survey is designed to compare the performance of 
these modified versions in terms of reliability and validity against the existing measure 
using various criteria. Essentially, if the existing exposure measure is not substantially 
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different from the modified versions, this would justify retaining the existing measures 
for investigating the associations between cancer-related DTCA and communication 
behaviors in the previously mentioned cancer patient survey. 
Validation approach 
The approach of this study is adapted from related validation frameworks for 
assessing the performance of alternative measures of exposure to cancer information 
(Romantan, Hornik, Price, Cappella, & Viswanath, 2008), scanned information exposure 
(Kelly, Niederdeppe, & Hornik, 2009), and contradictory health messages (Nagler & 
Hornik, 2012). This study examines how well each of the three candidate measures of 
cancer-related DTCA exposure performs based on the following seven criteria that are 
most relevant: 1) convergent validity, 2) nomological validity, 3) discriminant validity, 4) 
test-retest reliability, 5) face validity, 6) survey costs, and 7) respondent burden. These 
criteria are explicated further in Table 3.1. To assess the performance of the candidate 
measures of exposure to cancer-related DTCA among cancer patients, this research relies 
on two data sources—the Pennsylvania Cancer Patient Survey and an online survey of 
cancer patients across the U.S. The methods and findings from these two data sources are 
described separately, followed by an overall discussion.  
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Table 3.1 Operationalization of Validation Criteria 
Criteria Definition 
Convergent validity 
 
1. Moderate to strong inter-item correlations (Pearson’s 
correlation r ≥ 0.35),  
2. Items load on a unidimensional construct, and  
3. Internal consistency based on reliability measures 
(Cronbach’s alpha≥0.70). 
Nomological validity 
 
1. Correlations between patients’ exposure to cancer-
related DTCA with variables that would be expected 
to predict cancer-related DTCA exposure as well as 
those that would be affected by exposure to cancer-
related DTCA:  
a. General media usage,  
b. Health media exposure,  
c. Scanning of treatment information, and 
d. Discussing with physicians about information 
from lay media sources (where cancer-related 
DTCA would be encountered). 
Discriminant validity 
 
1. Candidate measures of cancer-related DTCA exposure 
would be more strongly associated with one another 
than with the variables assessed for nomological 
validity. 
Test-retest reliability 
 
1. Correlations between repeated measures of exposure 
to cancer-related DTCA over time. 
Face validity 
 
1. Subjective assessment of the extent that candidate 
measures accurately reflected the definition of cancer-
related DTCA.  
Survey costs  
 
1. Length of the measures in terms of word count and  
2. Number of responses required. 
Respondent cognitive 
burden 
 
1. Subjective assessment of the extent that measures 
demanded more cognitive effort to comprehend the 
instructions of the measures and report their exposure 
to cancer-related DTCA. 
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Study 1A—Pennsylvania Cancer Patient Survey 
Method 
Study Population 
Between 2006 and 2008, as part of a larger study, annual surveys were conducted 
among a probability sample of patients who were diagnosed with breast, prostate, or 
colorectal cancers and were reported, as legally required, to the Pennsylvanian Cancer 
Registry (PCR) in 2005. The data collection and survey instrument development 
procedures are detailed elsewhere (Nagler, Gray, et al., 2010). Survey questionnaires 
were designed following literature review, extended patient interviews, and expert 
consultation. The University of Pennsylvania Institutional Review Board approved the 
study. This present research focuses on the surveys in 2006 and 2007 (Rounds 1 and 2) 
that collected data about cancer patients’ exposure to cancer-related DTCA. In Round 1, 
2013 participants completed the survey (American Association for Public Opinion 
Research response rate 4 was 64%) (AAPOR, 2006). Among 1758 respondents who 
agreed to be re-contacted, 1293 (74%) completed the Round 2 survey. 
Measures 
Cancer-related DTCA exposure (Measure I) 
As described earlier, three items asked respondents about their frequency of 
seeing or hearing about advertisements concerning “treatment alternatives for your 
cancer”, “dealing with side effects of treatment”, and “hospitals or doctors offering 
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services for cancer”, measured on a 5-point scale (1 = Never to 5 = Almost every day) 
(see Appendix A). The numerical scores assigned to responses to these three items were 
treated as interval and averaged to form the measure of cancer-related DTCA exposure 
(Measure I) (Round 1: M = 2.41, SD = 1.02; Round 2: M = 2.21, SD = 0.95).  
Health media exposure 
Participants’ exposure to health information from media sources is expected to be 
positively associated with exposure to cancer-related DTCA. Participants reported how 
frequently they had found out about health information in the preceding 30 days from 
five media sources (i.e., newspapers or general magazines, medical magazines or 
newsletters, health segments on television news, television programs other than news, 
and the internet). Responses for these items ranges on a 4-point scale from ‘not at all’ to 
‘two or more times per week’ and were summed into an index of health media exposure 
(Round 1: M = 10.43, SD = 3.59; Round 2: M = 10.48, SD = 3.47). 
Scanning about treatment information 
Furthermore, encountering cancer treatment information during routine use of 
media sources is expected to be positively associated with cancer-related DTCA 
exposure. Respondents were asked “What information have you come across about your 
cancer from media sources (television, radio, newspapers, magazines, Internet) when you 
were not looking for it since your diagnosis?” and were able to select if they had come 
across information about “what treatments were the best for my cancer”, “which doctors 
of hospitals would be the best for me”, and “how to manage side effects of treatments”. 
41 
 
These binary responses (yes or no) were summed into a 0-5 point index of treatment-
related information scanning (Round 1: M = 1.05, SD = 1.03; Round 2: M = 0.56, SD = 
0.86).  
Discussion with treating doctors  
Prior research suggests that exposure to prescription drug DTCA prompts patients 
to discuss the advertised drug with their physicians (Aikin et al., 2004; Murray et al., 
2004). Cancer-related DTCA exposure is expected to be associated with discussion with 
one’s physicians about cancer-related information. Four survey items asked if 
respondents had discussed information they had gotten from media sources (i.e., 
television or radio; books, brochures, or pamphlets; newspapers or magazines; and 
internet excluding personal emails) with their treating doctors since the cancer diagnosis. 
These are media sources through which DTCA for cancer treatments tend to be noticed 
by cancer patients (Abel et al., 2009). The items were summed into an index (range of 0 – 
4) of discussion with treating doctors (Round 1: M = 0.78, SD = 1.07; Round 2: M = 0.59, 
SD = 1.01). 
Analyses 
 Analyses for assessing the performance of Measure I were conducted using the 
Stata release 11 statistical package (StataCorp, 2009). To assess convergent validity, 
correlation analyses between Measure I items, computation of the Cronbach’s alpha 
statistic, and principal component analysis were performed. Nomological validity was 
assessed with correlations between the DTCA exposure scale with health media 
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exposure, scanning about treatment information, and discussion with physicians at 
Rounds 1 and 2. Using the ‘CORRCI’ command in Stata, I examined discriminant 
validity by comparing the correlation and its confidence intervals between DTCA 
exposures in Rounds 1 and 2 against those between the DTCA exposures of each round 
with the nomological criterion variables. Erring on the side of being conservative, these 
correlations were deemed to be different if there is no overlap in the confidence intervals. 
Test-retest reliability was assessed with the correlation between cancer-related DTCA 
exposures in Rounds 1 and 2. 
Results 
At Round 1, half of the study sample was female (51%) and the average age was 
63 years. Other participant characteristics are reported in Table 3.2. The distributions 
(mean and standard deviation) of individual Measure I items in both rounds and the 
resulting DTCA exposure scales are summarized in Table 3.3.  
  
43 
 
Table 3.2 Participant Characteristics 
 
Study 1A  
N=2013 
 Study 1B  
N=363 
Characteristics M SD %  M SD % 
Age 66 12   53 16  
Gender – Female   51    52 
Education        
   Some high school and below   16    2 
   High school   41    23 
   Some college or two-year degree   22    36 
   4-year college degree or higher   22    39 
Race/ ethnicity        
   White   83    89 
   Black   13    6 
   Other   4    6 
Cancer type         
Colon cancer   34    10 
Breast cancer   34    21 
Prostate cancer   32    16 
Other   0    43a 
 
Note. aExamples of other cancer diagnoses were skin cancers (12%), endometrial cancer 
(4%), lymphoma (3%), and leukemia (3%).  
  
44 
 
Table 3.3 Distributions of Items and Scales of Candidate Measures of cancer-related 
DTCA Exposure 
 Study 1A  Study 1B 
 
Measure I 
Round 1a 
N=2013 
 Measure I 
Round 2b 
N=1293 
  Measure I 
N=363 
 Measure II 
N=216 
 Measure III 
N=147 
Individual Items M SD  M SD  M SD  M SD  M SD 
Treatment 
alternatives 
2.22 1.23  2.04 1.15  2.61 1.51  2.64 1.44  2.74 1.47 
Dealing with 
side-effects 
2.22 1.30  1.92 1.10  2.45 1.43  2.60 1.37  2.48 1.41 
Hospital or 
doctors offering 
services 
2.87 1.34  2.75 1.33  3.24 1.36  3.26 1.37  3.27 1.31 
               
Combined scale               
Cancer-related 
DTCA exposure 
2.41 1.02  2.21 0.95  2.77 1.22  2.83 1.19  2.83 1.14 
 
Note. Means are based on a five-point scale (1 = Never and 5 = Almost everyday).  
aThe number of cases with missing values for the individual items ranged from 519 to 
597; these were predominantly due to 369 cases who were randomized to receive a 
shortened form of the questionnaire in Round 1 that excluded these cancer-related DTCA 
items. The remainder was due to item non-response or multiple responses to an item. 
bThe number of cases with missing values for the individual items ranged from 129 to 
211 in Round 2; these were due to item non-response or multiple responses to an item. 
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Convergent validity—In this study population, Measure I items are moderately 
correlated with one another (inter-item Pearson’s r ranged from 0.420 to 0.477 in Round 
1 and from 0.461 to 0.474 in Round 2) (Table 3.4). In addition, the three items 
demonstrate reasonable internal consistency (Cronbach’s alpha=0.724 in Round 1 and 
0.742 in Round 2). Principal component analyses show that the items load on a single 
component with an eigenvalue greater than one in both Rounds 1 and 2, accounting for 
64% and 66% of the total variances respectively. 
Table 3.4 Inter-Item Pearson’s Correlations Between Measure I Items (Study 1A)  
 Round 1  Round 2 
 1 2 3  1 2 3 
1. Ads concerning treatment 
alternatives for cancer 
- 0.420 0.420  - 0.474 0.465 
2. Ads concerning dealing with side 
effects of treatment 
 - 0.477     - 0.461 
3. Ads concerning hospitals or 
doctors offering services for cancer 
  -    - 
Cronbach’s alpha 0.724  0.742 
 
Note. All Ps <.0005. 
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Nomological validity—The DTCA exposure scale derived using Measure I items 
is correlated with health media exposure and information scanning about cancer 
treatment from media sources in both Rounds 1 and 2. The DTCA exposure scale is also 
correlated with discussion with physicians about information from lay media sources 
across both Rounds 1 and 2 (Table 3.5). 
Test-retest reliability—The correlation of DTCA exposure scales between the two 
rounds is moderate (Pearson’s r = .492) (Table 3.5).  
Discriminant validity—Based on the results in Table 3.5, the association between 
DTCA scales in Rounds 1 and 2 is stronger than the correlations of each of these scales 
with the nomological criterion variables (no overlap of the confidence intervals). This 
supports the inference that the DTCA exposure scale may be a distinct measure 
comparing with these variables. 
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Table 3.5 Pearson’s Correlations Between Cancer-Related DTCA Exposure Scale 
and Health Media Exposure, Scanning for Treatment Information, and Discussion 
with Physicians (Study 1A) 
 Pearson’s r 95% CI 
DTCA exposure in Round 1 by DTCA exposure in 
Round 2 
0.492 0.441 - 0.540 
     
DTCA exposure in Round 1 by Health media exposure 
Round 1 
0.360 0.299 - 0.418 
DTCA exposure in Round 1 by Scanning for treatment 
information in Round 1 
0.309 0.246 - 0.369 
DTCA exposure in Round 1 by Discuss lay media 
information with treating doctor in Round 1 
0.194 0.127 - 0.258 
     
DTCA exposure in Round 2 by Health media exposure 
Round 2 
0.224 0.158 - 0.287 
DTCA exposure in Round 2 by Scanning for treatment 
information in Round 2 
0.270 0.206 - 0.332 
DTCA exposure in Round 2 by Discuss lay media 
information with treating doctor in Round 2 
0.179 0.113 - 0.244 
 
Note. All Ps <.0005 
Face validity—As discussed earlier, one limitation associated with the brevity of 
self-reported exposure items in the Pennsylvanian survey is patients may not be able to 
distinguish ads with different types of content precisely according to the brief 
descriptions in the items (i.e., alternative treatments for cancer, hospitals or doctors 
offering services, or dealing with side-effects of treatment). In addition, the items did not 
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prompt respondents to report coming across DTCA across various media. Therefore, 
these items may not have accurately captured patients’ exposure to DTCA across a 
variety of media sources (e.g., television, print magazines, billboards, or the internet). 
Patients’ self-reported exposure to DTCA based on these items may consequently 
underestimate their true exposure. However, the brevity of the items in Measure I could 
be easier to understand and less prone to confusion among respondents. As I will describe 
shortly in Study 1B, comparisons with more detailed versions of these items would be 
valuable in assessing whether the brevity of Measure I affected the performance of this 
measure in other criteria. 
Survey costs and respondent burden—Measure I items consist of 52 words and 
three distinct responses, suggesting that survey costs would be low to moderate. Although 
brief, these items are judged to have modest cognitive burden because respondents have 
to generate a summary estimate of their exposure to classes of DTCA, not just specific 
ads (i.e., treatment alternatives, dealing with treatment side effects, and hospital or 
doctors offering services) before giving their response. 
 To summarize, based on this study among a probability sample of Pennsylvanian 
patients diagnosed with breast, colorectal, or prostate cancers, Measure I items can be 
considered as reliable and valid means of assessing exposure to DTCA. These items 
demonstrate reasonable convergent validity, nomological validity against selected 
criterion measures, test-retest reliability between repeated measures over time, and 
discriminant validity. In addition, Measure I items are likely to impose low to moderate 
survey costs and cognitive burden for participants. However, the trade-off associated with 
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the brevity of these items may be reduced face validity. Another limitation of Study 1A is 
that the sample consisted of only Pennsylvanian patients diagnosed with three types of 
cancers. This may limit the generalizability of the validity and reliability of Measure I, 
although there are no a priori reasons to expect substantial differences in other patient 
populations with different cancer types. To address these limitations, a second study 
conducted among a sample of patients diagnosed with different cancers across the U.S. 
compares Measure I with more detailed alternate measures (II and III). 
Study 1B—Online Panel Cancer Patient Survey 
Method 
Study Population 
The data for this study is from a self-administered web-based survey between 
March and May 2012 among 363 adults who reported they had been diagnosed with 
cancer; these participants were recruited from an existing national opt-in panel 
maintained by Survey Sampling International (SSI) comprising persons who had a 
history of cancer. The criteria for inclusion to the study were having any cancer diagnosis 
within the past two years (from January 2010 onwards) and being aged 21 years or older. 
The criterion to include only patients who were recently diagnosed was necessary as it is 
assumed cancer-related DTCA would be more salient for these patients compared with 
those who had been diagnosed and treated many years ago. Because prior experience of 
online surveys indicated an under-representation of male participants, the study utilized 
quota sampling to ensure approximately half of the study participants would be male. The 
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University of Pennsylvania IRB approved this validation study as research that qualified 
for exemption from IRB review. 
Measures 
Cancer-related DTCA Exposure (Measures I to III) 
Measure I items are identical to those described in Study 1A. These items were 
averaged into a scale of DTCA exposure (M = 2.77, SD = 1.22). All the participants in 
this study were asked the Measure I items.  
Measure II comprises three items that showed respondents descriptions of the 
content of each category of DTCA (i.e., treatment alternatives, dealing with treatment 
side-effects, and hospitals or doctors offering services) and two exemplars of DTCA 
collated from television and print advertising sources. Participants were then asked to 
recall how frequently they saw each type of ads (Appendices A and B). To illustrate, 
respondents first read a description for ads about hospitals and doctors. Next, participants 
viewed two examples representing this category of ads (e.g., one print ad and one video 
ad showing hospitals and doctors providing cancer treatment services randomly chosen 
from a pool of four print ads and four video ads respectively). They were then asked how 
frequently they recalled encountering similar ads about hospitals and doctors offering 
treatment services since their cancer diagnosis. The three items were averaged into an 
alternate scale of DTCA exposure (M = 2.83, SD = 1.19). Approximately two-thirds of 
the study population was randomly assigned to respond to Measure II items.  
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Measure III is identical to Measure II with the exception that the items do not 
provide exemplars of ads (see Appendix A). The average of the three Measure III items 
formed another alternative DTCA exposure scale (M = 2.83, SD = 1.14). One-third of the 
study population was randomly assigned to answer Measure II items. 
Nomological Criterion Variables 
Items for health media exposure (M = 11.64, SD = 4.82), scanning for treatment 
information (M = 0.93, SD = 1.07), and discussion with physicians (M = 0.77, SD = 1.03) 
were included in the questionnaire. These measures are identical to those described in 
Study 1A. In addition, respondents reported on their frequency of use of eight media 
channels (i.e., newspaper, magazine, national and local news, television programs, radio, 
email, and the internet) in the past 7 days (between 0 to 7 times). Responses to these 
items were summed to create an index of general media use (M = 36.88, SD = 11.52).  
Analyses 
The validation analyses proceeded in a parallel manner to Study 1A. I first 
assessed the performance of Measures I to III using the criteria laid out in the earlier 
section on validation approach except for the test-retest reliability criterion because 
repeat measures of DTCA exposure using these items were not collected in Study 1B.  
In addition, I assessed the threat that respondents assigned to Measure II items 
reported their exposure to specific exemplars that they viewed rather than their recall of a 
general class of ads represented by the exemplars. To illustrate, if the mean recall for 
having seen or heard ads about medications to deal with treatment side-effects varied 
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significantly between participants who were shown an ad for Procrit (erythropoietin alfa) 
compared to those who were shown an ad for Neulasta (pegfilgrastim), this could signal 
respondents were not recalling their overall exposure to ads for dealing with treatment 
side-effects. Instead, respondents may be recalling their exposure to the individual ads 
that they viewed. To assess this possible threat, I performed one-way ANOVA tests to 
compare the means of each of the Measure II items with the ad shown as the between 
subjects factor.  
Another concern was the potential threat of ordering effects in the way the 
candidate measures were presented in the survey. I attempted to minimize this threat by 
separating Measure I items from Measures II/III items with other survey questions (e.g., 
nomological criterion measures). I further assessed the potential of ordering effects by 
randomly assigning half the participants to receive Measure I first while the remainder 
received Measure II or III first. The above validation analyses were repeated to detect the 
presence of any substantive differences in the findings due to the order of measures in the 
questionnaire. 
Results 
 Approximately 52% of the respondents were female and the mean age was 53 
years. Other participant characteristics are summarized in Table 3.2. This study 
population tended to be younger, have higher education levels, and was less ethnically 
diverse compared to the Pennsylvanian sample of cancer patients in Study 1A.  
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The distributions (mean and standard deviation) of individual items of Measures I 
– III and the resulting DTCA exposure scales are summarized in Table 3.3. The means of 
the corresponding exposure items do not differ appreciably between Measures I – III, 
leading to a first conclusion that there is no substantial under-reporting of DTCA 
exposure based on Measure I items compared with Measures II or III. 
Convergent validity—In Study 1B, the items in all three candidate measures of 
DTCA demonstrate moderate to strong inter-item correlations within the respective 
measures (inter-item Pearson’s r = 0.427 to 0.693). Furthermore, the items in these three 
measures are internally consistent (Cronbach’s alpha=0.743 to 0.814) (Table 3.6). 
Principal component analysis extracted one single component with an eigenvalue greater 
than one in all three measures (accounting for 73%, 71%, and 62% of the total variances 
in Measures I, II, and III respectively). Additionally, topic-matching items from 
Measures I and II tend to be more strongly correlated than with non-matching items; a 
similar pattern is also observed for correlations between matching items from Measures I 
and III (Table 3.7). The summed DTCA exposure scales derived from Measures I and II 
are strongly correlated (Pearson’s r = 0.713; 95% CI = 0.641 to 0.773). The scales from 
Measures I and III are also strongly correlated (Pearson’s r = 0.765; 95% CI = 0.689 to 
0.825).   
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Table 3.6 Inter-Item Pearson’s Correlations Within Alternative Measures of 
Exposure to Cancer-Related DTCA (Study 1B) 
 Measure I  Measure II  Measure III 
 1 2 3  1 2 3  1 2 3 
1. Treatment 
alternatives - 0.693 0.589  - 0.618 0.585  - 0.556 0.487 
2. Dealing with side-
effects  - 0.489   - 0.578   - 0.427 
3. Hospital or doctors 
offering services   -    -    - 
Cronbach’s alpha 0.813  0.814  0.743 
 
Note. All Ps <.0005. 
Table 3.7 Inter-Item Pearson’s Correlations Between Alternative Measures of 
Exposure to Cancer-Related DTCA (Study 1B) 
 Measure I      Measure II  Measure III 
      1 2 3  1 2 3 
1 Treatment alternatives  0.588 0.498 0.433  0.718 0.478 0.449 
2 Dealing with side-effects  0.528 0.583 0.407  0.563 0.662 0.367 
3 Hospital or doctors offering services  0.516 0.470 0.580  0.594 0.384 0.640 
 
Note. All Ps <.0005. Matching items across measures (in bold) tend to be more strongly 
correlated than non-matching items. 
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Nomological validity—The analysis show that all three exposure scales using 
Measure I-III items are significantly correlated with the nomological criterion variables 
of general media use, health media exposure, treatment information scanning, and 
discussion with physicians about cancer information from lay media sources (Pearson’s r 
= 0.298 to 0.632) (Table 3.8).  
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Table 3.8 Pearson’s Correlations Between Cancer-Related DTCA Exposure Measures and Nomological Criterion Measures 
(Study 1B) 
 Measure I  Measure II  Measure III 
 Pearson’s r 95% CI  Pearson’s r 95% CI  Pearson’s r 95% CI 
1. General media use  0.298 0.201 - 0.389  0.299 0.173 - 0.416  0.375 0.227 - 0.506 
2. Health media exposure 0.632 0.566 - 0.690  0.564 0.465 - 0.649  0.627 0.517 - 0.716 
3. Scanning for treatment 
information 0.510 0.430 - 0.582  0.410 0.293 - 0.515  0.491 0.357 - 0.604 
4. Discuss lay media information 
with treating doctor 0.395 0.305 - 0.479  0.343 0.220 - 0.456  0.373 0.224 - 0.504 
 
Note. All Ps <.0005.  
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Discriminant validity—The correlations between Measures I and II DTCA 
exposure scales and the correlations between Measures I and III exposure scales tend to 
be stronger compared with the correlations between Measures I-III and the nomological 
criterion variables. Comparing the confidence intervals of these correlations in Table 3.8, 
I conclude that the DTCA exposure scales are distinct from general media use, treatment 
information scanning, and discussion with physicians. However, the confidence intervals 
of correlations within candidate DTCA exposure measures overlap with those of 
correlations between these exposure measures and health media exposure.  
Face validity—Compared with Measure I, Measure II and III comprise more 
detailed items that prompt respondents to consider their exposure to DTCA across a 
variety of media sources and descriptions about each category of ads. Measure II items 
further provide exemplars of print and video ads. Accordingly, Measures II and III are 
deemed to have higher face validity compared to Measure I.  
Survey costs and respondent burden—As described above, Measure I items 
consist of 52 words and three distinct responses. In contrast, Measure II items consist of 
269 words while Measure III has 161 words, approximately three to five times as many 
words as Measure I. Both Measure II and III are also judged to have higher levels of 
cognitive burden on participants than Measure I because of the need to process and recall 
multiple sources of DTCA exposure that would match the textual descriptions. In the case 
of Measure II items, the cognitive burden would be the highest because participants 
would need to generate memories of encountering ads similar to the ad exemplars of each 
category of DTCA that they viewed.  
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Based on the ANOVA tests, mean DTCA exposure as reported with Measure II 
items do not differ significantly among ad exemplars of the three categories of DTCA 
shown. The eta-squared values for these tests range from 0.002 to 0.015, which further 
indicate the variance in DTCA exposure explained by the ad exemplars viewed is 
minimal (Table 3.9). Finally, there is no evidence of systematic ordering effects; 
comparing the above validation analyses between participants who answered Measure I 
items first and those who received the Measure I items later, there are no substantive 
differences. For example, the correlation between Measure 1 and II if Measure I appeared 
first in the survey (r=0.70) is slightly weaker in comparison to that if Measure II appeared 
first (r=0.81). Conversely, the correlation between Measures I and III when Measure I 
appeared first (r=0.83) is slightly stronger than the correlation if Measure III appeared 
first (r=0.75).  
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Table 3.9 One-Way Between-Participants Analysis of Variance of Effect of Ads 
Shown on Measure II Items in Study 1B 
Category of ads and specific ads M SD F(3, 212) P Eta-
squared 
Alternative treatment print ads   0.249 0.862 0.004 
1. Altoona Regional Radiosurgery (A) 2.50 1.414    
2. Altoona Regional Radiosurgery (B) 2.70 1.488    
3. Las Vegas Cyberknife at Summerlin 2.69 1.342    
4. St. Peter’s University Hospital Cyberknife 2.69 1.514    
      
Alternative treatment video ads   0.148 0.931 0.002 
1. Memorial Cancer Institute Cyberknife 2.65 1.507    
2. Fox Chase Cancer Center Minimally Invasive 
Surgery 
2.64 1.471    
3. Novalis TX at St Vincent’s Medical Center 2.53 1.424    
4. Phoenix Cyberknife 2.72 1.374    
      
Treatment side effects print ads   0.463 0.708 0.007 
1. Zuplenz (A) 2.46 1.410    
2. Aloxi 2.78 1.388    
3. Zuplenz (B) 2.63 1.369    
4. Zometa 2.56 1.350    
      
Treatment side effects video ads   0.873 0.456 0.012 
1. Neulasta 2.65 1.388    
2. Procrit (A) 2.36 1.266    
3. Procrit (B) 2.77 1.417    
4. Procrit (C) 2.67 1.438    
      
Doctor and hospital print ads   1.066 0.364 0.015 
1. Sylvester Comprehensive Cancer Center (A) 3.12 1.508    
2. Sylvester Comprehensive Cancer Center (B) 3.20 1.265    
3. Sylvester Comprehensive Cancer Center (C) 3.20 1.379    
4. Sylvester Comprehensive Cancer Center (D) 3.56 1.270    
      
Doctor and hospital video ads   0.150 0.930 0.002 
1. UNC Cancer Center 3.16 1.347    
2. Carle Cancer Center 3.33 1.476    
3. Hudson Valley Hospital Center 3.29 1.390    
4. Terrebonne General Medical Center – Mary 
Bird Perkins Cancer Center 
3.28 1.294    
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To summarize Study 1B findings, this web-based survey among an opt-in sample 
of patients across the U.S. diagnosed with a wide variety of cancers compares the 
performance of three candidate measures of DTCA exposure. Measures I to III display 
reasonable convergent validity and nomological validity. Discriminant validity is largely 
supported; discrimination between scales derived from Measures I to III and three out of 
four criterion variables are significant. Measures II and III are deemed to have higher 
face validity compared to Measure I. However, Measure I is likely to incur the lowest 
survey costs and respondent burden.  
Discussion 
 This validation study assesses the performance of three alternative measures of 
cancer-related DTCA exposure among cancer patients using a comprehensive set of 
criteria across two distinct study populations. Study 1A involved repeated mailed 
questionnaires among a probability sample of patients from Pennsylvania who were 
diagnosed with breast, colorectal, or prostate cancers. In comparison, Study 1B involved 
a cross-sectional web-based survey among patients who were diagnosed with a variety of 
cancers across the U.S.  
Due to the multiple validity criteria in this research, the findings of the 
performance of candidate measures of cancer-related DTCA exposure based on Studies 
1A and 1B are summarized for comparison in Table 3.10 (adapted from Nagler & Hornik 
(2012) and Romantan et al. (2008)). Across the criteria of convergent, nomological, and 
discriminant validity, Measures I-III performed equally well for the most part. All three 
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measures demonstrate adequate levels of convergent validity as evidenced by internal 
consistency and unidimensionality measures. They are also associated with variables that 
are likely to predict exposure to DTCA as well as behaviors that may arise from exposure 
(i.e., discussion with physicians). Discrimination between these measures and other 
associated measures (e.g., health media exposure and treatment information scanning) is 
replicated in both Studies 1A and 1B. Measure 1 is further evaluated for test-retest 
reliability. However, these three measures differ in terms of face validity, survey costs, 
and respondent burden. Measure 1 had lower face validity compared with the detailed 
versions of Measures II and III. However, the brevity of Measure I did not appear to 
affect its performance in other validity criteria when compared to the more detailed 
measures. Measures II and III are more costly and impose higher cognitive burden on 
respondents. Strikingly, respondents were able to extrapolate their exposure to categories 
of DTCA from viewing two exemplars of each ad category using Measure II items; their 
responses did not suggest they were merely recalling exposure to specific exemplars that 
they viewed. Weighing these findings across the criteria, Measure I would be appropriate 
as the first option for eliciting DTCA exposure in either mailed or web-based survey 
formats. If resources permit and face validity is a priority, Measure III may be an 
alternative choice. The added advantage of face validity from Measure II (including print 
and television ad exemplars) should be considered against the disadvantages of cost, 
participant burden, and limitation to data collection methods requiring audiovisual 
technologies. 
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Table 3.10 Summary of Analyses Across Validity Criteria 
Candidate 
Exposure 
Measures 
Convergent 
validity 
Nomological 
validity 
Discriminant 
validity 
Test-retest 
reliability 
Face 
validity 
Survey 
costs 
Respondent 
burden 
Measure I 4 4 3 4 2 4 4 
Measure II 4 4 3 n/a 4 1 1 
Measure III 4 4 3 n/a 3 3 3 
 
Note. 1 = worst performance; 4 = best performance 
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The replication of validity testing for Measure I across these two studies and 
exploration of alternative measures (II and III) in Study 1B provides increased confidence 
in the performance Measure I to assess DTCA exposure among a diverse population of 
cancer patients. The representative sample of cancer patients in Study 1A, although from 
a single state, can be viewed as an improvement from studies that are limited to 
convenience samples of cancer patients or those that involve patients from a single health 
system. While the study population in Study 1B is not a representative sample of cancer 
patients across the U.S., I argue that Study 1B complements the findings from Study 1A 
through the inclusion of a more diverse population of cancer patients (i.e., broader 
geographic locations and cancer diagnoses). Moreover, the web-based survey in Study 
1B enables testing exposure measures that include audiovisual exemplars of DTCA; this 
would be precluded by mailed questionnaires or phone interviews. This validation 
approach involving a combination of study populations, survey designs, and modes of 
data collection described here may serve as an illustrative example for future research 
aimed at developing and validating self-reported measures of exposure to DTCA 
associated with other illnesses.  
This study is limited in terms of the narrow context of DTCA promoting cancer-
related treatments and health services. Despite an expanded operationalization of DTCA 
exposure beyond prescription medications only for cancer treatment, it may be argued 
that the validation findings here may not generalize to measures of exposure to DTCA for 
other illnesses. Future investigations should consider adapting measures described in this 
current study for measuring exposure to other disease-specific DTCA and to 
64 
 
systematically validate these adapted measures. Although substantial modification may 
be needed for Measure II because of the content-specific exemplars, Measures I and III 
may be more easily adapted into survey items that measure exposure to DTCA of other 
illnesses.  
The study is also limited by the reliance on self-reported and closed-ended 
measures of exposure to cancer-related DTCA. Recall biases are a threat to inferences 
about whether self-reported DTCA exposure truly reflects participants’ past exposure or 
more likely their memory of encoded exposure to such advertising in the media 
(Southwell, Barmada, Hornik, & Maklan, 2002; Southwell & Langteau, 2011; Southwell, 
2005). Consequently, population-level measures of exposures through media market 
gross rating points of televised health campaign advertising or news reporting have been 
increasingly implemented as predictors of behaviors instead of individual-level self-
reported media exposure measures (Farrelly, Davis, Haviland, Messeri, & Healton, 2005; 
Hwang & Southwell, 2009; Wakefield et al., 2008). Closed-ended survey questions that 
specify a particular subject matter may also contain researchers’ biases and may miss the 
content that is most meaningful for the study population compared to open-ended 
questions that permit more in-depth assessment of exposures that are of most interest to 
the target population (Clarke & Kline, 1974). Nevertheless, these alternatives to self-
reported and closed-ended measures are not without their limitations. For instance, 
media-market gross rating points represent environmental availability of media messages 
and therefore reflect the opportunity to be exposed to media messages; individuals within 
the media market may not necessarily be exposed at all (Slater, 2004). Responses to 
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open-ended questions about exposure may reflect one’s knowledge about a health topic 
rather than merely exposure (Salmon, 1986) and are often more costly and complex to 
collect and analyze (Romantan et al., 2008) than closed-ended items.  
Despite these limitations, this validation study offers novel insights into valid, 
reliable, and field-tested measures of cancer-related DTCA exposure among cancer 
patients that have the potential to be adapted for measuring exposure to DTCA of other 
illnesses. The validation approach encompassing complementary study populations, 
designs, modes of data collection, and comprehensive criteria may also serve as a model 
for future research aimed at systematic comparisons of candidate measures of DTCA 
exposure.   
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Chapter 4 A STUDY OF THE FREQUENCY AND CORRELATES OF 
EXPOSURE TO CANCER-RELATED DIRECT-TO-CONSUMER 
ADVERTISING AMONG BREAST, PROSTATE, AND COLORECTAL CANCER 
PATIENTS (STUDY 2) 
Abstract 
Cancer-related direct-to-consumer advertising (DTCA) is controversial because 
cancer treatment is complex and entails more risks and costs than typical treatments that 
are advertised for other conditions. Contributing to the growing research on DTCA, this 
study describes the prevalence and correlates of cancer patients’ frequency of DTCA 
exposure. A sample of 2013 patients diagnosed with breast, prostate, or colorectal 
cancers and reported to the Pennsylvania Cancer Registry in 2005 responded to a mailed 
questionnaire. Three survey items assessed patients’ frequency of encountering ads 
concerning treatment alternatives for cancer, dealing with side effects of treatment, and 
doctors or hospitals offering services for cancer following their diagnosis. These items 
were summed to form the overall exposure DTCA measure. Descriptive and multivariate 
analyses were performed. Overall exposure to DTCA in the sample was modest (median 
was once per week). Breast cancer patients reported significantly higher overall 
exposures to DTCA than prostate and colorectal cancer patients (all Ps<0.0005). Older 
patients consistently reported lower overall exposure to DTCA across the three cancer 
types. Other significant correlates included ethnicity (higher exposures among African-
American prostate cancer patients vs. white; lower exposures in Hispanic colorectal 
cancer patients vs. white), and cancer stage (higher exposures in stage IV prostate cancer 
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patients vs. stages 0-II). Disparities in exposure to DTCA are present based on age, 
ethnicity and cancer stage and have important implications on clinical and regulatory 
practice in cancer care.  
  
68 
 
Introduction 
 Direct-to-consumer advertising (DTCA) of medical treatments remains highly 
controversial and generates intense debate between proponents and critics of the value (or 
detrimental effect) of such promotional efforts (Bonaccorso & Sturchio, 2002; Mintzes, 
2002). Extending from this broader debate, DTCA for cancer-related products and 
services has attracted an increasing level of scrutiny and attention from researchers and 
practitioners involved in cancer care and survivorship. Special considerations about the 
appropriateness of DTCA in oncology arise because of the highly specialized nature of 
cancer diagnosis and treatment compared to other disease conditions, potential risks of 
cancer-related medications or services, costs involved in cancer care, and possible 
widening of communication disparities (Bloss, Darst, Topol, & Schork, 2011; Gollust, 
Hull, & Wilfond, 2002; Kontos & Viswanath, 2011; Lippi, Favaloro, & Plebani, 2011; 
Lovett, Liang, & Mackey, 2012; Lovett & Liang, 2011). 
In a recent review, Gray and Abel classified the rapidly diversifying types of 
consumer marketing in oncology into DTCA for cancer-related medications, cancer 
facilities, imaging services, genetic tests, and cancer screening or surveillance tests (Gray 
& Abel, 2012). This provides a useful overview of the spectrum of DTCA of products 
and services for cancer screening, diagnosis, treatment, and follow-up surveillance. While 
research is accumulating on specific forms of DTCA (e.g., prescription medications, high 
technology imaging services, and genetic testing) (Abel et al., 2007; Finney Rutten, 
Gollust, Naveed, & Moser, 2012; Illes et al., 2004), information about the extent of 
DTCA promoting cancer facilities appears to be lacking in the literature. Furthermore, 
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although several studies have described the content of DTCA for cancer-related products 
and services (Abel et al., 2007; Illes et al., 2004; Lachance, Erby, Ford, Allen, & 
Kaphingst, 2010; Larson et al., 2005; Lovett et al., 2012), less research has been 
conducted on how frequently the public at large or cancer patients were exposed to such 
DTCA (Abel et al., 2009; Finney Rutten et al., 2012). 
This present study aims to contribute to the apparent gap in the literature by 
describing cancer patients’ frequency of exposure to types of DTCA in oncology using 
data from a population-based survey. In this article, cancer-related DTCA (DTCA) is 
broadly defined as “promotional efforts by a pharmaceutical company, healthcare 
provider, or medical facility to present information about treatments for patients 
diagnosed with cancer in the lay media environment” (Wilkes et al., 2000). Recognizing 
that different patients may have varying experiences, the study compares DTCA 
exposures between patients diagnosed with breast, prostate, and colorectal cancer and 
explores whether individual patient characteristics are correlated with advertising 
exposures. The findings in this study would generate much needed evidence on the 
frequency of exposures to DTCA among cancer patients, identify potential areas of 
communication disparities, and inform clinical and regulatory practice.  
Method 
Study Population  
This study relied on survey data from patients who were diagnosed with breast, 
prostate, or colorectal cancers and whose names were sent to the Pennsylvanian Cancer 
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Registry in 2005. Patients with these three cancer types were randomly selected to 
participate in the survey in September 2006, approximately 9 to 21 months after their 
initial diagnoses. After the initial data collection, an oversample among patients 
diagnosed with colorectal cancer, those with Stage IV disease, and African American 
patients was added to increase sample sizes for subgroup analyses. Overall, 679 breast 
cancer patients, 650 prostate cancer patients, and 684 colorectal cancer patients 
completed the survey. The American Association for Public Opinion Research response 
rates (AAPOR RR#4) (The American Association for Public Opinion Research, 2006) for 
breast, prostate, and colorectal cancer  patients were 68%, 64%, and 61% respectively. 
The survey questionnaire was designed following literature review, patient interviews, 
and expert consultation. These questionnaires were mailed to participants based on 
Dillman’s procedure for mail surveys (Dillman & Dillman, 2000). Further details of the 
data collection and survey instrument development procedures are described fully 
elsewhere (Nagler, Gray, et al., 2010). The university’s institutional review board 
approved the study.  
Measures  
Exposure to DTCA was operationalized as patients’ self-reported frequency of 
encountering three different types of ads since their cancer diagnosis: 1) treatment 
alternatives for cancer, 2) drugs for dealing with side effects of treatment, and 3) 
hospitals or doctors offering services for cancer. Responses for each survey item ranged 
along a 5-level scale (never, less than every month, about twice a month, about once a 
week, almost every day). To allow easier interpretation of these response options in the 
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descriptive analyses, each response choice was recoded to represent the frequency of 
encountering the aforementioned ads per week (i.e., 0, 0.2, 0.5, 1, and 7 respectively). An 
overall exposure to DTCA was computed by adding participants’ responses to the three 
survey items (ranging from 0 to 21). Of the 2013 participants, 369 were not asked these 
questions on DTCA exposure because they randomly received a short version of the 
questionnaire with fewer items as part of another study (Kelly, Fraze, & Hornik, 2010). 
An additional 150 to 228 respondents for each of the three DTCA exposure items were 
missing because of item non-response. Therefore, data on overall DTCA exposure was 
available for 1505 or 75% of the initial sample.  
Potential predictor variables of exposure to DTCA were participants’ age, sex, 
ethnicity, education, marital status, and AJCC/UICC stage of cancer at diagnosis 
(Greene, American Joint Committee on Cancer, & American Cancer Society, 2002) 
(derived from cancer registry data). Of the 2013 participants, missing values for predictor 
variables ranged from 3 to 132 cases due to item non-response or insufficient information 
for cancer staging in the registry. All participants were included in the analyses described 
below. 
Analyses 
Descriptive analyses were performed using SPSS version 20.0 (IBM Corp, 2011) 
to describe the distributions of frequency of exposure to each category of ads and the 
overall frequency of exposure to DTCA across the three cancer types. Initial analyses 
showed that these variables were not normally distributed (skewness ranged from 2.05 to 
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3.61; kurtosis ranged from 2.40 to 11.74; all univariate Shapiro-Wilk tests were 
significant at p < 0.0005). Pairwise comparisons of exposure to each category of ads and 
overall exposure to DTCA between cancer types were performed with the Kruskal-Wallis 
tests corrected for Type I errors using the Bonferroni approach. Multivariate analyses 
were performed using the Mplus software (Muthén & Muthén, 1998) to fit full 
information maximum likelihood (FIML) models predicting the overall exposure to 
DTCA within each cancer type. Research has demonstrated that the FIML technique is 
superior to ad hoc methods for dealing with missing data in predictor variables (e.g., 
listwise deletion, pairwise deletion, mean imputation) and has the benefits of reducing 
bias and sampling variability in multiple regression models (Enders & Bandalos, 2001; 
Enders, 2001). Huber-White covariance adjustments were applied to the estimated 
standard errors as these are robust to non-normality in the data. The models applied post-
stratification sample weights to adjust the final sample to represent the patient population 
from the cancer registry in terms of race, age, gender, marital status, time of diagnosis, 
and stage at diagnosis; adjust for survey non-response; and account for the oversampling 
of certain subgroups of patients.  
Results 
 Table 4.1 summarizes the characteristics of the overall sample and patients within 
each cancer type. Overall, the average age of the sample was 66 years, half was female, 
44% had some college education or higher, 83% were white, 67% were married, and 71% 
had early stage cancer (stages 0 to II). Approximately equal numbers of patients from 
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each of cancer type were represented in the sample. Additional details by cancer type are 
available in Table 4.1.  
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Table 4.1 Demographic Characteristics Of Study Participants By Cancer Type 
 
 
All patients  
(n=2013) 
Breast  
(n=679) 
Prostate  
(n=650) 
Colorectal 
(n=684) 
 % or M (SD) % or M (SD) % or M (SD) % or M (SD) 
Age at diagnosis (years)a 66.1 (12.4) 60.8 (13.4) 66.9 (9.6) 66.6 (12.6) 
Femalea 50.9 100.0 0.0 50.6 
Education levelb     
   High school and lower 56.5 53.9 53.0 62.6 
   Some college and higher 43.5 46.1 47.0 37.4 
Race     
   White 83.1 83.1 80.5 85.5 
African-American  12.8 12.8 15.2 10.4 
Hispanic and other 4.2 4.1 4.3 4.1 
Marital statusb      
   Not married 32.9 42.0 21.3 35.0 
   Married 67.1 58.0 78.7 65.0 
Stage of diseasec      
   Stage 0-II 71.0 77.9 77.2 58.0 
Stage III  12.9 6.6 6.0 25.9 
Stage IV  16.1 15.4 16.8 16.1 
 
Note. a3 missing values.  
b34 missing values. 
c132 missing values. 
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Figure 4.1 displays the distribution of overall exposure to DTCA in the study 
sample. The summary statistics of exposure to each category of ads and overall exposure 
to DTCA for the study sample and within each cancer type are presented in Table 4.2. 
The overall reported exposure to DTCA in the sample was modest (M=2.6 times per 
week, SD=4.3, median=once per week). However, a small proportion of the sample 
(16.1%) reported having more substantial exposure to DTCA ads of seven times a week 
or more. Based on the Kruskal-Wallis test (corrected for Type I errors using the 
Bonferroni approach), the distribution of overall exposure to DTCA among breast cancer 
patients was significantly different from those of prostate and colorectal cancer patients 
(all ps<.0005). Several pairwise comparisons of the distributions of exposure to each 
category of DTCA also showed significant differences across cancer types (all ps<.0005). 
For ads about treatment alternatives, exposure among breast and prostate cancer patients 
differed from colorectal cancer patients. The exposure to ads about dealing with side 
effects was significantly different in all pairwise comparisons between these three cancer 
types. In addition, the distribution of exposure to ads on hospitals or doctors for breast 
cancer patients differed significantly when compared with those of prostate and 
colorectal cancer patients.  
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Figure 4.1 Distribution Of Overall Weekly Exposure To Cancer-Related Direct-To-
Consumer Advertising (n=1505) 
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Table 4.2 Distribution Of Weekly Exposure To Cancer-Related Direct-To-Consumer Advertising By Cancer Type 
   
All patients 
(n=1505)  
Breast 
(n=511)  
Prostate 
(n=470)  
Colorectal 
(n=524) 
  M (SD) Median  M (SD) Median  M (SD) Median  M (SD) Median 
Treatment alternatives (0 to 7)  0.7 (1.6) 0.2  0.9 (2.0) 0.2  0.5 (1.2) 0.2  0.5 (1.4) 0.2 
Dealing with side effects (0 to 7)  0.7 (1.7) 0.2  1.1 (2.1) 0.2  0.4 (1.2) 0.0  0.7 (1.6) 0.2 
Hospitals or doctors (0 to 7)  1.3 (2.3) 0.5  1.9 (2.7) 0.5  0.8 (1.7) 0.2  1.2 (2.2) 0.5 
             
Summed exposure (0 to 21)  2.6 (4.3) 1.0  3.7 (5.3) 1.4  1.7 (2.9) 0.7  2.2 (4.1) 0.7 
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Table 4.3 presents the multivariate models predicting overall DTCA exposure for 
patients diagnosed with breast, prostate, or colorectal cancers. Older patients consistently 
reported less frequent overall exposure to DTCA across the three cancer types (decreased 
frequency of exposure between 0.03 to 0.06 times per week for each additional year in 
age). Among prostate cancer patients, African-American patients reported encountering 
DTCA 1.1 times per week more than white patients. Prostate cancer patients with 
advanced disease (stage IV) reported encountering DTCA 0.9 times per week more than 
patients with stages 0 to II. Conversely, colorectal cancer patients who identified as 
Hispanic or other groups reported being exposed to 1 ad/week less than white patients. 
Across the three cancer types, the explanatory power of these multivariate models was 
small (R2 ranged from 3% to 6%). 
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Table 4.3 Predictors Of Summed Weekly Exposure To DTCA By Cancer Type 
 Breast cancer (n=679) Prostate cancer (n=650) Colorectal cancer (n=684) 
Predictor variables B 95% CI B 95% CI B 95% CI 
Age at diagnosis 
(years) -0.063** -0.101 - -0.024 -0.044*** -0.067 - -0.020 -0.031* -0.058 - -0.004 
Gendera – Female -    -    0.715 -0.096 - 1.526 
Educationb – Some 
college and higher -0.358 -1.419 - 0.702 0.196 -0.258 - 0.649 -0.324 -1.178 - 0.529 
Race-ethnicityc             
African-American  0.812 -0.774 - 2.398 1.121** 0.281 - 1.960 1.131 -0.222 - 2.483 
Hispanic and other 0.521 -2.244 - 3.285 -0.388 -1.217 - 0.442 -1.073* -1.905 - -0.241 
 Marital statusd – 
Married -0.288 -1.491 - 0.916 0.014 -0.596 - 0.625 -0.155 -1.043 - 0.734 
Stage of diseasee              
Stage III  0.002 -2.469 - 2.473 -0.121 -0.836 - 0.594 0.445 -0.501 - 1.391 
Stage IV  0.673 -0.620 - 1.965 0.900** 0.261 - 1.539 0.786 -0.638 - 2.209 
Intercept 7.629    4.101    3.121    
             
R-squared 0.031    0.060    0.034    
 
Notes. B denotes weighted full information maximum likelihood estimates of unstandardized coefficients.  
*p<.05; **p<.01; ***p<.001.  
aMale is the reference category. 
bHigh school and lower is the reference category. 
cWhite is the reference category 
dNot married is the reference category 
eStage 0 to II is the reference category (because there were no prostate cancer patients with stages 0 or I) 
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Discussion 
In this study population, patients diagnosed with breast, prostate, or colorectal 
cancers reported modest levels of exposure since their diagnosis to DTCA that concern 
cancer treatment alternatives, dealing with side effects of treatments, and hospitals or 
doctors offering cancer treatment services. Median frequency ranged from 0 to 0.5 times 
per week for each type of ad. The overall exposure to DTCA was correspondingly low 
(median frequency ranged from 0.7 to 1.4 times per week out of a maximum of 21). This 
level of reported exposure to DTCA is consistent with an earlier study reporting cancer 
patients being treated for breast or hematologic malignancies were aware of a small 
number of advertised cancer medications (median of 3 out of a list of 24 medications 
advertised in print magazines) (Abel et al., 2009). The low levels of overall exposure 
observed in this present study further corroborates findings that ad spending for DTCA is 
generally much lower than DTCA for other conditions (Bell, Kravitz, & Wilkes, 2000; 
Donohue et al., 2007; Larson et al., 2005; M. B. Rosenthal et al., 2002; Welch Cline & 
Young, 2004; Wilkes et al., 2000; Woloshin et al., 2001). Although concerns that DTCA 
may have substantial impact on patient outcomes appear less worrisome given the modest 
exposures reported in this patient population as a whole, increasing trends of various 
forms of DTCA in oncology through diverse channels warrant continued monitoring of 
patient’ exposures. Furthermore, this study found that about 16% of the study population 
reported encountering DTCA seven times per week, which can be considered a 
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substantial amount of exposure for deliberate public health communication. The impact 
of DTCA on this group of patients deserves careful study.  
The analysis shows that patients diagnosed with breast cancer tend to report more 
frequent DTCA exposure than prostate or colorectal cancer patients. Earlier content 
analyses found that general DTCA and cancer-related DTCA are more likely to target 
female audiences or occur in female-oriented print magazines (Abel et al., 2007; Bell, 
Kravitz, et al., 2000). Therefore, one interpretation of this finding could be female cancer 
patients are reporting higher DTCA exposures than male cancer patients. However, the 
multivariate analysis among colorectal cancer patients indicated that gender is not a 
significant correlate of DTCA exposure, meaning the differences observed in this study is 
more likely a function of differences between cancer type than of gender-based targeting. 
Potential reasons could be higher ad spending on breast cancer-specific treatments (e.g., 
anastrazole for breast cancer in women) leading to variations in cancer patients 
encountering ads that are most salient for their diagnosis. Future research should consider 
comparing the extent of cancer-specific DTCA and assessing the potential disparities 
between patients with various cancer types in terms of patient awareness of approved 
treatments, patient-provider discussions, and treatment decision-making. 
The multivariate analysis of correlates of exposure to DTCA across cancer types 
suggest that there is little evidence of communication disparities arising from DTCA 
exposure across several patient characteristics. With the exception of age, the variation in 
exposure to DTCA was not explained consistently by patient characteristics among 
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patients with the three cancer types. For instance, while older patients consistently report 
lower exposures across all cancer types, patient ethnicity is correlated to DTCA exposure 
only among prostate and colorectal cancer patients. The implications for these observed 
disparities in exposures on patient outcomes are uncertain at this point. Varying 
recommendations for treatment, availability of safe and effective treatment options, and 
risk versus benefit considerations for an advertised treatment or service for the different 
cancer types and stages of disease complicate drawing implications from these 
disparities. For instance, if an advertised treatment is appropriate based on treatment 
guidelines, patients who report less exposure to such DTCA might be less aware and less 
likely to receive this treatment. Conversely, if an advertised service entails greater risks 
and costs but is no more effective than standard care, patients who have higher ad 
exposure and pursue this treatment may be harmed.  
A recent study by Abel and colleagues in the context of breast cancer treatment 
offers an example for assessing the implications of disparities in exposures (Abel et al., 
2013). The authors reported that overall spending on DTCA for aromatase inhibitors 
(anastrozole, exemestane, and letrozole) is associated with a small but significant 
increase in appropriate prescriptions for women diagnosed with breast cancer (i.e., 
women aged above 60 years) at the population level. Conversely, ad spending is not 
associated with an increase in inappropriate prescriptions (those for women aged below 
40 years) (Abel et al., 2013). If older breast cancer patients are less exposed to DTCA 
about aromatase inhibitors as might be implied in this present study, the age disparity in 
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exposure could have a meaningful impact on older patients’ receipt of such medications. 
Similar considerations depending on the specific treatment and cancer type and patient 
subgroup may yield different implications.  
There are some limitations in this study. First, the sample is limited to cancer 
patients within the state of Pennsylvania. It is plausible that interstate variations in DTCA 
by cancer facilities may occur due to varying levels of competition between local or 
regional cancer centers. Future research involving a national sample of cancer patients 
may be necessary to detect if geographical variation in DTCA exposure is present. 
Second, there are limitations associated with the survey measures of DTCA exposure. 
Patients had to summarize their encounters of categories of ads and were not asked to 
recall specific advertised treatments. In contrast, Abel and colleagues measured 
awareness to specific cancer prescription drugs advertising by listing 24 specific 
medications that have appeared in print magazines (Abel et al., 2009). Furthermore, the 
questions asked for recall of exposure to DTCA “since diagnosis” and that ranged 
between 9 to 21 months prior to their responding. The measures may also be subject to 
recall bias leading to under-reporting (e.g., if patients fail to recall exposure from over a 
year ago) or over-reporting (e.g., if patients telescoped their exposure to include non-
cancer DTCA or across a longer period of time). Despite these limitations, the validation 
study in this research (Study 1) offers evidence that the survey items for measuring 
exposure used here in Study 2 compares favorably with more detailed versions across 
multiple validity criteria.  Still, additional research would be necessary to validate self-
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reported exposure to DTCA with objective data including ad buys of DTCA on various 
media channels (television, newspapers or magazines, radio, and internet). Such data on 
DTCA spending at the aggregate level has been used extensively in prior research on 
DTCA for cancer and other illnesses (Abel et al., 2013; Bradford et al., 2006; Donohue & 
Berndt, 2004; Law, Majumdar, & Soumerai, 2008). Third, there may be potential 
confounders that are not included in these analyses due to constraints of survey length. 
Future research should incorporate a wider array of predictor variables.  
This study is strengthened by a few design characteristics. First, although limited 
to Pennsylvania, the population-based sample of cancer patients across three cancer types 
compares favorably to earlier studies conducted with population-based samples who are 
predominantly healthy and for whom DTCA was not personally salient (Aikin et al., 
2004; Bell, Kravitz, et al., 1999; DeLorme, Huh, & Reid, 2006; Deshpande et al., 2004; 
Finney Rutten et al., 2012; Murray et al., 2004; Sumpradit et al., 2002; Weissman et al., 
2003; Wilkes et al., 2000). In addition, this study also represents a more diverse sample 
of cancer patients when compared to studies that also focused on cancer patients but were 
limited by convenience samples of patients treated within a single hospital (Abel et al., 
2009). Third, the study examines additional categories of DTCA including treatment 
alternatives and hospitals or doctors offering treatment services. This enables a more 
comprehensive assessment of cancer patients’ exposures to these additional forms of 
cancer treatment advertising that are increasingly prevalent (American Medical 
Association, 2006; Jin et al., 2011; Larson et al., 2005; E. T. Rosenthal, 2010a). In 
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contrast, earlier research focused predominantly on DTCA of prescription medications, 
imaging services, or genetic testing (Abel et al., 2007; Finney Rutten et al., 2012; Illes et 
al., 2004).    
 In conclusion, this study finds that frequency of overall exposure to cancer-related 
DTCA among a population-based sample of cancer patients in Pennsylvania is modest. 
However, continued monitoring of the content, ad spending, and patient awareness to 
various types of DTCA is recommended as some patients reported substantial frequency 
of exposure. There is minimal evidence of major communication disparities in terms of 
DTCA exposure across several patient characteristics. While patients’ exposure to DTCA 
differs across cancer types and age, other patient characteristics are not consistently 
associated with DTCA exposure. 
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Chapter 5 HOW IS EXPOSURE TO DIRECT-TO-CONSUMER ADVERTISING 
ASSOCIATED WITH ACTIVE HEALTH INFORMATION SEEKING 
BEHAVIORS? RESULTS FROM A LONGITUDINAL ANALYSIS AMONG 
CANCER PATIENTS (STUDY 3) 
Abstract 
Previous research on the communication impact of exposure to direct-to-
consumer advertising (DTCA) of prescription treatments largely focused on patients’ 
inquiry about specific treatments or requests for these prescriptions as outcome 
behaviors. In contrast, the spillover effect of DTCA exposure on general health 
information seeking behaviors is less well-studied. The first part of this study examines 
the effects of exposure to cancer-related DTCA on subsequent health information seeking 
behaviors from clinician and non-clinician sources among a population-based panel of 
cancer patients. The analyses indicate that exposure to DTCA is significantly associated 
with increased levels of patients’ subsequent active health information seeking from their 
clinicians at one year follow-up, controlling for prior seeking behavior and potential 
confounders. In addition, exposure to DTCA is marginally significant in predicting active 
health information seeking from non-clinician (lay media and interpersonal) sources. 
Guided by the Integrative Model of Behavioral Prediction, the second part of this study 
conducts a focused analysis on psychosocial mechanisms through which DTCA may 
influence information seeking from non-clinician sources among cancer patients. This 
analysis shows a significant indirect path between DTCA exposure and subsequent 
information seeking from non-clinician sources at one year follow-up, mediated through 
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attitudes and intention toward active information seeking from these sources. Research, 
practice, and policy implications of this investigation are discussed. 
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Introduction 
 The ongoing debate over the benefits and harms of direct-to-consumer advertising 
(DTCA) of medical treatments has spawned a significant amount of research over the 
past three decades aimed at dissecting the impact of this unique form of public health 
communication on patients, healthcare providers, and the broader healthcare ecosystem 
(for comprehensive reviews of this debate, see Almasi, Stafford, Kravitz, & Mansfield, 
2006; Auton, 2004, 2006; Gilbody, Wilson, & Watt, 2005; Harker & Harker, 2007; 
White, Draves, Soong, & Moore, 2004). From a health communication perspective, this 
accumulating body of research has accomplished much in terms of piecing together 
important insights on the content and effects of DTCA on a variety of psychosocial 
outcomes, communication behaviors, and relationships between patients and their 
physicians (Aikin et al., 2004; Bell, Kravitz, et al., 1999; Deshpande et al., 2004; Murray 
et al., 2004). The overall evidence appears to support viewing DTCA as a potentially 
beneficial communication strategy—if harnessed appropriately to minimize potential 
harms—that could shift the process of healthcare delivery away from a paternalistic 
physician-centered model to a more patient-centered model that emphasizes shared 
decision-making (Almasi et al., 2006; Deshpande et al., 2004; Harker & Harker, 2007). 
This is echoed in a recent essay by Beltramini (2010, p. 574) summarizing the impact of 
DTCA research on the field of health communication: “consumers have been empowered 
with additional information to “level the field” with the health care community, 
contributing to more efficient doctor-patient exchanges”. 
89 
 
 How DTCA might empower consumers and “level the field” in terms of health 
and medical information is the subject of this present inquiry. Despite the large body of 
DTCA research—a systematic review in 2005 identified 2835 publications on DTCA 
(Gilbody et al., 2005)—significant gaps remain in two main areas. These include the 
understanding of implications of DTCA on important communication behaviors among 
patients and studying theoretically grounded mechanisms for possible effects of DTCA 
on communication behaviors.  
The majority of DTCA communication research focuses on whether DTCA 
influences patients to inquire specifically about an advertised drug or to request a 
prescription for the medication from their providers (Aikin et al., 2004; An, 2007; Bell, 
Wilkes, Kravitz, & others, 1999; Deshpande et al., 2004; Herzenstein et al., 2004; 
Khanfar, Polen, & Clauson, 2009; A. L. Lee, 2009; Liu et al., 2005; Mendonca, 
McCaffrey, Banahan, Bentley, & Yang, 2011; Murray et al., 2004). This line of research 
has important implications for clinical practice because it informs various stakeholders 
including regulators and health professionals concerned with adverse changes in patient-
physician relationships or undue pressure leading to inappropriate prescribing; patients 
who are exposed to DTCA and receiving prescription treatments they may not need; and 
advertisers who wish to know if the advertising campaign was effective in generating 
drug sales.  
Largely unstudied is the potentially beneficial spillover effects of DTCA in 
prompting health information seeking about an advertised treatment and about other 
important information relevant to managing the illness. In economic theory terms, these 
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spillover effects are termed as positive externalities. Some examples of additional seeking 
include seeking information related to illness prevention, screening and diagnosis for new 
health symptoms, or non-drug ways to improve health (Calfee, 2002, p.185-186). 
Notably, this concept of broad-based information seeking across health topics is widely 
recognized in the field of health communication to be an essential determinant that 
influences numerous health behaviors and outcomes (e.g., preventive health behaviors, 
health screening, illness coping, and psychosocial outcomes). The impact of health 
information seeking has been observed across individual and population levels in various 
disease contexts including cancer care (Brashers, Goldsmith, & Hsieh, 2002; Cegala et 
al., 2008; Cline & Haynes, 2001; Czaja, Manfredi, & Price, 2003; Dutta-Bergman, 2004; 
Finney Rutten, Squiers, & Hesse, 2006; Johnson & Case, 2012; Kelly, Hornik, et al., 
2010; Lambert & Loiselle, 2007; J. Niederdeppe et al., 2007; Shim, Kelly, & Hornik, 
2006; Tian & Robinson, 2008).  
The first part of this present study is an attempt to address these research gaps in 
DTCA communication research by examining the associations between DTCA exposure 
and patients’ general health information seeking behaviors in a population-based panel of 
cancer patients (Study 3A). In particular, this analysis centers on two active information 
seeking behaviors—patient-clinician information engagement and active information 
seeking from non-clinician sources. The second part of this study (Study 3B) is guided by 
the Integrative Model of Behavioral Prediction (IM) (Fishbein & Ajzen, 2010; Fishbein 
& Yzer, 2003; Fishbein, 2000, 2008) and elaborates the findings in Study 3A by 
exploring potential psychosocial mechanisms for the associations between DTCA 
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exposure and information seeking behaviors from non-clinician sources. The following 
sections describe the extant literature, research hypotheses, and analyses of these two 
studies separately. These are followed by a discussion of the overall findings and 
implications for future research and practice surrounding DTCA and patient 
communication behaviors. 
Study 3A Main Effects of DTCA Exposure on Information Seeking Behaviors 
DTCA and Health Information Seeking Behaviors 
It is unsurprising to expect DTCA to stimulate information seeking specific to the 
advertised treatment; after all, that is one of the primary objectives of product advertising. 
But it is less obvious to expect that DTCA would also influence patients to seek more 
generally about coping with one’s health condition or to search for related information 
such as prevention and alternative treatment options.  
Nonetheless, the idea that DTCA might motivate general health information 
seeking appears at least plausible for a few reasons. First, ads for prescription treatments 
are required by the Food and Drug Administration (FDA) guidelines on broadcast DTCA 
to include “adequate provisions” to refer consumers to doctors and pharmacists for more 
information as well as detailed product information through a website, toll-free number, 
and print ads (FDA, 1999, p.326-328). For the most part, to comply with these FDA 
provisions, DTCA frequently encourages viewers to ask their doctor if an advertised 
treatment is appropriate for their condition (e.g., “Ask your doctor if XGEVA is right for 
you to prevent these serious bone problems caused by bone metastases”). More relevant 
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for this research, DTCA may also include more general messages for viewers to ask their 
doctor about health symptoms and conditions apart from promoting seeking about the 
medication (e.g., “Quitting isn’t easy; and when willpower isn’t enough, it’s time to talk 
to your doctor” in an ad for Chantix, a prescription medication for smoking cessation).  
Another reason for assuming DTCA’s potential effects on general health 
information seeking is derived from prior studies that conducted content analyses on a 
variety of DTCA of prescription drugs. These studies systematically quantified the 
ubiquitous presence of cues or messages directing patients to look for drug-related 
information and also general health information about the condition from different 
sources. For instance, Kaphingst and colleagues (2004) analyzed the content of 23 
broadcast ads for prescription drugs which were indicated for a variety of illnesses and 
appeared on national television networks. All 23 ads included statements encouraging 
viewers to seek for more information from other sources. As expected, the majority of 
ads directed viewers to look for more information about the advertised drug (20 ads). All 
the ads contained references to available additional information about the advertised 
product through print ads (e.g., in consumer magazines), product website addresses, or 
toll-free telephone numbers. In addition to promoting information seeking about the 
advertised drugs, over half of the ads (13 ads) were coded as containing broader 
statements that asked viewers to seek “more information” in general about the health 
condition without specifying what topics the viewers should seek about. The most 
common sources of information referred to in these ads were doctors and pharmacists. 
Another study by Bell and colleagues (Bell, Kravitz, et al., 2000) analyzed 320 unique 
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magazine print ads of 101 brands of prescription medications that were indicated for 
different illnesses. The researchers coded these ads for the presence of offers for where to 
get additional information about the drug or health condition available in print or 
audiotape/video form and reported that 35% of these ads (112 ads) contained these offers 
for more information. In another study, Abel and colleagues (2007) analyzed 49 unique 
magazine print ads for 22 cancer-related medications. In contrast to Bell et al. (Bell, 
Kravitz, et al., 2000), they found that 84% of these cancer-related ads (41 ads) mentioned 
where to get more information about the advertised drug and about the condition more 
generally, most frequently through a web site. These latter two studies were limited by 
the coding for the inducements for additional information as it was not possible to 
distinguish between ads offering additional sites for more information about the 
medication only from those that also offered information about the health condition more 
generally. Admittedly, evidence from DTCA content analyses cannot establish whether 
patients would perceive these vague inducements to be encouraging them to seek more 
broadly about their illness.  
In the course of searching for specific information about an advertised drug, 
patients may also be inclined to search for overlapping health information relevant for 
their health condition. Evidence from national consumer surveys partially supports the 
notion that DTCA would prompt patients to seek more general information about their 
health condition and treatment from their healthcare provider or other information 
channels. National surveys conducted by the U.S. Food and Drug Administration (FDA) 
indicated most consumers agreed that DTCA increased their awareness of new drugs 
94 
 
(77%) (Aikin et al., 2004, p.3). A sizable proportion of consumers (43%) reported DTCA 
prompted them to look for more information about the advertised drug and also about 
their health condition from their healthcare provider, reference books, interpersonal 
contacts, and the internet (Aikin et al., 2004, p.2). Correspondingly, Weissman and 
colleagues (2003) surveyed a national U.S. sample of 3000 adults and found that one in 
three (35%) respondents reported a prescription drug ad had previously prompted them to 
have a discussion about the advertised drug, a new health concern, or a possible change 
in treatment for an existing illness with their physician. The above survey items were 
limited by the inability to distinguish between being prompted to seek information about 
the advertised drug alone, seeking about one’s health condition alone, or seeking about 
both topics. Therefore it is unclear what proportion of respondents agreed that DTCAs 
prompted broader searches about the condition in general. 
Other studies among convenience patient samples added tentative support to the 
expectation of spillover informational effects of DTCA. In one study, Abel and 
colleagues (2009) surveyed patients undergoing active treatment for breast and 
hematologic cancers at a cancer institute. Over half of the patients (62%) agreed that 
cancer-related DTCA increased their awareness about treatments they did not know about 
previously and 57% agreed DTCA “led to better discussions about health or medical 
care” with their doctor or nurse. Bell and colleagues (2010) further found that among a 
convenience sample of participants of an online depression support group, over half 
(53%) reported they visited official websites of advertised antidepressants, 40% had 
talked to their doctor about a specific brand or about antidepressants in general, and 18% 
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talked to a friend or family member about possibly having depression. While the first two 
communication behaviors are more directed at seeking about the advertised medications, 
the last behavior is more clearly about discussion with others about health concerns apart 
from the advertised treatment.  
Additional evidence comes from a study by Iizuka and Jin (2005) that reported 
aggregate levels of DTCA media expenditure were associated with administrative data of 
physician visits in a nationally representative sample of patients. The study estimated that 
every $28 increase in DTCA spending led to one additional physician visit within 12 
months. However, the study was not designed to provide details about the content of 
patient-physician discussions during these additional visits, only that they had occurred in 
association with higher DTCA spending. 
In sum, prior literature based on content analysis, patient surveys, and 
administrative data analysis offer limited support for the potential effect of DTCA on 
health information seeking behavior that could comprise specific information seeking 
about an advertised treatment and also about the health condition in general. Drawing 
from the above literature review, this study posits the following research question: 
RQ1: How is exposure to DTCA associated with patients’ active health 
information seeking? 
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Methods 
Study Population 
Data was obtained from part of a longitudinal population-based study on cancer-
related information engagement behaviors and health outcomes among cancer patients in 
Pennsylvania. The overall study population comprised patients who were diagnosed with 
breast, prostate, or colorectal cancers and were notified to the Pennsylvania Cancer 
Registry in 2005. The Pennsylvania State Health Department granted permission to 
access patient data for this research. Patients with one of these three cancer types were 
randomly invited to participate in the round 1 survey in September 2006, approximately 9 
to 21 months after their diagnoses. Following the initial phase of data collection, an 
oversample of colorectal cancer patients, those with Stage IV disease, and African 
American patients was added to facilitate planned subgroup analyses (not presented 
here). A total of 2013 participants (679 breast cancer patients, 650 prostate cancer 
patients, and 684 colorectal cancer patients) completed the round 1 survey. The American 
Association for Public Opinion Research response rates (AAPOR RR#4) (AAPOR, 2006) 
for breast, prostate, and colorectal cancer  patients were 68%, 64%, and 61% 
respectively. In the fall of 2007, one year after they were first surveyed, 1293 respondents 
(64.2% of participants from round 1) completed a follow-up survey (round 2). Non-
response to the round 2 survey was due to refusal to be re-contacted after round 1 (255 
patients; 12.7%) and non-response to a repeat mailed survey at round 2 (465 patients; 
23%).  
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Survey questionnaires were designed following literature review, patient 
interviews, and expert consultation. Questionnaires were mailed to participants based on 
a standardized procedure for mail surveys (Dillman & Dillman, 2000). Briefly, a notice 
letter with the study objectives and opt-out instructions were first mailed to potential 
participants, followed by the survey, a small monetary incentive (either $3 or $5 in round 
1 and $3 in round 2), and a stamped envelope to return survey questionnaires. For 
participants who did not indicate their wish to opt out of the study and had not returned 
the survey 2 weeks later, an additional letter and survey was mailed to them. Further 
details of the data collection and survey instrument development procedures are 
described fully elsewhere (Kelly, Fraze, et al., 2010; Martinez et al., 2009; Nagler, Gray, 
et al., 2010; Smith-McLallen, Fishbein, & Hornik, 2011; Tan, Bourgoin, Gray, 
Armstrong, & Hornik, 2011). The university’s institutional review board approved the 
study.  
Measures  
Prior research suggests that seeking information from physician or health 
professional sources is a distinct and complementary communication behavior compared 
to seeking information from sources other than one’s health care provider (Dutta-
Bergman, 2004; Finney Rutten et al., 2006; C. J. Lee, 2008, 2009; Ling, Klein, & Dang, 
2006; Nagler, Romantan, et al., 2010; Tian & Robinson, 2008). Therefore, to evaluate the 
first research question that DTCA would predict increased health information seeking, 
two separate outcome measures were included—patient-clinician information 
engagement and information-seeking from non-clinician sources, both measured at round 
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2. The independent variable was exposure to DTCA since cancer diagnosis measured at 
round 1. Survey items for these variables are provided in Appendix C. Potential 
confounders in this analysis were prior PCIE and information-seeking from non-clinician 
sources, demographic variables, and disease characteristics, all measured at round 1. 
Patient-clinician information engagement (PCIE) is conceptualized as a measure 
of cancer survivors’ reported engagement with their physicians and other health 
professionals broadly about information related to their cancer that comprises treatments, 
quality of life issues, and other topics. The PCIE measure is adapted from a similar 
measure described in prior studies (Martinez et al., 2009; Tan, Moldovan-Johnson, 
Parvanta, et al., 2012; Tan et al., 2011). The PCIE variable comprised 6 binary items 
(yes/no) measured in the round 2 survey. Participants were asked to recall if they 1) 
actively looked for information about their cancer (about treatments but also about other 
topics) from their doctors, 2) actively looked for information about their cancer from 
other doctors or health professionals, 3) actively looked for information about quality of 
life issues from their doctors, 4) actively looked for information about quality of life 
issues from other doctors or health professionals, 5) discussed information from other 
sources with their doctors, and 6) received suggestions from their doctors to go to other 
sources for more information. The average of these 6 items formed the PCIE scale at 
round 2 (Cronbach’s α=0.73). Parallel survey items measured in round 1 of the survey 
were averaged into PCIE scale at round 1 (Cronbach’s α=0.69). It should be noted that 
while these survey items do not elicit patients’ information seeking about an advertised 
cancer treatment, some of the items may conceivably capture patients’ underlying 
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engagement with their clinicians about a specific ad that they have encountered (e.g., 
items 1 and 2 ask about looking for information about treatments while item 5 ask about 
discussing other sources with doctors). 
Information seeking from non-clinician sources is conceptualized as a measure of 
cancer survivors’ seeking from sources other than their clinicians about information 
related to their cancer including treatments, quality of life issues, and other topics. This 
measure comprised 20 items in the round 2 survey and was adapted from a similar 
measure described in previous research (Lewis et al., 2011; Tan, Moldovan-Johnson, 
Gray, Hornik, & Armstrong, 2012). Participants were asked to recall if they actively 
looked for two topics (information about their cancer or information about quality of life 
issues) from 10 different sources (family members, friends or co-workers; other cancer 
patients; face-to-face support groups; online support groups; telephone hotlines; 
television or radio; books, brochures or pamphlets; newspapers or magazines; internet 
other than personal email or online support groups; or other). The average of these 20 
items formed the information seeking from non-clinician sources scale at round 2 
(Cronbach’s α=0.82). In the same way, matching survey items in round 1 were averaged 
to form the information seeking from non-clinician sources scale at round 1 (Cronbach’s 
α=0.81). As in the PCIE measure, information seeking from non-clinician sources may 
also capture patients’ active seeking about an advertised treatment from these sources. 
This multi-item scale differs substantively from the variable analyzed in the study by 
Smith-McLallen and colleagues (2011). That study utilized a binary measure categorizing 
patients as seekers (sought from at least one source other than doctors or health 
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professionals about issues related to their cancer) or nonseekers (did not seek from any 
source or only from a doctor or health professional) and did not include information 
seeking about quality of life issues.  
Exposure to DTCA is operationalized as frequency of encountering DTCA since 
cancer diagnosis. Participants were asked at round 1: “Since your cancer diagnosis, how 
often have you seen or heard advertisements concerning each of the following? Check all 
that apply.” Responses to three items (treatment alternatives for cancer, dealing with side 
effects of treatment, and hospitals or doctors offering services for cancer) along a 5-level 
scale (never, less than every month, about twice a month, about once a week, almost 
every day) were averaged to form the exposure to DTCA scale at round 1 (Cronbach’s 
α=0.72).  
Potential confounders of the observed associations between DTCA recall and 
PCIE or information seeking from non-clinician sources at round 2 included prior PCIE 
and seeking from non-clinician sources at round 1, demographic variables (age, sex, 
race/ethnicity, and education level) and disease characteristics (cancer type, stage, health 
status, and worry about cancer (Lerman et al., 1991)) found in prior studies to be 
significant predictors of information engagement behaviors (Nagler, Gray, et al., 2010) or 
of exposure to DTCA (Study 2). Cancer stage was derived from the Pennsylvania Cancer 
Registry and corresponded to the American Joint Committee on Cancer / International 
Union Against Cancer TNM classification (Greene et al., 2002). All other covariates 
were based on self-reports in the round 1 survey. 
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Analyses 
Bivariate analyses were first performed to assess cross-sectional associations 
between exposure to DTCA at round 1 and the dependent variables (PCIE and 
information seeking from non-clinician sources) at round 2. The assumption of linearity 
for the relationships between each of the outcome variables and exposure to DTCA was 
evaluated through visual inspection of the respective scatterplots and tests of linearity. 
The loess curves of the scatterplots approximated linear relationships closely. 
Furthermore, tests of linearity were significant for the bivariate relationships between 
each of the information seeking variables at Round 2 and exposure to DTCA in Round 1 
(all Ps<.0005). The eta-squared and R-squared values for both associations were close in 
value (difference of 0.014 in both instances). Tests of deviation from linearity were not 
statistically significant.  
Multivariate analyses were performed using the Mplus software version 7 
(Muthén & Muthén, 1998) to fit full information maximum likelihood (FIML) models 
predicting PCIE and information seeking from non-clinician sources at round 2 with 
exposure to DTCA in round 1. To address the concern about causal direction and 
potential spuriousness in inferences about these associations, lagged analyses were 
performed controlling for the corresponding information engagement behaviors at round 
1 and other potential confounders.  
The FIML technique is reported to be superior to ad hoc methods for dealing with 
missing data in predictor variables (e.g., listwise deletion, pairwise deletion, mean 
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imputation) and has the benefit of reducing bias and sampling variability in multiple 
regression models (Enders & Bandalos, 2001; Enders, 2001). Missingness in the 
predictor and mediator variables mainly involved DTCA exposure (25%), attitudes 
(29%), PNP (25%), PBC (24%), and intentions (24%). These missing values were largely 
because 369 patients were randomly selected to answer a short version of the 
questionnaire in round 1 that excluded these items. Missing values for PCIE and 
information seeking at both rounds 1 and 2 were minimal (1-2%).  
Huber-White covariance adjustments were applied to the estimated standard 
errors to adjust for non-normality in the data. The models applied post-stratification 
sample weights to adjust the final sample to represent the patient population from the 
Pennsylvania Cancer Registry in terms of race, age, gender, marital status, time of 
diagnosis, and stage at diagnosis; adjust for survey non-response; and account for the 
oversampling of certain subgroups of patients. This permitted inferences to be made 
about the broader population of patients with colon, breast, or prostate cancer in 
Pennsylvania based on the present analyses. The analyses with and without sampling 
weights were substantively identical. Therefore, only the weighted analyses are reported 
here. 
Results 
Table 5.1 summarizes the distribution of the key measures and characteristics of 
the study population. The average age of the study participants at round 1 was 66 years, 
51% was female, 44% had some college education or higher, 83% were white, 67% were 
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married, and 71% had early stage cancer (stages 0 to II). Approximately equal numbers 
of patients from each of cancer type were represented in the sample (684 colon cancer 
patients, 679 breast cancer patients, and 650 prostate cancer patients). Preliminary 
univariate analyses revealed that the distribution of the information seeking and DTCA 
exposure variables were non-normal (skewness ranged from -0.866 to 1.040; kurtosis 
ranged from -1.229 to 0.498; all univariate Shapiro-Wilk tests were significant at 
p<.00005).  
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Table 5.1 Summary Statistics And Characteristics Of Study Population At Round 1 
(N = 2013) 
 
Range Mean SD % 
Principal variables (Study 3A) 
 
   
Exposure to DTCA at round 1 1.00 to 5.00 2.41 1.02 
 
Patient-clinician information engagement (PCIE) at 
round 2 0.00 to 1.00 0.29 0.28  
Information seeking from non-clinician sources at 
round 2 0.00 to 1.00 0.14 0.16  
Mediator variables (for information-seeking from 
non-clinician sources) (Study 3B)     
Attitude at round 1 -3.00 to 3.00 -0.15 1.98 
 
Perceived normative pressure at round 1 -3.00 to 3.00 -0.61 1.93 
 
Perceived behavioral control at round 1 -3.00 to 3.00 1.16 1.92 
 
Intention at round 1 -3.00 to 3.00 -0.92 2.16 
 
Control variables 
    
Patient-clinician information engagement (PCIE) at 
round 1 0.00 to 1.00 0.51 0.29  
Information seeking from non-clinician sources at 
round 1 0.00 to 1.00 0.20 0.17  
Age (years) 
 
66.2 12.4 
 
Sex 
    
     Female 
   
50.9 
     Male 
   
49.1 
Race/Ethnicity 
 
   
White 
 
  
83.1 
African-American 
 
  
12.8 
Hispanic or other race/ethnicity 
 
  
4.2 
Education 
 
   
High school or below 
 
  
56.5 
Some college or above 
 
  
43.5 
Cancer Type 
 
   
Breast cancer 
 
  
33.7 
Prostate cancer 
 
  
32.3 
Colon cancer  
 
  
34.0 
Lerman Cancer Worry Scale (not at all to almost all 
the time) 1.00 to 5.00 2.43 1.00 
 
Cancer Stage 
    
     Stage 0 to II 
   
71.0 
     Stage III 
   
12.9 
     Stage IV 
   
16.1 
Health Status (poor to excellent) 1.00 to 5.00 3.11 0.94 
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From the bivariate correlation analyses, exposure to DTCA at round 1 is 
significantly associated with PCIE at round 2 (Pearson’s r=0.213, p<.00005) and seeking 
from non-clinician sources at round 2 (Pearson’s r=0.288, p<.00005). Table 5.2 
summarizes the weighted FIML models predicting PCIE and information seeking form 
non-clinician sources at round 2 with exposure to DTCA at round 1, controlling for the 
respective information engagement behaviors measured at round 1 and other potential 
confounders. The results show that exposure to DTCA at round 1 is significantly 
associated with subsequent PCIE (unstandardized coefficient B=0.023, 95% CI = 0.005 
to 0.040, p = 0.012). However, the association between exposure to DTCA and 
information seeking from non-clinician sources at round 2 is marginally significant, 
although as follow-up analyses reported below will show, the indirect path from DTCA 
to information seeking from non-clinician sources reaches the conventional level of 
significance. Other significant predictors for both analyses are prior PCIE or information 
seeking from non-clinician sources at round 1, education level (higher active seeking 
with some college or higher education), race/ethnicity (higher active seeking in African-
American compared to white patients), and cancer-related worry.  
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Table 5.2 Predicting Patient-Clinician Information Engagement (PCIE) And Information Seeking From Non-clinician Sources 
At Round 2 (N=1293) 
  PCIE at round 2  Seeking at round 2 
Independent variables  B 95% CI p  B 95% CI p 
DTCA at round 1  0.023 0.005 - 0.040 0.012  0.009 -0.001 - 0.018 0.067 
PCIE at round 1  0.348 0.291 - 0.405 <0.001  -     
Seeking at round 1  -      0.466 0.410 - 0.522 <0.001 
Age  0.001 -0.001 - 0.002 0.334  0.000 0.000 - 0.001 0.361 
Education             
   Some college or higher  0.043 0.013 - 0.074 0.005  0.015 0.000 - 0.030 0.056 
Race/Ethnicity             
   African-American  0.090 0.038 - 0.142 0.001  0.041 0.011 - 0.071 0.008 
   Hispanic or other  0.026 -0.047 - 0.099 0.486  0.015 -0.033 - 0.064 0.533 
Cancer Type             
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   Female colon cancer  0.043 -0.014 - 0.099 0.139  0.021 -0.006 - 0.048 0.120 
   Breast cancer  0.040 -0.011 - 0.091 0.123  -0.004 -0.027 - 0.019 0.709 
   Prostate cancer  0.024 -0.029 - 0.078 0.377  -0.024 -0.047 - -0.001 0.038 
Lerman Cancer Worry Scale  0.039 0.021 - 0.057 <0.001  0.013 0.004 - 0.022 0.003 
Cancer Stage             
   Stage III  0.051 -0.007 - 0.110 0.084  -0.009 -0.033 - 0.014 0.431 
   Stage IV  0.071 0.016 - 0.126 0.011  0.013 -0.013 - 0.038 0.329 
Health Status  -0.003 -0.021 - 0.014 0.700  -0.001 -0.010 - 0.008 0.772 
Constant  0.161      0.044     
             
R2  0.243       0.348    
 
Notes. Full information maximum likelihood models presented here; B refers to unstandardized maximum likelihood coefficients; 
referent group for education level is high school and below; referent group for race/ethnicity is white; referent group for cancer type is 
male colon cancer; cancer type and gender was combined into a single variable to reflect the different gender-specific cancer types 
(breast and prostate cancers); referent group for cancer stage is stage 0-II. 
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Study 3B Mediational Analysis of DTCA Exposure on Information Seeking from 
Non-Clinician Sources Through Integrative Model Variables 
Extending from the above findings described in Study 3A, Study 3B explores 
potential psychosocial mechanisms for the associations between DTCA exposure and 
information seeking behaviors. I first review prior literature on the psychosocial 
pathways of DTCA effects on patients’ inquiry about the advertised medication to draw 
general hypotheses about theoretical mechanisms between DTCA exposure and health 
information seeking behaviors more broadly. Next, guided by the Integrative Model of 
Behavioral Prediction (IM), I elaborate specific hypotheses about the relationships 
between DTCA exposure, IM variables, and active information seeking and test these 
hypotheses with a structural equation modeling approach. 
Psychosocial Mediators of DTCA Effects on Drug Information Seeking 
Prior research relied on wide-ranging theoretical models or constructs in 
examining psychosocial mechanisms through which DTCA may influence health 
knowledge acquisition in consumers. For example, in a series of content analyses based 
on Social Cognitive Theory to evaluate visual and textual cues of DTCA, Welch Cline 
and Young (2004, 2005) reported frequent occurrences of cues that modeled identity 
rewards (e.g., models depicted as healthy, active, or friendly in the ads) and relational 
rewards (e.g., models depicted as a family or as romantic partners) in conjunction with 
the advertised product. The authors posited that these cues served as vicarious motivators 
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for patients to either find out more about the advertised treatment or to seek treatment for 
symptoms similar to those in the ads. Subsequent survey research by the same authors 
among young women further suggested that positive outcome expectancies of discussing 
about an advertised drug with their physicians were associated with increased intention to 
communicate with physicians about the drug (H. N. Young et al., 2005). However, the 
study did not elaborate on the role of outcome expectancies of discussing health 
information more generally in predicting patient-physician discussions about health 
concerns. 
Grounded in the Theory of Planned Behavior and Self-Efficacy Theory, Liu and 
colleagues (2005) found that attitudes and subjective norms toward seeking drug 
information from physicians and pharmacists predicted intention to seek from these 
sources among a sample of patients with osteoarthritis. In contrast, only attitudes toward 
seeking drug information from the internet predicted intention to seek from the internet. 
Perceived difficulty was not predictive of intentions to seek from all three sources. 
Moreover, as predicted by the theoretical models, intentions predicted actual behavior of 
seeking drug information from all three sources at 6-weeks follow-up. Similar to the 
studies by Welch Cline and Young (Welch Cline & Young, 2004; H. N. Young et al., 
2005; H. N. Young & Welch Cline, 2005), the study was focused on specific drug 
information seeking behaviors and did not examine parallel models to explain patients’ 
general information seeking about osteoarthritis.  
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Deshpande and colleagues (2004) investigated a shared decision-making model of 
public perceptions of DTCA and showed that more favorable opinions about DTCA 
utility (a scale derived from items asking participants to rate their agreement with three 
statements of whether DTCA allowed people to be more involved with their health care, 
make decisions about prescription medicines, and educate people about risks and benefits 
of prescription medicines) were associated with increased likelihoods of engaging in drug 
inquiry behavior about a drug with physicians, requesting a drug from physicians, and 
inquiring about a medical condition or illness. Of particular relevance to the present 
dissertation research is the finding that positive opinion about DTCA utility was 
associated with an increased odds of 2.12 times that respondents utilized ad information 
to talk to their doctor about a medical condition. In comparison, positive opinion of 
DTCA utility was associated with increased odds of 2.25 times that respondents used ad 
information to talk to their doctor about a prescription drug. The parallel findings suggest 
that similar pathways through opinions of DTCA utility may be operating in the 
associations between DTCA and drug inquiry or more general information seeking 
behaviors.  
Two recent studies examined the role of general attitudes toward DTCA on 
intentions to search for specific medication information. In the first, Herzenstein and 
colleagues (2004) found that favorable attitudes toward DTCA was associated with 
increased likelihood to search for more information about an advertised drug and 
increased likelihood to ask their physician about such a drug in a cross-sectional survey 
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among a national telephone sample of 1081 adults. Independently, the second study by 
An (2007) noted similar findings that positive general attitudes toward DTCA predicted 
higher intentions to ask doctors about a specific medication or advertised treatment in a 
cross-sectional telephone survey of 203 residents in a Midwestern town. 
To summarize, the majority of existing literature exploring the psychosocial 
mechanisms of DTCA effects on patient information seeking behaviors focused primarily 
on drug information seeking. There is limited empirical research available to identify the 
psychosocial mediators of DTCA effects on more general health information seeking 
related to patients’ condition. Study 3B is aimed at addressing this research gap to 
analyze whether similar pathways may be operating in explaining the associations 
between DTCA and broader health information seeking behaviors. 
The Integrative Model of Behavioral Prediction 
Extending from the findings in Study 3A and the prior research evidence on the 
predictors of drug inquiry behavior, this study explores the roles of psychosocial 
mediators of health information seeking guided by the Integrative Model (IM) of 
Behavioral Prediction—a model that is based on well-established explanatory models of 
health behaviors (i.e., Health Belief Model (Rosenstock, 1974), Theory of Reasoned 
Action/ Theory of Planned Behavior (Ajzen, 1991; Fishbein & Ajzen, 1975, 2010), and 
Social Cognitive Theory (Bandura, 1986)).  
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The IM specifies a causal pathway between one’s intention to perform a behavior 
and the actual engagement in the behavior. Additionally, behavioral intention is theorized 
to be influenced by individuals’ underlying attitudes toward the behavior, perceived 
normative pressure (PNP) to perform the behavior, and perceived behavioral control 
(PBC) associated with enacting the behavior. Intention is operationalized as an 
individual’s self-reported likelihood of performing a behavior in a future timeframe. 
Intention is further defined in terms of specific time, action, context, and target to be 
compatible with the behavior of interest. Attitude toward the behavior is defined as 
“degree to which a person has a favorable or unfavorable evaluation or appraisal of the 
behavior in question” (Ajzen, 1991, p.188) (i.e., whether performing the behavior would 
be good or bad for oneself, beneficial or harmful, wise or foolish). PNP is a person’s 
“perceived social pressure to perform or not to perform the behavior” (Ajzen, 1991, 
p.188) or whether important others think one should or should not perform the behavior 
and whether others who are similar are also performing the behavior. PBC refers to 
“people’s perception of the ease or difficulty of performing the behavior of interest” 
(Ajzen, 1991, p183), that is whether someone believes that he or she would have the 
ability to perform the behavior and that it would be under his or her control to engage in 
the behavior. 
Based on these constructs of attitudes, PNP, and PBC from the IM, Smith-
McLallen and colleagues (2011) conducted an earlier study using the same data source as 
this present analysis to examine the predictors of cancer patients’ information seeking 
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from sources other than their doctor. The analysis showed that attitudes, PNP, and PBC 
were significantly associated with intentions to seek information. In addition, consistent 
with the predictions in the IM, intentions to seek information predicted actual behavior or 
information seeking at one-year follow-up. This present study aims to build on the above 
analysis in assessing the relationships between DTCA exposure and these IM constructs 
and evaluating whether the IM variables mediate the association between DTCA 
exposure and active information seeking. 
Applying the above IM constructs to this present study, DTCA exposure is 
hypothesized to influence attitudes, PNP, and PBC regarding active information seeking 
in the following ways. For instance, spokespersons featured in DTCA may serve as role 
models for patients to actively engage with their physicians to talk about their health 
condition. These portrayals of patient-doctor discussions convey positive outcome 
expectations about the health information seeking that are associated with positive 
attitudes toward the behavior. They may also influence perceived descriptive norms that 
other patients in a similar situation are likely to consult their doctor for information about 
treatment options. DTCA may further improve behavioral control through observing 
spokespersons enacting discussions effectively in the ad. In addition, DTCA may offer 
additional information aimed at empowering patients’ ability or self-efficacy to discuss 
with their doctor about their condition. Existing DTCA for prescription drugs serve to 
illustrate the potential mechanisms through these IM constructs. For example, in an ad for 
Detrol LA (tolterodine), an actor depicted having overactive bladder symptoms. She 
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modeled the behavior of navigating a dedicated website (DetrolLA.com) that provided 
tips on how she could get the discussion started with her physician about her symptoms. 
The ad concluded with this actor having improved symptoms and the message to “Have 
the Detrol Discussion with your doctor”. A second example is the Chantix ad described 
earlier in Study 3A. In these examples, the main message was for viewers to talk to their 
physician about their symptoms and secondarily about whether the advertised medication 
would be appropriate for them. In both cases, cues corresponding to positive outcome 
expectancies, descriptive norms, and self-efficacy associated with enacting information 
seeking (e.g., about tips to manage health concerns or about how to discuss a health 
concern with one’s doctor) are featured in varying extents and may potentially influence 
patients’ attitudes, PNP, and PBC regarding information seeking behaviors. 
The above review of prior literature precludes generalizing from the observed 
psychosocial mechanisms underlying DTCA effects on drug inquiry to explain DTCA 
effects on general information seeking behaviors. Thus far, there is insufficient research 
directly related to general information seeking following DTCA exposure. However, 
conceptually there is an argument to be made that seeking information about an 
advertised treatment, while a distinct behavior, may be a subset of general cancer-related 
information seeking. Therefore, it is reasonable to assume that parallel mechanisms may 
be operating in the relationship between DTCA and general information seeking, 
mediated through the IM constructs of attitudes, PNP, and PBC. Furthermore, existing 
examples of broadcast DTCA indicate the presence of cues that correspond closely with 
 these IM constructs pertaining to general information seeking behaviors.
study proposes to test the following hypothes
H1: The association between DTCA and active health information seeking would 
be mediated by the
5.1 for a graphical representation).
 
Figure 5.1 Hypothesized Mediation Model Predicting Information Seeking From 
Non-clinician Sources At Round 2
Notes. DTCA = cancer-related direct
normative pressure; PBC = perceived behavioral control; all predictor
variables are measured at round 1 of the survey; each path implied in the above model 
was adjusted for information seeking at round 1 and other confounders (age, education, 
race/ethnicity, cancer type, gender, Lerman worry scale, cancer stage
which are omitted in the figure for clarity; disturbance terms of attitudes, PNP, and PBC 
are specified to be correlated with one other.
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is: 
 psychosocial constructs of the Integrative Model (see Figure 
 
 
-to-consumer advertising exposure; PNP = perceived 
 and mediator 
, and health status) 
 
Therefore, this 
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Method 
Study Population 
The study population for Study 3B is as described in Study 3A above. This 
analysis utilized data from Rounds 1 and 2 of the longitudinal survey among breast, 
prostate, and colorectal cancer patients in Pennsylvania. 
Measures 
 To test the above mediation hypothesis, IM variables included intention, attitudes, 
perceived normative pressure (PNP), and perceived behavioral control (PBC) associated 
with information-seeking from non-clinician sources, all measured at round 1. Due to 
survey constraints, parallel IM measures for patient-clinician information engagement 
were not collected in this study and are not tested here. 
The IM variables are defined as described in an earlier study with this data source 
by Smith-McLallen and colleagues (2011). Survey items for these variables are provided 
in Appendix C. Intention to actively seek information from non-clinician source was 
measured with a single item: “How likely is it that you will actively seek information 
about issues related to your cancer from a source other than your doctor in the next 12 
months?” along a 7-point scale (anchored between unlikely to likely).  
Attitudes comprises three semantic differential items that asked participants if 
their actively seeking information about issues related to their cancer from a source other 
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than their doctor in the next 12 months would be “useless/useful”, “unenjoyable/ 
enjoyable”, and “foolish/wise” along a 7-point scale. The average of these three items 
formed the attitude scale (Cronbach’s α=0.89).  
Perceived normative pressure (PNP) is the average of ratings of two statements 
along a 7-point scale from “disagree” to “agree”: “Most people who are important to me 
think I should actively seek information about issues related to my cancer from a source 
other than my doctor in the next 12 months” and “Most people like me (e.g., other cancer 
patients) actively seek information about issues related to their cancer from a source other 
than their doctors” (inter-item correlation r=0.53).  
Perceived behavioral control (PBC) is the average of ratings of two items. The 
first item asked participants if their actively seeking information from a source other than 
their doctor in the next 12 months would be “not up to me/ up to me”. The second item 
asked participants to rate the statement “If I really wanted to, I could actively seek 
information about issues related to my cancer from a source other than my doctor in the 
next 12 months” along a 7-point scale from “disagree” to “agree” (inter-item correlation 
r=0.37). All above mediator variables were measured at round 1 and ranged from -3 to 3. 
Analyses 
The structural equation model implied in Figure 1 is fitted using the Mplus 
software to assess the mediation hypothesis. In short, exposure to DTCA is modeled to 
predict attitudes, PNP, and PBC associated with information seeking from non-clinician 
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sources at round 1. Consistent with the IM, these constructs are modeled to predict 
intention at round 1 which in turn predicts information seeking from non-clinician 
sources at round 2. As recommended by Preacher and Hayes (2008, p.882), covariances 
between the IM constructs (attitudes, PNP, and PBC) are permitted by specifying 
correlations between the disturbance terms of these endogenous variables. The model 
further controls for prior information seeking from non-clinician sources at round 1 and 
potential confounders and applies post-stratification sample weights as described in the 
earlier section. Model goodness of fit is assessed using a combination of indices 
including the overall χ2 test of model fit, comparative fit index (CFI), Tucker-Lewis 
Index (TLI), root mean square error of approximation (RMSEA), and the standardized 
root mean square residual (SRMR). Parameter residuals and modification indices are 
inspected for areas of poor fit and examined for theoretically supported alternative 
models.  
Results 
  Figure 5.2 summarizes the results from the mediation analysis testing the indirect 
effects of DTCA exposure on information seeking from non-clinician sources through the 
IM variables. Standardized parameter estimates for the structural coefficients are 
presented along with the unstandardized estimates in parentheses. The overall χ2 test for 
model fit is statistically significant (χ2(5)=14.948, p=0.011). However, this test is 
sensitive to large sample sizes (Kline, 2011). Other indices of model fit suggest that the 
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model is a reasonably good fit to the observed data RMSEA=.031, CFI=.995, TLI=.924, 
SRMR=.007). An inspection of residuals and modification indices did not reveal 
theoretically meaningful points of poor fit in the model and the hypothesized model is 
retained. The analysis shows that controlling for prior information seeking from non-
clinician sources and potential confounders, intention at round 1 is a significant predictor 
of active seeking from non-clinician sources at round 2. Attitudes and PNP are 
significantly associated with intention but PBC is not significantly associated with 
intention. DTCA exposure is significantly associated with all three IM constructs of 
attitudes, PNP, and PBC related to active seeking from non-clinician sources. Table 5.3 
displays standardized estimates of the indirect mediational chains from DTCA exposure 
through the IM variables to information seeking from non-clinician sources based on the 
structural model. The results show that the total indirect path from DTCA through the IM 
variables is statistically significant and suggest evidence partially supporting Hypothesis 
2. Of the three possible mediated pathways, the indirect effect from DTCA through 
attitudes and intention is statistically significant while the indirect effect through PNP and 
intention approaches significance.  
  
 Figure 5.2 Mediation Model Predicting Information Seeking From 
 
Notes. Model fit was assessed based on the overall 
other fit indices (RMSEA=.031, CFI=.995, TLI=.924, SRMR=.007); DTCA = cancer
related direct-to-consumer advertising exposure; PNP = perceived normative pressure; 
PBC = perceived behavioral control; all predictor and mediator variables are measured at 
round 1 of the survey; sta
coefficients in parentheses) based on full information maximum likelihood models are 
presented here; *p<.05, **p<.01, ***p<.0005; each path implied in the above model was 
adjusted for information seeking at round 1 and other confounders (age, education, 
race/ethnicity, cancer type, gender, Lerman worry scale, cancer stage, and health status) 
which are omitted in the figure for clarity; error terms of attitudes, PNP, and PBC are 
assumed to be correlated with one other.
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Table 5.3 Indirect Effects Of Exposure Cancer-Related Direct-To-Consumer 
Advertising (DTCA) On Information Seeking From Non-clinician Sources At 
Round 2 (N=2013) 
Paths  b 95% CI p 
     
DTCA to Attitude to Intention to Seeking  0.007 0.001 - 0.012 0.017 
DTCA to PNP to Intention to Seeking  0.002 0.000 - 0.005 0.067 
DTCA to PBC to Intention to Seeking  -0.001 -0.001 - 0.000 0.176 
Total indirect effects  0.008 0.002 - 0.015 0.016 
 
Notes. b refers to standardized maximum likelihood estimates of indirect effects through 
each path; DTCA = cancer-related direct-to-consumer advertising exposure; PNP = 
perceived normative pressure; PBC = perceived behavioral control; the model controlled 
for prior information seeking at round 1 and other confounders (age, education, 
race/ethnicity, cancer type, gender, Lerman Cancer Worry Scale, cancer stage and health 
status) which are omitted in the table for clarity. 
 
Discussion 
Much of the controversy surrounding the societal value and risks of DTCA 
centers around the argument over the idea that patients’ interests are better served with 
this form of public health communication. From a patient empowerment standpoint, 
proponents contend that DTCA places valuable health information in the hands of 
patients, fosters a patient-centered model of health care delivery, and strengthens patient-
physician communications by emphasizing patients to be active participants in managing 
their health conditions and treatment decisions (Calfee, 2002; Holmer, 1999, 2002). 
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Opponents counter that reliance on DTCA, which is at heart motivated by profit 
generation for advertisers and manufacturers, to perform such a crucial public education 
role would be a “haphazard approach to health promotion” (Hollon, 2005) and could 
undermine the public’s health (Avorn, 2003; Hollon, 1999; Wilkes et al., 2000).  
This current study offers new empirical evidence to inform the ongoing debate of 
the communication impact of DTCA by assessing the spillover effect of DTCA on cancer 
patients’ active health information seeking behaviors from clinicians and non-clinician 
sources. The analyses in Study 3A indicate that exposure to DTCA is significantly 
associated with subsequent cancer patients’ active information seeking from physicians 
and other health professionals. In comparison, the relationship between DTCA exposure 
and subsequent information seeking from non-clinician sources approaches significance. 
The first substantive finding supports the inference that DTCA about cancer 
treatment is associated with the beneficial externalities of increasing patient information 
engagement with health professionals about general cancer-related information, 
consistent with such benefits outlined in a review about DTCA in general by Calfee 
(2002). This finding supplements earlier empirical evidence from patient or consumer 
surveys that showed associations between DTCA and information inquiry about 
advertised medications (Abel et al., 2009; Aikin et al., 2004; Bell et al., 2010; Weissman 
et al., 2003). A related assumption made here is increased patient-clinician 
communication about health information is a beneficial outcome for patients’ well-being 
and this assumption is supported by previous theorizing and empirical findings from this 
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research group and elsewhere (Epstein & Street Jr., 2007; Martinez et al., 2009; Mello, 
Tan, Armstrong, Schwartz, & Hornik, 2012; Street Jr. & Epstein, 2008; Street Jr. et al., 
2009).  
The current study contributes new evidence to the debate on the societal value of 
DTCA by emphasizing that DTCA may have a previously unmeasured and unintended 
benefit of gradually shifting the paradigm of a paternalistic health care delivery model to 
a patient-centered one by encouraging patients to be more active participants in 
understanding their health condition and treatment options (Beltramini, 2010; Deshpande 
et al., 2004). This inference about possible DTCA externalities invites consideration of 
the potential implications on practice and policy regulations surrounding DTCA. On one 
hand, the inference would lend support to the argument by proponents that DTCA 
indirectly benefits patients by encouraging broader health information seeking behaviors. 
As a result, policies governing DTCA should be relaxed to promote greater dissemination 
of valuable health information to consumers (Calfee, 2002). On the other, the question 
arises as to whether there might be more cost-effective and direct means than DTCA to 
achieve improved patient information seeking from health professionals (Avorn, 2003).  
One limitation in Study 3A is the information seeking measures may have 
included patients’ drug inquiry behaviors as well. The outcome measures therefore do not 
clearly distinguish between specific information seeking about advertised cancer 
treatments from seeking about other health topics related to cancer (e.g., other treatment 
options or quality of life issues). However, it is unlikely that the seeking measures are 
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fully accounted for by patients’ inquiries about advertised treatment alone. First, the 
survey items asked participants about their seeking of broad topics over the course of 12 
months and not just about advertised treatments. Moreover, multiple items pertain to 
seeking information about quality of life issues and these are less likely to overlap with 
drug inquiry behaviors. Third, unlike prior studies that relied on single items to elicit the 
impact of DTCA on patient behaviors (e.g., “Has an advertisement for a prescription drug 
prompted you to talk to your cancer doctor or nurse about a drug for yourself?” (Abel et 
al., 2009)), this research relies on independent items for DTCA exposure and information 
seeking behaviors. There is less risk that participants were only responding about their 
seeking of information about advertised treatment in answering the survey items on 
active information seeking. Despite these reasons, future surveys should consider 
designing items that measure patients’ inquiry about advertised treatments independently 
from patients’ health information seeking about other cancer-related topics following 
DTCA exposure. 
This research further draws on the IM to identify the psychosocial mechanisms 
that may account for the relationship between DTCA exposure and health information 
seeking behaviors. Expanding from the findings in Study 3A and relying on available 
survey items related to information seeking from non-clinician sources, the analyses in 
Study 3B found an indirect mediation pathway between DTCA exposure and active 
seeking from non-clinician sources through patients’ attitudes and intention associated 
with seeking from these sources. This analysis points to an inference about a potential 
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mediational pathway for the influence of DTCA on information seeking behaviors 
through favorable attitudes about active information seeking and intention to seek cancer-
related information from non-clinician sources. These findings corroborate those reported 
in earlier research describing the roles of similar psychosocial constructs (e.g., favorable 
outcome expectancies or attitudes toward DTCA) in predicting intention or behaviors of 
drug inquiry and prescription requests (An, 2007; Deshpande et al., 2004; Herzenstein et 
al., 2004; Liu et al., 2005; H. N. Young et al., 2005). The accumulated evidence so far 
offers intriguing insights into one possible underlying mechanism to explain the spillover 
effects of DTCA on patients’ health information seeking behaviors. These insights may 
generate additional research hypotheses for programmatic research to study the 
communication effects and pathways of DTCA.  
Due to survey limitations, parallel IM measures for patient-clinician 
communication were not available to test a similar mediation pathway leading from 
DTCA exposure to active seeking from clinician sources. Additional research to examine 
whether corresponding patterns of mediation by IM constructs may be required. Building 
on the present study, a follow-up content analysis may be directed at describing the 
prevalence and content of specific DTCA messages that are likely to be associated with 
the IM constructs of attitudes or perceived norms about engaging in active health 
information seeking. Documenting the presence of these messages linked to the 
theoretical constructs systematically would strengthen the explanatory inference of the 
observed relationships between exposure to DTCA and attitudes, PNP, and PBC in this 
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study. Despite the efforts to establish temporal order and controlling for prior information 
seeking and other potential confounders, the causal direction between DTCA exposure 
and the IM constructs remain unclear since these variables were all measured at round 1. 
For instance, it is plausible that attitudes about information seeking may have led to 
patients’ recalling more DTCA exposures. Another follow-up study may focus on 
assessing the causal relationship between DTCA exposure, IM constructs, and 
information seeking behaviors using an experimental design to compare patients’ 
information seeking behaviors following random assignment to a treatment condition 
receiving DTCA (e.g., embedded in patient-directed health magazines) or a control 
condition receiving no DTCA. Findings from the follow-up would provide additional 
evidence about the causal relationships between DTCA and information seeking 
behaviors through the IM constructs.  
It is essential to exercise caution in interpreting these results more generally to be 
applicable for all forms of DTCA or across diverse types of patients with different health 
conditions. Because the severity, nature of treatment, and characteristics of afflicted 
patients may differ dramatically across various health conditions, it is plausible that the 
relationships observed in this study among cancer patients may not be identical for other 
patient populations. To illustrate, cancer treatment is considerably more complex, often 
requires care across multiple specialties, and involves significant risks and adverse effects 
compared to other forms of treatments that commonly appear in DTCA. Instead of 
advertising limited to just prescription medications, cancer treatment advertising also 
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extends to marketing campaigns by health care providers (e.g., physicians, hospitals, or 
comprehensive treatment centers) and ads related to non-drug therapies such as 
radiosurgery. Further research would be necessary to investigate if the relationships 
observed in this study may be replicated in other health conditions and patient 
populations before drawing more general inferences about overall DTCA effects on 
health information seeking behaviors. Another limitation in this study, inherent in survey 
research, is the reliance on self-reported measures for exposure to DTCA and other 
principal variables, which may be subject to recall bias (Schutt, 2009). A separate study 
evaluated the validity of the DTCA exposure measure used in this present research 
among an independent sample of cancer patients and is described earlier (Study 1).  
This present study differs from previous research on informational effects of 
general DTCA that strengthens the study inferences in a few ways. First, recognizing the 
unique context of cancer treatment in comparison to other disease conditions, this study 
focuses on the effects of exposure to a specific subset of advertising (i.e., cancer-related 
DTCA) among cancer patients. This ensures that the DTCA exposure in question is 
highly salient for the study population. In contrast, earlier research typically measured 
exposure to DTCA in general among healthy consumers for whom the DTCA may have 
little salience (Aikin et al., 2004; Weissman et al., 2003). Second, prior surveys tended to 
rely on cross-sectional survey designs in analyzing associations between DTCA exposure 
with information seeking behaviors or psychosocial measures. These surveys were 
therefore limited in their ability to untangle the causal direction of the associations. In 
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comparison, this study relies on panel data to establish temporal order between DTCA 
exposure and information seeking behaviors and further controls for prior information 
seeking behaviors as means to strengthen inferences about the causal direction. Third, the 
majority of research on DTCA effects has insufficiently integrated study findings within 
theoretical frameworks to inform future research programs. This study is an attempt to 
add to the understanding of DTCA influences on communication behaviors using the IM 
approach.  
In sum, this study analyzes the effects of exposure to DTCA on subsequent 
cancer-related health information seeking behaviors (from health professionals and non-
clinician sources) in the context of cancer treatment advertising in a population-based 
panel of cancer patients. The findings show that increased exposure to DTCA 
significantly predicts increased levels of active health information seeking from health 
professionals. DTCA is marginally significant in predicting information seeking from 
non-health professional sources and attitudes and intention toward active information 
seeking mediate this relationship. These results offer important insights into the practice 
and policy debate surrounding DTCA and stimulate additional research questions to 
explore theoretical mechanisms of the impact of DTCA on patient communication 
behaviors.  
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Chapter 6 EXPLORING COMMUNICATION INEQUALITIES ASSOCIATED 
WITH EXPOSURE TO CANCER-RELATED DIRECT-TO-CONSUMER 
ADVERTISING IN CANCER SURVIVORS (STUDY 4) 
Abstract 
This study draws from the Structural Influence Model of Communication as a 
framework to explore potential communication inequalities arising from patients’ 
exposure to cancer-related direct-to-consumer advertising (DTCA). The model posits that 
communication inequalities associated with cancer-related DTCA may arise at three 
distinct but related levels: 1) certain groups may be less likely to gain exposure to DTCA, 
2) differential attention and processing of DTCA may occur, and 3) some groups may not 
engage in additional information seeking after viewing DTCA. These inequalities, if 
substantial, may in turn propagate disparities in cancer outcomes in certain disadvantaged 
patient populations. Earlier studies from this dissertation research and prior literature 
support the claim that there are inequalities in exposure to cancer-related DTCA across 
various patient characteristics. However, studies that examine attention and processing or 
additional information seeking following DTCA exposure show mixed results regarding 
inequalities in these communication outcomes. To contribute to the literature in 
communication inequalities associated with public health information, this study analyzes 
the moderation effects of age, educational level, race/ethnicity, and cancer type on the 
associations between cancer patients’ reported exposure to DTCA and their active 
information seeking behaviors from their clinicians or from non-clinician sources of 
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health information. Based on a series of cross-sectional and lagged analyses of 
longitudinal survey data from a population-based sample of 2013 cancer patients from 
Pennsylvania, the results do not suggest that the association between DTCA exposure and 
active information seeking behaviors are contingent on patients’ age, educational level, 
race/ethnicity, or cancer type. Implications on the debate about communication 
inequalities of DTCA and suggestions for future research questions are discussed.  
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Introduction 
 Recent critical reviews and extant research surrounding both general and cancer-
related direct-to-consumer advertising (DTCA) highlight increasing concerns that given 
the presence of communication inequalities among different social groups in the 
population (e.g., by class, race, ethnicity), these forms of advertising may inadvertently 
result in widening disparities in cancer outcomes between social groups. In a review 
focusing on the potential for disparate effects of cancer-related DTCA in the population, 
Kontos & Viswanath (2011) advocated “…closer and critical scrutiny of the effects of 
DTCA and other types of marketing communications on a variety of cancer-related 
outcomes, including patient engagement, patient-provider relationships, adherence, 
compliance and treatment outcomes, is warranted.” Thus far, few empirical studies have 
directly assessed the presence of social inequalities of cancer-related health behaviors or 
outcomes in association with DTCA exposure despite the prevalence of consumer 
advertising of medical products and services for the past thirty years. 
 The previous study of this dissertation project (Study 3) examined whether cancer 
survivors’ exposure to cancer-related DTCA predicted subsequent information seeking 
behaviors (i.e., patient-clinician information engagement (PCIE) and seeking from non-
clinician sources) and explored potential mechanisms for this relationship. The present 
study examines whether such DTCA may have disproportionate influences on cancer-
related information seeking behaviors across different social groups. I first summarize 
theoretical and practical justifications for expecting such differential effects by describing 
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various levels of communication inequalities based on a literature review. Next, I propose 
hypotheses and research questions testing specific moderating factors pertaining to 
DTCA exposure and information seeking behaviors. Following this, research methods 
and results based on an analysis using data from the Cancer Patient Survey (2006 and 
2007) are described. Finally, implications of the findings for future research, practice, and 
policies relevant to DTCA will be discussed. 
Structural Influence Model of Communication 
Kontos & Viswanath (2011) described the Structural Influence Model of 
Communication as a framework to study disparities in health communication and the 
roles these disparities play in mediating relationships between social determinants (e.g., 
race, education, and income), access to healthcare resources, and more distal health 
outcomes (e.g., health behaviors, adherence, and treatment outcomes). As outlined in an 
earlier chapter, the underlying premise for this model is the notion that “control of 
communication is power and that whoever has the capacity to generate, access, use and 
distribute information enjoys social power and advantages that accrue from it”. 
According to the model, communication inequalities that may lead to health outcomes 
disparities include differences between social groups in terms of their: 1) exposure, 2) 
attention, 3) external information seeking, and 4) processing of health information.  
Applying concepts of this model to the studying the population impact of cancer-
related DTCA, Kontos & Viswanath (2011) hypothesized communication inequalities 
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associated with DTCA may arise at three distinct but related levels: 1) certain groups may 
be less likely to gain exposure to DTCA, 2) differential attention and processing of 
DTCA may occur, and 3) some groups may not engage in additional information seeking 
after viewing DTCA. If such inequalities exist, DTCA may have differential effects on 
cancer outcomes between certain groups of patients. One concrete example is if some 
groups were more likely to be exposed to DTCA or attend to such ads, they may be more 
aware of a wider variety of effective treatment options available for their cancers than 
others. Second, if certain groups were better able than others to process the risk and 
benefit information of advertised treatments for their specific cancer diagnosis conveyed 
in DTCA, they may be more likely to participate more actively in shared treatment 
decision-making with their physicians. Third, if some groups had greater access to 
resources for additional information seeking about advertised treatments, they may be 
better informed of potential side-effects and be more prepared to cope with these 
problems during treatment. These communication disparities may widen cancer outcomes 
disparities between these groups of patients. Therefore, research is necessary to assess 
whether certain groups of cancer patients have higher exposure to DTCA than others (as 
described in Study 2) and whether certain groups are more likely to engage in additional 
information seeking following exposure to DTCA (Study 4). 
Communication Inequalities and DTCA 
For the purposes of this research, communication inequalities among cancer 
survivors associated with DTCA are categorized broadly in terms of: 1) exposure, 2) 
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attention and information processing, and 3) external information seeking (adapted from 
Kontos & Viswanath (2011) and Viswanath et al., 2006). I discuss each of these levels of 
inequalities as they relate to DTCA and where relevant, implications of these inequalities 
for the present research on cancer survivors’ information seeking behaviors. 
First, opportunities for exposure to DTCA may differ between social groups and 
this in turn may lead to different levels of actual exposure. Disparities in exposure arise 
because ads tend to be intentionally placed in media outlets that target specific social or 
ethnic groups and not others. To illustrate, Omunuwa (2001) reported in a content 
analysis of women’s magazines that frequency and type of pharmaceutical ads differed 
depending on the target audience of magazines. The author found the overall number of 
pharmaceutical ads in white-oriented magazines exceeded those in black-oriented 
magazines by four to eight times during the study period. Additionally, ads in white-
oriented magazines but absent in black-oriented magazines promoted medications for 
conditions such as osteoporosis, menopause, Alzheimer’s disease, weight reduction, 
arthritis, high cholesterol, and tobacco cessation. In contrast, certain ads in black-oriented 
magazines did not appear in white-oriented magazines, including those that promoted 
antiviral treatment for HIV or oral contraception. It should be noted the study did not 
measure actual exposure among women across ethnic groups. Rather, the focus was on 
opportunity for exposure through magazines. It is possible that black women’s overall 
exposure to prescription ads may not differ appreciably from white women if they also 
read white-oriented magazines, which are more prevalent and widely circulated. Another 
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related reason for differential exposure across groups could be selective media use or 
limited access to certain media by different groups. One example of such a scenario is 
when a health service or treatment is advertised through the internet but certain groups 
would not view these ads because they are less likely to use the internet (e.g., those with 
lower educational attainment, low household income, and Hispanics are least likely to 
have access to the internet) (Kontos, Emmons, Puleo, & Viswanath, 2010). Together, 
selective placement by advertisers and selective media usage by groups may result in 
communication inequalities among cancer survivors and create situations where some 
groups are more likely to be exposed to DTCA while others are not. To the extent that the 
above exposure inequalities may be operating, this may lead to some groups benefitting 
disproportionately from the availability of DTCA compared to others in the population, 
and perpetuate further disparities in cancer outcomes. 
The second level of inequality is the presence of differential attention and 
processing of cancer treatment information presented in DTCA. One important reason for 
differential attention and information processing across groups is the high level of 
literacy demanded to comprehend content presented in many ads or supplemental 
information materials. This is supported by studies reporting that content in the majority 
of general DTCA of prescription medications (83%) exceeded the eighth-grade reading 
level typically recommended for the public (Chao, 2005). Correspondingly, Kaphingst et 
al. (2004) reported the average reading grade level of supplemental information for 
DTCA—print ads in magazines, drug manufacturer websites, and mailed brochures—was 
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in the high school range (grades 10.5-11.6) for main texts of these materials and in the 
college-level range (grades 13.7-14.1) for summary sections of materials. Another related 
issue for differential processing is the format of DTCA that typically emphasized benefits 
of products over risks involved (Kaphingst & DeJong, 2004). Particularly for those with 
limited literacy skills, existing DTCA formats which privilege promotion of benefits of 
medications may result in poorer comprehension of adverse side effects of advertised 
drugs. In a study among a convenience sample of 50 adults with limited literacy, 
researchers found respondents were less likely to answer comprehension questions about 
risks of three advertised drugs correctly than questions about benefits of these drugs 
(Kaphingst, Rudd, DeJong, & Daltroy, 2005). The interaction between health literacy 
level (as measured using the Rapid Estimate of Adult Literacy in Medicine or REALM 
score) and country of birth adds another complexity in predicting comprehension of 
information presented in DTCA in that study. Extending the results from these studies 
based on general DTCA of prescription medications, the implications for potential 
inequalities in attention and processing of cancer-related DTCA (not just about 
medications, but also about health providers and alternative treatments) by different 
groups would be concerns that cancer patients with average health literacy may find it 
difficult to understand and process treatment-related information in such advertising, 
assess the attendant risks of treatments, and make meaningful decisions about treatments 
based on their exposure to DTCA.  
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Third, additional health information seeking arising from cancer-related DTCA 
may differ between social groups, even with adequate exposure, attention, and processing 
of content in such DTCA. Given short durations of most televised DTCA (usually one 
minute or shorter), which precludes presentation of detailed or complex information 
about treatments, viewers are typically directed to find out more information from 
external sources (e.g., print ads, toll-free number, health providers, and manufacturer’s 
website). This is especially necessary for cancer-related DTCA because cancer treatments 
entail higher risks and can involve multiple complex decisions that include consultations 
with a variety of medical specialists. There is evidence to support the notion that health 
information seeking behaviors are driven by social determinants including education, 
social class, or ethnicity (Jeff Niederdeppe, 2008; Ramanadhan & Viswanath, 2006). One 
reason leading to differential information seeking is the issue of barriers to access media 
channels or medical advice. Barriers including time or financial costs associated with 
searching information on the internet or arranging for physician consultations may 
prevent certain social groups from seeking external information after viewing a specific 
cancer treatment ad. A related explanation is that differences in information seeking 
behavior are due to variations between groups in their ability or motivation to act on the 
information from DTCA. For instance, patients from low socioeconomic statuses are less 
likely to request advertised medications from their health providers (Parnes et al., 2009). 
This is partially attributable to medication costs being a substantial financial burden for 
these patients, thereby discouraging low-income patients from requesting advertised 
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brand-name medications. One key implication for the above disparity in the context of 
cancer survivors following exposure to DTCA is the potential that some vulnerable 
groups may miss getting important additional relevant information for their treatment 
decision-making process. If so, a crucial gap may arise between those who are seeking 
information and those who do not seek external information following DTCA exposure, 
leading to widened disparities in downstream cancer outcomes.  
To summarize, communication inequalities associated with cancer-related DTCA 
may arise at three distinct but related levels: 1) certain groups may be less likely to be 
exposed to DTCA, 2) differential attention and processing of DTCA may occur even with 
adequate exposure, and 3) some groups may not engage in additional information seeking 
after viewing DTCA. Arising from these inequalities, the concerns are that DTCA may 
have differential effects among certain social groups. For example, beneficial effects of 
DTCA information and knowledge may accrue disproportionately in one group and not in 
others. Conversely, detrimental effects of DTCA leading to inappropriate use of 
treatments may affect one group more than others due to differential processing and 
comprehension of the information. The net impact of these contingent effects is DTCA 
may exacerbate existing disparities in cancer outcomes.  
The Current Study 
Information-Seeking Behaviors in Cancer Survivors 
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This present study primarily addresses concerns arising from the third level of 
communication inequality described above—the potential for DTCA to generate higher 
levels of external information seeking behaviors in certain groups of cancer survivors and 
not others. Specifically, extending from the results in Studies 2 and 3 in this dissertation 
and relevant published literature, this study will assess the presence of moderation effects 
due to individual patient characteristics on the relationship between DTCA exposure and 
information-seeking behaviors (from clinicians and non-clinician sources). The four 
moderating factors tested in this study are 1) age, 2) educational attainment, 3) ethnicity, 
and 4) cancer type (by gender). Each of the research hypotheses and questions pertaining 
to these moderators is accompanied by justifications based on prior empiric evidence, 
where available, and a regression equation to illustrate the planned moderation analyses. 
Age. Prior research is lacking on whether DTCA is associated with 
communication inequalities based on the age of cancer survivors. One study showed 
older cancer survivors receiving active treatment in a comprehensive cancer institute 
reported less awareness of DTCA of prescription cancer drugs (Abel et al., 2009). The 
analysis of predictors of DTCA exposure among Pennsylvanian cancer survivors (Study 
2) was consistent in finding older cancer survivors reported lower levels of DTCA 
exposure. In addition, an earlier analysis by Nagler et al. (2010) reported older 
Pennsylvanian cancer survivors actively sought information about fewer topics related to 
their cancer and sought information from fewer sources compared to younger survivors, 
after adjusting for demographic and disease characteristics. In a study to assess age 
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differences in consumer behaviors prompted by exposure to DTCA, DeLorme et al. 
(2006) found healthy older (65 years and older) and mature (45-64 years) participants 
were more likely than younger participants (18-44 years) to talk to a pharmacist about an 
advertised prescription drug. However, talking to a doctor, talking with friends or 
relatives, or searching for more information about an advertised drug did not differ 
significantly between participants in these age groups. Owing to the equivocal findings of 
the moderation effect of age, the following research questions were proposed:  
Research Question 1: Does the association between DTCA exposure and patient clinician 
information engagement (PCIE) differ by age of cancer survivors? 
PCIE = b0 + b1 DTCA + b2 Age + b3 DTCA*Age  
Research Question 2: Does the association between DTCA exposure and information-
seeking from non-clinician sources (Seeking) differ by age of cancer survivors?  
Seeking = b0 + b1 DTCA + b2 Age + b3 DTCA*Age 
Education. Educational attainment is another potential moderator of the 
relationship between DTCA and information engagement with physician sources. Abel et 
al. (2009) reported that among cancer patients undergoing active treatment for breast or 
hematologic malignancies, those without college education were more likely to report 
that DTCA (of prescription cancer medications) led to better discussions about health or 
medical care with their health provider compared to those with college education (65% 
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vs. 52%, p=.03). Based on this finding, one expectation would be education might 
interact with DTCA such that those with lower education would benefit more from 
exposure to DTCA in terms of additional information seeking. Conversely, prior studies 
indicate that DTCA content as well as the supplemental information in other forms tend 
to be at high difficulty reading levels (Chao, 2005; Kaphingst, Rudd, et al., 2004), which 
may in turn deter patients with lower educational levels from external information 
seeking. Therefore, a counter hypothesis would be DTCA has a lower effect on 
information seeking among survivors with lower education. Due to these competing 
hypotheses, the moderation effects of education are posed as research questions: 
Research Question 3: Does the association between DTCA exposure and patient clinician 
information engagement (PCIE) differ between cancer survivors with higher education 
attainment and those with lower education attainment?  
PCIE = b0 + b1 DTCA + b2 Education + b3 DTCA*Education  
Research Question 4: Does the association between DTCA exposure and information-
seeking from non-clinician sources (Seeking) differ between cancer survivors with higher 
education attainment and those with lower education attainment?  
Seeking = b0 + b1 DTCA + b2 Education + b3 DTCA*Education 
 Ethnicity or race. As raised in the earlier discussion about inequalities in access 
and information processing, Kontos and Viswanath (2011) proposed social determinants 
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including race and ethnicity may influence whether people seek additional information. 
There is however scant evidence or theoretical justification for ethnic or racial disparities 
in cancer communication behaviors above and beyond other important indicators of 
socio-economic status including education and household income. For instance, adjusting 
for household income, education, and employment, results from the 2007 HINTS 
indicated black and Hispanic adults were not significantly different from white adults in 
terms of having heard about genetic testing or finding medical statistics difficult to 
understand (Kontos & Viswanath, 2011). Moreover, results from the analysis in Study 2 
were mixed with regards to race/ethnicity as a predictor of DTCA. Among breast cancer 
patients, there were no significant differences in reported exposure to DTCA between 
patients across groups. However, in patients diagnosed with prostate cancer, white 
patients reported less exposure to DTCA compared to black patients. Hispanic patients 
(and those who identified as being other than white or black) who were diagnosed with 
colorectal cancer reported less exposure to DTCA than white patients. Likewise, other 
large population studies have not found empirical evidence that ethnicity is associated 
with cancer information seeking behaviors. For instance, Hesse et al. (2008) reported 
ethnicity did not predict cancer survivors’ level of information seeking, information 
source preference, information source use, or their information seeking experiences. This 
was corroborated by earlier findings from the Pennsylvanian Cancer Patient Survey that 
black and Hispanic cancer patients were similar in numbers of information sources and 
cancer topics they sought compared to white patients (Nagler, Gray, et al., 2010). 
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Furthermore, cancer patients’ ethnicity was not associated with information seeking 
beyond that given by the health provider or with patients’ level of health information 
seeking behaviors (HISB) for a variety of cancer-related topics (Galarce et al., 2011; 
Ramanadhan & Viswanath, 2006). Despite the above information, this study submits that 
research to understand the role of ethnicity in potentially moderating associations 
between DTCA and information seeking behaviors would be practically important and 
meaningful. Therefore, the assessment of ethnicity as a potential moderator proceeded 
with the following research questions:  
Research Question 5: Does the association between DTCA exposure and patient clinician 
information engagement (PCIE) differ between cancer survivors of different ethnic 
groups (referent group is white)?  
PCIE = b0 + b1 DTCA + b2 black + b3 Hispanic/other + b4 DTCA*black +  
b5 DTCA*Hispanic/other 
Research Question 6: Does the association between DTCA exposure and information-
seeking from non-clinician sources (Seeking) differ between cancer survivors of different 
ethnic groups (referent group is white)?  
Seeking = b0 + b1 DTCA + b2 black + b3 Hispanic/other + b4 DTCA*black +  
b5 DTCA*Hispanic/other 
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Cancer type. Prior research based on the Cancer Patient Survey data found 
patients diagnosed with colon cancer consistently reported less information seeking from 
different sources when compared with breast and prostate cancer patients (Nagler, Gray, 
et al., 2010). The authors proposed these differences may be due to cancer-specific needs 
varying between patients diagnosed with these cancers and differing levels of relevant 
health information available in the overall media environment for each of these cancers. 
In addition, analysis of the predictors of DTCA (Study 2) found exposure to DTCA 
differed by gender and cancer types. Breast cancer patients reported more frequent 
DTCA exposure, more so than patients diagnosed with colon cancer or prostate cancer. 
These findings may be due to differences in availability of DTCA targeted at female and 
male patients or variations in levels of advertising targeted at specific types of cancer 
patients. In a content analysis of cancer-related DTCA of prescription drugs, Abel et al. 
(2007) found such DTCA in popular magazines were predominantly placed in women’s 
magazines. In contrast, no cancer-related DTCA was found in any of the men’s popular 
magazines analyzed in the study. The above observations warrant further assessment into 
whether communication inequalities pertaining to information seeking and DTCA 
exposure exist across patients diagnosed with specific cancers. Due to the lack of prior 
studies addressing this concern, the following research questions were posed to assess 
potential moderation effects of cancer type and gender: 
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Research Question 7: Does the association between DTCA exposure and patient clinician 
information engagement (PCIE) differ between survivors diagnosed with breast, 
colorectal, or prostate cancers (reference category is male colon cancer survivors)?  
PCIE = b0 + b1 DTCA + b2 Female colon cancer + b3 (female) Breast cancer + b4 
(Male) Prostate cancer + b5 DTCA*Female colon cancer + b6 DTCA*Breast cancer + b7 
DTCA*Prostate cancer 
Research Question 8: Does the association between DTCA exposure and information-
seeking from non-clinician sources (Seeking) differ between survivors diagnosed with 
breast, colorectal, or prostate cancers (reference category is male colon cancer 
survivors)? 
Seeking = b0 + b1 DTCA + b2 Female colon cancer + b3 Breast cancer + b4 
Prostate cancer + b5 DTCA*Female colon cancer + b6 DTCA*Breast cancer + b7 
DTCA*Prostate cancer 
Method 
Study Population 
This study relies on data collected for the Cancer Patient Survey described in 
detail earlier in Studies 2 and 3. The present analyses will focus on data collected during 
baseline and follow-up surveys (conducted in 2006 and 2007).  
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Measures  
The dependent variables are Patient-Clinician Information Engagement (PCIE) 
and information-seeking from non-clinician sources measured at baseline (Round 1) and 
in the follow-up (Round 2) survey as described in Study 3. Briefly, PCIE represents 
cancer survivors’ reported engagement with their physicians and other health 
professionals on information related to their cancer and quality of life issues. The PCIE 
variable comprised survey items that asked participants if they actively looked for 
information about their cancer from their doctors or other health professionals. 
Conversely, seeking from non-clinician sources comprised items that asked participants 
to recall if they actively looked for information about their cancer and quality of life 
issues from 10 different lay interpersonal sources (i.e., family members, friends or co-
workers; other cancer patients; face-to-face support groups; online support groups; or 
telephone hotlines) or media sources (i.e., television or radio; books, brochures or 
pamphlets; newspapers or magazines; internet other than personal email or online support 
groups; or other). 
The independent variable is participants’ exposure to DTCA since their cancer 
diagnosis measured at baseline (ranges from 9 to 21 months from diagnosis). As 
described in earlier chapters, this is operationalized as self-reported DTCA exposure and 
comprises ads about treatment alternatives for cancer, dealing with side effects of 
treatment, and hospitals or doctors offering services for cancer. The DTCA exposure 
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measure is formed from the average of individuals’ responses to each of the three survey 
items.  
Four moderating variables are tested in these analyses. They include age at cancer 
diagnosis (measured in years), highest educational attainment (some high school and 
below, high school or GED, some college, and college and above), ethnicity (white, 
black, or Hispanic and other), and cancer type (male colon cancer, female colon cancer, 
breast cancer, prostate cancers).  
Analyses 
The analyses include cross-sectional multiple regressions (associations with PCIE 
and seeking from non-clinician sources at Round 1) and lagged multiple regressions 
(predicting PCIE and seeking at Round 2 while controlling for these behaviors at Round 
1) to assess moderating roles of individual predictors described in the hypotheses and 
research questions above. Individual moderators are tested by introducing interaction 
terms between a moderating variable and DTCA exposure as implied in each of the 8 
research questions. For each model, the main effects of the other moderators were 
included even when they were not the moderator of interest. As an example, in evaluating 
Research Question 1 (moderation by age analysis), education, ethnicity, and cancer type 
were included in the model as covariates. In addition, other potential confounders were 
included in the regression models (cancer stage at diagnosis, Lerman cancer worry scale, 
and self-reported health status).   
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The rationale for testing the presence of moderation by these covariates in both 
cross-sectional and lagged models was threefold. First, the interactions between DTCA 
and each of the covariates might influence more immediate health information seeking 
behaviors in survivors. Performing the cross-sectional tests would permit the ability to 
detect such short-term impacts. However, cross-sectional analyses are limited in terms of 
establishing causal direction of the associations. Therefore, the second rationale for 
including lagged models was to strengthen causal inferences by addressing concerns 
about temporal precedence of predictors in relation to PCIE and seeking from non-
clinician sources. Third, patterns of moderation by the four covariates may differ over 
time. Moderation analyses for PCIE and seeking from non-clinician sources at baseline 
and follow-up would provide additional insights of such possibilities.  
To address the presence of missing values in the predictor variables, the Mplus 
software (Muthén & Muthén, 1998) was utilized to fit full information maximum 
likelihood (FIML) models. The majority of missing values occurred in the DTCA 
exposure variable because of 369 participants who were randomly assigned to answer a 
shortened version of the survey at Round 1 that excluded items about DTCA exposure. 
The models further applied post-stratification sample weights to adjust the final sample to 
represent the Pennsylvania Cancer Registry patient population diagnosed with breast, 
prostate, or colorectal cancers in terms of race/ethnicity, age, gender, marital status, time 
of diagnosis, and stage at diagnosis. These weights also adjusted for survey non-response 
and accounted for the oversampling of certain subgroups of patients. 
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Preliminary univariate analyses revealed that the distribution of the key variables 
(DTCA exposure, PCIE, and information seeking from non-clinician sources) were non-
normal (skewness ranged from -0.058 to 1.040; kurtosis ranged from -0.882 to 0.498; all 
univariate Shapiro-Wilk tests were significant at p<0.0005). Huber-White covariance 
adjustments were applied to the estimated standard errors as these are robust to non-
normality in the data. 
Results 
 Table 6.1 summarizes the characteristics of the study population at Round 1 and 
Round 2 including the four moderating variables and additional covariates measured at 
Round 1. The average age of the sample in Round 1 was 66 years, 44% had some college 
education or higher, 83% were white, and 71% had early stage cancer (stages 0 to II). 
These characteristics of the sample who participated at Round 2 were similar. 
Participation in Round 2 was higher among patients who were white (versus African-
American) or those who had higher education levels (versus some high school or below), 
stage 0 to 2 disease (versus stage 4), lower Lerman worry, or higher health status. 
Summary statistics for DTCA exposure, PCIE, and information seeking from non-
clinician sources are displayed in Table 6.2. Post-stratification sample weights were 
applied to adjust the analyzed samples in Round 1 and Round 2 to represent the 
Pennsylvania Cancer Registry patient population in the moderation analyses. 
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Table 6.1 Characteristics Of Study Population At Round 1 and 2 
  
Round 1 (N=2013) Round 2 (N=1293) 
 
Range Mean SD % Mean SD % 
Age at round 1 (years) a 24 to 105 66.2 12.4 
 
65.5 11.9 
 
Educationb 
       
Some high school or below 
   
15.8 
  
12.8 
High school or GED 
   
40.7 
  
39.5 
Some college or 2 year degree 
   
21.9 
  
22.5 
College degree and above 
   
21.6 
  
25.0 
Race/Ethnicity 
       
White 
   
83.1 
  
86.2 
African-American 
   
12.8 
  
10.4 
Hispanic or other race/ethnicity 
   
4.2 
  
3.4 
Cancer Typec 
       
Male colon cancer  
   
16.7 
  
15.4 
Female colon cancer 
   
17.1 
  
16.6 
Breast cancer 
   
33.7 
  
34.8 
Prostate cancer 
   
32.3 
  
33.3 
Lerman Cancer Worry Scale at round 1d  1 to 5 2.43 1.00 
 
2.35 0.97 
 
Cancer Stagee 
       
     Stage 0 to II 
   
71.0 
  
73.8 
     Stage III 
   
12.9 
  
13.0 
     Stage IV 
   
16.1 
  
13.2 
Health Status at round 1f  1 to 5  3.11 0.94 
 
3.22 0.9 
 
 
Notes. Missing values at round 1: a1; b34; c3 (gender was unknown for three patients); 
d62; e132; f113. Missing values at round 2: a0; b3; c0; d29; e77; f60. 
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Table 6.2 Summary Statistics Of Key Variables 
 Range Mean SD 
Exposure to DTCA at round 1a 1 to 5 2.41 1.02 
Patient-clinician information engagement (PCIE) at 
round 1b 0 to 1 0.51 0.29 
Patient-clinician information engagement (PCIE) at 
round 2c 0 to 1 0.29 0.28 
Information seeking from non-clinician sources at 
round 1d 0 to 1 0.20 0.17 
Information seeking from non-clinician sources at 
round 2e 0 to 1 0.14 0.16 
 
Notes. n=2013 at round 1 and n=1293 at round 2. 
Missing values: a508 (369 participants were not asked these items because they were 
randomly selected to receive a short form of the survey that omitted these items); b26; 
c14; d20; e14. 
 
Results of the cross-sectional and lagged moderation analyses are summarized in 
Tables 6.3 through 6.6. The parameters of note are the respective interaction terms 
between DTCA exposure and each of the four moderating variables. The cross-sectional 
analyses indicated that controlling for potential confounders, age, educational level, 
race/ethnicity, and cancer type did not significantly moderate the association between 
DTCA exposure and PCIE or information seeking from non-clinician sources at Round1. 
Similarly, based on the lagged analyses controlling for PCIE or information seeking from 
non-clinician sources at Round 1, no significant moderation was detected in the 
associations between DTCA exposure and these information engagement behaviors at 
Round 2 by the four moderators investigated here.  
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Table 6.3 Cross-Sectional And Lagged Moderation Analyses By Age 
Cross-
sectional 
analyses 
(n=2010) 
PCIE at round 1  Seeking from non-clinician 
sources at round 1 
 B 95% CI p  B 95% CI p 
DTCA at 
round 1 0.023 -0.055 - 0.102 0.559  0.049 0.006 - 0.091 0.026 
Age (years) -0.004 -0.007 - -0.001 0.022  -0.003 -0.004 - -0.001 0.002 
DTCA by 
age 0.000 -0.001 - 0.001 0.670  0.000 -0.001 - 0.000 0.572 
            
Lagged 
analyses 
(n=1293) 
PCIE at round 2  Seeking from non-clinician 
sources at round 2 
 B 95% CI p  B 95% CI p 
DTCA at 
round 1 0.061 -0.031 - 0.154 0.194  0.038 -0.014 - 0.089 0.152 
Age (years) 0.002 -0.002 - 0.006 0.285  0.001 -0.001 - 0.003 0.184 
DTCA by 
age -0.001 -0.002 - 0.001 0.444  0.000 -0.001 - 0.000 0.268 
 
Notes. B = unstandardized regression coefficients estimated using full information 
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95% 
confidence intervals based on Huber-White standard errors; baseline post-stratification 
weights could not be computed for 3 cases because of missing information about gender 
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed 
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity, 
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for 
the same covariates as well as PCIE or seeking from non-clinician sources at round 1. 
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Table 6.4 Cross-Sectional And Lagged Moderation Analyses By Highest 
Educational Level 
Cross-sectional 
analyses (n=2010) PCIE at round 1  
Seeking from non-clinician 
sources at round 1 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.020 -0.033 - 0.072 0.464 
 
0.032 0.010 - 0.054 0.004 
Some high school or 
below (referent) -      -     
High school or GED -0.062 -0.199 - 0.074 0.371 
 
0.011 -0.044 - 0.067 0.694 
Some college or 2 
year degree -0.059 -0.205 - 0.087 0.429  0.007 -0.052 - 0.066 0.816 
College degree and 
above 0.090 -0.062 - 0.242 0.247  0.064 -0.001 - 0.129 0.054 
DTCA by high 
school 0.028 -0.028 - 0.084 0.323  0.002 -0.024 - 0.027 0.903 
DTCA by some 
college 0.036 -0.022 - 0.095 0.227  0.015 -0.011 - 0.042 0.255 
DTCA by college 
and above 0.012 -0.050 - 0.073 0.710  0.001 -0.028 - 0.031 0.927 
Lagged analyses 
(n=1293) PCIE at round 2  
Seeking from non-clinician 
sources at round 2 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.026 -0.020 - 0.071 0.271 
 
0.001 -0.021 - 0.022 0.937 
Some high school or 
below (referent) -      -     
High school or GED -0.002 -0.137 - 0.134 0.982 
 
-0.018 -0.079 - 0.043 0.561 
Some college or 2 
year degree 0.065 -0.080 - 0.210 0.379  -0.002 -0.066 - 0.063 0.954 
College degree and 
above 0.016 -0.131 - 0.163 0.829  -0.011 -0.082 - 0.061 0.769 
DTCA by high 
school 0.000 -0.054 - 0.053 0.987  0.010 -0.015 - 0.035 0.448 
DTCA by some 
college -0.010 -0.064 - 0.045 0.734  0.010 -0.016 - 0.036 0.451 
DTCA by college 
and above 0.009 -0.049 - 0.067 0.762  0.011 -0.018 - 0.040 0.470 
 
Notes. B = unstandardized regression coefficients estimated using full information maximum likelihood 
and adjusted with post-stratification weights; 95% CI = 95% confidence intervals based on Huber-White 
standard errors; baseline post-stratification weights could not be computed for 3 cases because of missing 
information about gender and these cases were dropped from the cross-sectional analyses, resulting in an 
analyzed sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity, cancer type, 
Lerman worry, cancer stage, and health status; lagged analyses adjusted for the same covariates as well as 
PCIE or seeking from non-clinician sources at round 1. 
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Table 6.5 Cross-Sectional And Lagged Moderation Analyses By Race/Ethnicity 
Cross-sectional 
analyses 
(n=2010) 
PCIE at round 1 
 
Seeking from non-clinician 
sources at round 1 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.041 0.022 - 0.061 <0.001 
 
0.034 0.024 - 0.044 <0.001 
White (referent) - 
     
- 
    
Black 0.009 -0.118 - 0.135 0.892 
 
-0.041 -0.109 - 0.028 0.247 
Hispanic or other -0.025 -0.223 - 0.172 0.801 
 
-0.013 -0.117 - 0.091 0.804 
DTCA by Black -0.006 -0.049 - 0.037 0.790 
 
0.016 -0.009 - 0.042 0.210 
DTCA by 
Hispanic 0.006 -0.073 - 0.085 0.888  0.012 -0.031 - 0.055 0.576 
Lagged analyses 
(n=1293) PCIE at round 2  
Seeking from non-clinician 
sources at round 2 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.025 0.006 - 0.045 0.010 
 
0.011 0.001 - 0.021 0.024 
White (referent) - 
     
- 
    
Black 0.115 -0.022 - 0.253 0.100 
 
0.101 0.018 - 0.184 0.017 
Hispanic or other 0.011 -0.162 - 0.183 0.904 
 
0.034 -0.152 - 0.220 0.720 
DTCA by Black -0.010 -0.057 - 0.037 0.680 
 
-0.022 -0.050 - 0.006 0.121 
DTCA by 
Hispanic 0.006 -0.061 - 0.073 0.860  -0.008 -0.075 - 0.060 0.826 
 
Notes. B = unstandardized regression coefficients estimated using full information 
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95% 
confidence intervals based on Huber-White standard errors; baseline post-stratification 
weights could not be computed for 3 cases because of missing information about gender 
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed 
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity, 
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for 
the same covariates as well as PCIE or seeking from non-clinician sources at round 1. 
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Table 6.6 Cross-Sectional And Lagged Moderation Analyses By Gender And 
Cancer Type 
Cross-sectional 
analyses (n=2010) PCIE at round 1  
Seeking from non-clinician 
sources at round 1 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.049 -0.002 - 0.100 0.060 
 
0.037 0.014 - 0.060 0.002 
Male colon cancer 
(referent) -      -     
Female colon cancer 0.046 -0.104 - 0.195 0.549 
 
0.039 -0.030 - 0.109 0.267 
Breast cancer 0.084 -0.049 - 0.218 0.216 
 
0.099 0.040 - 0.157 0.001 
Prostate cancer 0.156 0.028 - 0.283 0.017 
 
0.033 -0.023 - 0.090 0.251 
DTCA by female 
colon cancer -0.029 -0.094 - 0.036 0.377  -0.009 -0.043 - 0.024 0.584 
DTCA by breast 
cancer 
-0.007 -0.064 - 0.050 0.808 
 
-0.011 -0.038 - 0.016 0.427 
DTCA by prostate 
cancer 
-0.001 -0.059 - 0.057 0.982 
 
0.020 -0.008 - 0.049 0.165 
Lagged analyses 
(n=1293) PCIE at round 2  
Seeking from non-clinician 
sources at round 2 
 
B 95% CI p 
 
B 95% CI p 
DTCA at round 1 0.016 -0.027 - 0.059 0.470 
 
-0.006 -0.024 - 0.013 0.552 
Male colon cancer 
(referent) -      -     
Female colon cancer -0.035 -0.179 - 0.108 0.629 
 
-0.034 -0.097 - 0.029 0.291 
Breast cancer 0.033 -0.094 - 0.160 0.610 
 
-0.045 -0.101 - 0.010 0.106 
Prostate cancer 0.008 -0.124 - 0.141 0.902 
 
-0.058 -0.116 - 0.001 0.053 
DTCA by female 
colon cancer 0.036 -0.025 - 0.097 0.252  0.025 -0.002 - 0.052 0.070 
DTCA by breast 
cancer 
0.004 -0.045 - 0.054 0.868 
 
0.018 -0.005 - 0.040 0.121 
DTCA by prostate 
cancer 
0.008 -0.046 - 0.063 0.769 
 
0.016 -0.010 - 0.042 0.239 
 
Notes. B = unstandardized regression coefficients estimated using full information 
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95% 
confidence intervals based on Huber-White standard errors; baseline post-stratification 
weights could not be computed for 3 cases because of missing information about gender 
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed 
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity, 
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for 
the same covariates as well as PCIE or seeking from non-clinician sources at round 1. 
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Discussion 
 This research was conceptualized based on the premise that communication 
disparities may arise as a result of differential levels of cancer-related DTCA exposure, 
attention and processing, or additional information seeking following exposure as 
described in the Structural Influence Model of Communication. The series of studies 
presented in this dissertation project thus far examined various aspects of this underlying 
premise of communication disparities. Study 2 analyzed the predictors of DTCA 
exposure to evaluate if exposure differed based on several patient characteristics. Study 3 
focused on testing the hypotheses that DTCA exposure was associated with additional 
information seeking behaviors. Building upon Studies 2 and 3, Study 4 explored whether 
the associations between DTCA and seeking behaviors were contingent upon patients’ 
age, education, race/ethnicity, or cancer type.  
The findings from these three studies reveal interesting insights into the 
postulated communication disparities of DTCA in terms of exposure levels and additional 
information seeking. Study 2 found that breast cancer patients reported more DTCA 
exposure than prostate and colorectal cancer patients; older patients had lower exposures 
than younger patients; African-American prostate cancer patients had higher exposures 
than white patients; and Hispanic colorectal cancer patients reported lower exposures 
than white patients. These findings supported the notion that there are differential levels 
of DTCA exposure across patient subgroups within this study population. Study 3 further 
described a significant lagged association between DTCA exposure and patients’ active 
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information seeking from their clinicians at follow-up; the association between DTCA 
exposure and active seeking from non-clinician sources was positive but marginally 
significant. Study 4 found that age, education, race/ethnicity, or cancer type did not 
moderate the associations between exposure to DTCA and active information seeking 
behaviors in the cross-sectional or lagged analyses. Taken together, it can be concluded 
that although DTCA exposure varied by patient characteristics, there was little evidence 
to warrant concern that DTCA exposure was associated with communication disparities 
associated with differential additional information seeking between patient subgroups.  
 In response to concerns about DTCA resulting in communication disparities in 
cancer patients and exacerbating cancer outcomes disparities, results from Study 4 
provide empirical evidence that is reassuring. These findings are likely to contribute to 
the ongoing practice and policy debates surrounding DTCA of medical treatments in a 
few ways. First, although DTCA of medical treatments have existed and attracted much 
debate and research in the past three decades, few studies have been conducted to 
systematically examine social inequalities of communication behaviors and health 
outcomes in association with DTCA exposure. This current research represents an 
attempt to evaluate the issue of communication disparities in DTCA in the specific 
context of cancer treatment. Second, contrary to claims that DTCA exposure might result 
in disadvantaged groups of patients to be disproportionately less informed about their 
treatment because they do not seek additional health information, this population-based 
study among colorectal, breast, and prostate cancer patients found little indication that 
158 
 
DTCA exposure influenced differential levels of active information seeking from 
clinicians or non-clinician sources. Rather, DTCA exposure was significantly associated 
with improved patient-clinician information engagement (results from Study 3) and this 
relationship was similar across the different patient characteristics tested in the present 
study.  
It is important to stress here that the findings in this research should not be taken 
to infer that DTCA does not contribute to any disparities in cancer outcomes. Notably, 
this study only analyzed one form of communication behavior (active information 
seeking) as the outcome. It did not assess whether attention or information processing of 
DTCA messages—one of the levels of communication disparities in the Structural 
Influence Model—differed across patient characteristics. Furthermore, the study did not 
consider other important outcomes (e.g., healthcare utilization or health outcomes) that 
might differ following DTCA exposure or other important social determinants as 
potential moderators (e.g., access to healthcare, socio-economic position, or social 
capital). This study was constrained by the availability of survey information relevant for 
studying these outcomes and moderating variables. Future research will be necessary to 
examine if DTCA exposure might produce or widen disparities in other important cancer 
outcomes and across additional patient characteristics. 
There were other limitations in this study that deserve mention. First, the study 
was limited to cancer patients who were diagnosed with colorectal, breast, or prostate 
cancers. Because of the diversity in the availability and complexity of treatments for 
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other forms of cancers, the lack of supporting evidence for communication disparities in 
this study population may not necessarily apply to other cancer patients. In addition, the 
study also pertains to the specific context of cancer-related DTCA and active information 
seeking about cancer care. The results may differ for other forms of DTCA and health 
conditions. A second limitation in this study was the reliance on self-reported measures 
for exposure to DTCA and the information seeking behavior measures. These may be 
subject to social desirability bias to misreport recalling DTCA exposure or seeking 
behaviors in certain patient groups and result in attenuation of contingent effects. Third, 
there was an underrepresentation of cancer patients from certain groups (e.g., patients 
who were Hispanic or of other race/ethnicity). This may have restricted the ability to 
obtain reliable estimates of the associations between DTCA and information seeking 
behaviors in these groups and reduced the statistical power to detect significant 
contingent effects. 
The study was strengthened by the multi-wave cohort design which enabled 
testing the presence of communication disparities at baseline and at round 2. This was 
important in testing for both short and longer term communication disparities associated 
with DTCA that would not be possible with a cross-sectional survey. Compared to prior 
DTCA research involving convenience samples of cancer patients (e.g., within a single 
treatment facility), this study invited a population-based sample from the Pennsylvania 
Cancer Registry. While not generalizable to cancer patients across the United States, the 
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results here could be viewed as representative of Pennsylvanian cancer patients with the 
most commonly occurring cancers (i.e., colorectal, breast, and prostate). 
In sum, this study analyzed the effects of cancer patients’ exposure to DTCA on 
subsequent active information seeking behaviors across various characteristics based, 
drawing from levels of communication disparities described in the Structural Influence 
Model of Communication. Contrary to concerns about potential communication 
disparities due to cancer-related DTCA, the analyses here did not indicate that the 
association between DTCA exposure and active information seeking behaviors were 
contingent on patients’ age, educational level, race/ethnicity, or cancer type. This study 
provides empirical research to inform the ongoing policy debates on the utility of DTCA 
as a form of public health communication.  
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Chapter 7 DISCUSSION AND LIMITATIONS 
Discussion 
The practice of DTCA is likely to endure in the foreseeable future, not only in the 
specific context of cancer treatment, but also for promoting novel treatments or medical 
services targeting other health conditions. This trend will invariably trigger further 
debates concerning the risks and benefits of DTCA as a ubiquitous source of public 
health information.  
This dissertation research contributes to the broader debate about DTCA in 
multiple ways. First, it offers empirical evidence that enhances the understanding of 
implications of cancer-related DTCA exposure on cancer patients’ health information 
seeking behaviors. Second, it further explores potential communication disparities that 
may arise from DTCA exposure. The key findings can be summarized as follows: 
• The present research suggests there are positive informational spillover effects of 
DTCA exposure about cancer-related treatments in terms of increased patients’ 
health information engagement with their physicians and other healthcare 
professionals. While it is recognized that these communication behaviors overlap 
with patients’ inquiry about advertised cancer treatments to a small extent, these 
behaviors are believed to involve a broader range of cancer-related health topics 
that would be relevant and potentially beneficial for patients’ ability to manage 
and cope with their condition. The finding that DTCA exposure is associated with 
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higher levels of patient-clinician communication is therefore reassuring given that 
previous research strongly suggests effective communication is an important 
determinant of improved patient outcomes and constitutes a core component of a 
patient-centered model in healthcare delivery.  
• Guided by the Integrative Model, a focused analysis involving one form of 
information seeking behavior—active seeking from non-clinician sources—
provides new evidence that DTCA exposure may indirectly influence information 
seeking through attitudes and intentions related to seeking from these sources, 
even though the direct effect between DTCA and seeking from non-clinician 
sources was marginally significant. This finding offers theoretical insights into 
one possible underlying mechanism of how DTCA exposure impacts patients’ 
health information seeking behaviors and contributes to the understanding of 
communication effects of DTCA.  
• Addressing concerns about potentially harmful communication disparities arising 
from DTCA, this research observed mostly small differences in terms of exposure 
levels to cancer-related DTCA across patient characteristics including cancer 
type, age, race/ethnicity, and cancer stage. Apart from age, the correlates of 
DTCA exposure were inconsistent between patients diagnosed with different 
cancer types. There are several underlying reasons for these minor variations in 
the frequency of reported DTCA exposure across patient groups. As suggested 
from a review of the literature, differential advertising spending on treatments for 
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the three cancer types or selective placement of ads in channels to target certain 
demographic groups of patients may result in varying opportunities for being 
exposed to DTCA in some patients. The variations in reported DTCA exposure 
may also arise from disparities in gaining access to channels where DTCA are 
commonly placed (e.g., lack of internet access hindering exposure to cancer 
treatment advertising through web-based ad) or differences in overall media 
consumption patterns across groups such that some patients tend to report higher 
DTCA exposure.  
• Apart from the findings of modest differential levels of DTCA exposure in some 
groups of cancer patients, this research did not identify compelling evidence to 
suggest that DTCA exposure contributes to disparities in additional information 
seeking across these individual patient characteristics. Contrary to hypothesized 
communication disparities proposed in the Structural Influence Model, the 
associations between DTCA and active information seeking behaviors (from 
clinicians and non-clinician sources) were not contingent on cancer type, age, 
educational attainment, or race and ethnicity. It should be cautioned, however, 
that these null results do not imply that DTCA is therefore harmless in terms of 
inequalities in other communication or downstream cancer outcomes. The impact 
of DTCA on these outcomes poses empirical questions that remain unanswered at 
this juncture and would require further investigation. Despite this caveat, the 
present study concludes that there is minimal cause for concern that DTCA 
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exposures may propagate divergent patterns of seeking about cancer-related 
information across groups in this study population. 
An additional contribution from this dissertation project to studying DTCA effects 
includes the methodological approaches described here. First, the assessment of the 
reliability and validity of various measurement options for the DTCA exposure variable 
using a battery of criteria may be adapted in future research to design and test candidate 
measures that are appropriate for assessing exposure to other forms of subspecialty 
DTCA in various health domains. Second, this research explored theoretical mechanisms 
of DTCA effects on information seeking behaviors based on the Integrative Model 
constructs using structural equation modeling. This theoretically grounded approach has 
the potential to assist future research in explicating meaningful psychosocial pathways of 
DTCA’s effects on patient communication behaviors, patient-provider relationships, and 
ultimately health outcomes.   
Strengths and Limitations 
The study is strengthened by a few design features. First, the present research 
emphasizes an assessment of the quality of the DTCA exposure measure across different 
reliability and validity criteria as a prerequisite for subsequent analyses on the impact of 
DTCA on communication outcomes. The validation study compared the performance of 
existing survey items of DTCA with alternative versions that were more elaborate (with 
text explanations or ad exemplars) and replicated the validation based on data collected 
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from two different samples of cancer patients (a probability-based sample of patients 
from a single state versus a national sample from an opt-in survey panel). This provides 
increased confidence that the DTCA exposure measure is reasonably reliable and 
performs consistently in different cancer patient populations before proceeding to utilize 
this measure in the various analyses in Studies 2 to 4. 
Second, the principal measures for DTCA exposure and information seeking 
behaviors are conceptualized more broadly compared to previous research. In the case of 
DTCA exposure, the measure incorporates exposure to ads about alternative cancer 
treatments, dealing with treatment side-effects, and healthcare providers; this contrasted 
with the majority of past research that focuses almost exclusively on exposure to DTCA 
of prescription drugs alone. The broader DTCA exposure may be viewed as a better 
reflection of the growing presence of non-drug related ads in cancer treatment and other 
subspecialty DTCA. Also, the information seeking measures integrate multiple cancer-
related topics that are most salient for cancer patients; this allows for analyses of the 
impact of DTCA exposure on broader information seeking compared with earlier studies 
that focused primarily on patients’ inquiry about an advertised medication alone.  
Another crucial feature in this research study includes the ability to measure 
patient communication behaviors and DTCA exposure in a large and representative 
sample of cancer patients over time. First, in terms of the sampling strategy, the 
probability-based sample of cancer patients from the Pennsylvania Cancer Registry is an 
improvement from past surveys that tended to involve convenience samples of cancer 
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patients attending a single clinic or cancer center at one time point. While not 
generalizable to cancer patients across the United States, the results here could be viewed 
as representative of Pennsylvanian cancer patients with the most commonly occurring 
cancers (i.e., colorectal, breast, and prostate). Second, the longitudinal design in this 
research enables testing for both short and longer term communication disparities in 
association with DTCA that is not possible within a cross-sectional survey. The panel 
design further affords the capacity to clarify the temporal order between patients’ DTCA 
exposures at an earlier time point and subsequent information seeking behaviors. In 
addition, the lagged analyses control for underlying seeking habits or motivation by 
adjusting for previously reported seeking behaviors.  
However, a few limitations in this research deserve mention and these may be 
addressed in future studies. The first limitation concerns the fact that all the principal 
variables are based on self-reported survey items. Inherent to survey research, self-
reported measures may be subject to recall biases arising from unreliable memory of 
actual exposures or seeking behaviors or social desirability for instance. While this 
research includes a validation of the DTCA exposure measure with alternative survey 
items, further research may be necessary to externally validate this self-reported measure. 
For instance, future studies may compare patients’ self-reported DTCA exposure over 
time with aggregate-level data sources of ad expenditures by manufacturers of cancer-
related medications or cancer centers.  
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Likewise, the information seeking measures rely on patients’ recall of active 
seeking about various topics. These measures may suffer from imprecision because much 
information exchange occurs between patients and their clinicians in the course of 
patients’ treatment and follow-up. As reviewed earlier, cancer patients also seek from a 
wide number of information sources apart from their clinicians. Patients may not be 
expected to recall these exchanges or seeking of topics from multiple sources with great 
accuracy over a long period of time (e.g., over 12 months). The established literature on 
patient-doctor communication provides ample means of capturing dyadic interactions 
accurately in small settings (e.g., direct observation, audio or video recording, and use of 
standardized patients) but these methods are prohibitively difficult to apply on a large 
scale. The limitations of self-reported measures are therefore compromises in exchange 
for the ability to describe the patterns of DTCA exposure and information seeking in a 
large and representative sample of patients.  
Another related measurement issue is the timing of the information seeking 
measures one year after DTCA exposure. It is possible that effects on additional 
information seeking may occur soon after DTCA exposure and therefore, the follow-up 
measure of information seeking may not detect this relationship appropriately. However, 
baseline reports of DTCA exposure may serve as an estimate of continuing DTCA 
exposure throughout the intervening year, coinciding with the period of recall about 
information seeking behaviors. Future research may require shorter intervals of follow-up 
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surveys to assess information seeking effects following DTCA exposure in a timely 
manner.  
A further limitation relates to generalizability of the findings. As the study 
population was restricted to cancer patients with three types of cancer (i.e., breast, 
prostate, and colorectal cancer) from one state, it is plausible that different patterns in 
DTCA exposure and communication behaviors may occur for other cancer patients or in 
other regions. In the case of DTCA exposures, promotional ads for cancer treatment may 
be more prevalent in geographic regions where there is intense competition between 
cancer centers and hospitals (e.g., in the mid-Atlantic region) compared with regions 
where there is less competition. Access to information sources may also differ between 
patients across the U.S. (e.g., rural versus urban areas) and this may pose barriers for 
patients to actively conduct information seeking from their clinicians or other sources 
following exposure to DTCA. These issues merit further study to assess if the observed 
findings in this research would differ in other cancer patient populations. 
Although the panel design of the study among cancer patients from the 
Pennsylvania Cancer Registry is helpful in clarifying the temporal order of DTCA 
exposure and information seeking behaviors, there is may be unmeasured confounders 
that explain the observed associations. For instance, patients’ underlying need for 
information may influence their attentiveness to DTCA as well as their active information 
seeking about their condition from different sources. While several covariates including 
past seeking behaviors are included in these analyses to account for patients’ interest and 
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motivation to seek information, the threat that a causal inference from the association 
between DTCA and active information seeking may be spurious remains due to the 
observational study design. One suggestion is for future studies to consider examining the 
hypothesized relationship between DTCA exposure and patient information seeking 
behaviors by analyzing the associations between naturally occurring variations in DTCA 
expenditures across different regions and these communication behaviors.  
Future Research Directions 
This dissertation research provides the starting point for developing a program of 
research to address additional questions surrounding the impact of DTCA as a form of 
public health communication. One continuing concern is to build a theoretically driven 
understanding of DTCA effects on communication behaviors, drawing from this research 
and previous literature based on relevant constructs described in the Social Cognitive 
Theory, Integrative Model, and other frameworks. Study 3 indicates that attitudes and 
perceived normative pressure to engage in information seeking from sources other than 
one’s physician may mediate DTCA effects on cancer patients’ seeking from such 
sources. Perceived behavioral control, however, did not mediate this relationship. One 
future research direction is to explore the roles of other theoretical constructs suggested 
by earlier research (e.g., shared decision making preferences (Deshpande et al., 2004)) in 
mediating DTCA effects on patient information seeking behaviors. This will enrich the 
understanding of underlying mechanisms of DTCA’s impact on these important 
communication behaviors. 
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Another future research direction is aimed at investigating the impact of DTCA 
during the first few months following patients’ cancer diagnoses. The study population in 
this research participated in the first survey about 9 to 21 months following the initial 
cancer diagnosis. In an earlier cross-sectional study within one institution, Abel and 
colleagues (2009) surveyed cancer patients (diagnosed with breast cancer and 
hematologic malignancies) who were already undergoing active treatment about their 
opinions of DTCA of cancer-related prescription medications. In both instances, the 
studies are limited by the timing of the surveys—data collection began after treatment 
decisions have been made. In other words, for the surveys described in this dissertation, 
most of the patients had already completed or were undergoing active treatment for their 
cancer by the time they completed the first survey. Accordingly, while the analyses 
indicate that DTCA exposure is associated with subsequent information seeking 
behaviors, it is not possible to assess whether DTCA exposure influences cancer patients’ 
treatment decision process because of the timing of the survey in relation to their receipt 
of treatment. Similarly for the study by Abel et al. (2009), participants were already 
receiving treatment at the point of the survey data collection. Therefore, the temporal 
order of events (DTCA exposure and treatment decision making) could not be 
distinguished. Research is lacking in assessing if cancer-related DTCA is associated with 
patients’ treatment decision processes as they weigh the risks and benefits of treatment 
options. One suggestion to explore this relationship may involve interviewing a 
representative sample of newly diagnosed cancer patients (within 3 months of diagnosis; 
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because most patients make treatment decisions in the first few weeks following 
diagnosis and complete treatment within 6 months) to assess their exposure to DTCA 
exposure during this period in relation to their subsequent decision making and receipt of 
various treatment options. The proposed study would involve longitudinal surveys among 
newly diagnosed cancer patients within 3 months of diagnosis and followed up over one 
year. Survey items on DTCA exposure may be adapted from previously validated scales 
and published questionnaires (from the Pennsylvania Cancer Patient Survey described 
here and others including Weissman et al. (2003) and Abel et al. (2009)) while survey 
items on treatment decision making processes would derive from established scales (e.g., 
patient involvement scale (Katz et al., 2005), patient decisional conflict scale, or patient 
satisfaction with decision making subscale (O’Connor, 1995)). Additionally, receipt of 
treatment may be obtained from patient self-reports or extracted from medical records at 
follow-up.  
Conclusion 
DTCA is an established and growing source of novel information about treatment 
for patients with complex medical conditions including cancer. The findings from this 
research provide the first steps to uncovering the impact of DTCA as a unique form of 
public health communication on cancer patients’ information seeking from their 
clinicians and other sources. Stakeholders involved in the ongoing debate about the 
societal implications of DTCA may need to consider the potential role for DTCA in 
influencing additional information seeking behaviors among patients and balancing this 
172 
 
with concerns about disparities in communication or cancer outcomes that may arise due 
to DTCA exposure. More research is advised to fully understand the consequences and 
harness the benefits of DTCA appropriately in the context of a rapidly evolving 
healthcare environment. 
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Appendix A Survey Questionnaire for Study 1B 
[Programming instruction: These are the screening questions for the survey] 
Variable name  
Age How old are you?  ______ years old. 
 
[Programming instruction: If 21 years and older, proceed to the next question. If 20 years 
and younger, screen out as ineligible] 
Variable name  
Yeardx When were you diagnosed with cancer? 
 
 
1 2012  
2 2011 
3 2010  
4 Others: Specify 
____________________ 
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[Programming instruction: If either 2012, 2011, or 2010, proceed to the next question. If 
diagnosed earlier than 2010, screen out as ineligible] 
Variable 
name 
 
setup During this survey, you may be requested to view short video clips. In 
order to view the clips, you should have Adobe Flash Player installed on 
your computer and the speakers should be turned on during the survey. 
Please note that some mobile devices might not be able to play Flash 
videos.  
 
Please click on the button below to test if you are able to hear the 
following audio clip.  
 
Were you able to hear the audio clip clearly? 
 
 
No 0      [Programming instruction: Route to end of survey, consider ineligible] 
Yes 1      [Programming instruction: Proceed to next item] 
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[Instructions for participants: Please answer each of the following questions by selecting 
the number that best describes your experience. Some of the questions may appear to be 
similar, but they do address somewhat different topics. Please read each question 
carefully.] 
PART I ITEMS (3 QUESTIONS – ASK ALL PARTICIPANTS) 
 
[Programming instruction: Randomize half of participants to get PART I items first 
followed by PART IA, then PART II or III; Randomize the other half of participants to 
get PART II or III items first, then PART IA, followed by PART I items] 
 
[Programming instruction: All questions are required; participants will not be able to 
proceed if they do not answer all the items. If participants leave out answers for an item 
on the screen, display the following message: “Please answer all the items before 
proceeding.”] 
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Since your diagnosis, how often have you seen or heard advertisements concerning each 
of the following? Check all that apply: 
 
Variable 
name 
 Never Less 
than 
every 
month 
About 
twice a 
month 
About 
once a 
week 
Almost 
every 
day 
cps_treatalt Treatment 
alternatives for your 
cancer 
0 1 2 3 4 
cps_sideeff Dealing with side 
effects of treatment 
0 1 2 3 4 
cps_hospdoc Hospitals or doctors 
offering services for 
cancer 
0 1 2 3 4 
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PART IA ITEMS (ASK ALL PARTICIPANTS) 
 
The questions in the next pages explore different situations.  
 
 Sometimes you might have been actively looking for information about a specific 
cancer topic (e.g., treatment).  
 Other times you might not have been looking for cancer information at all, but 
just came across it.   
 
Please note what each question asks about. 
 
Variable 
name 
  
 
 Did you actively look for information about your cancer 
(about treatments but also about other topics) from any 
sources since your diagnosis?  
Noseek  I did not actively look for information about my cancer since 
my diagnosis. 
 
 I did actively look for information about my cancer since my 
diagnosis from the following sources (Check all that apply): 
Seektreatdoc  My treating doctors  
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Seekothdoc  Other doctors or health professionals  
Seekfam  Family members, friends, coworkers 
Seekpat  Other cancer patients 
Seekfacegp  Face-to-face support groups 
Seekonlinegp  On-line support groups 
Seektvrad  Telephone hotlines (e.g. from the American Cancer Society) 
Seekhotline  Television or radio 
Seekbook  Books, brochures or pamphlets  
Seeknews  Newspapers or magazines 
Seekinternet  Internet  (other than personal email and on-line support groups) 
Seekoth  Other 
 
Variable name   
 
 Sometimes people get information from other sources and 
discuss it with their treating doctors.  Where have you gotten 
information that you discussed with your treating doctors 
since your diagnosis?  
 
Nodiscuss  I have not discussed information from another source with my 
treating doctors since my diagnosis. 
 
 I have discussed information with my treating doctors that I got 
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from the following sources (Check all that apply):  
discussothdoc  Other doctors or health professionals  
discussfam  Family members, friends, coworkers 
discusspat  Other cancer patients 
discussfacegp  Face-to-face support groups 
discussonlinegp  On-line support groups 
discusstvrad  Telephone hotlines (e.g. from the American Cancer Society) 
discusshotline  Television or radio 
discussbook  Books, brochures or pamphlets  
discussnews  Newspapers or magazines 
discussinternet  Internet  (other than personal email and on-line support groups) 
discussoth  Other 
 
Variable 
name 
  
 
 Sometimes doctors suggest that their patients go to other sources 
to find out more information. Where have your treating doctors 
suggested you go since your diagnosis?  
 
Nosend  My doctors have not suggested I get information from other 
sources since my diagnosis. 
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 My doctors have suggested I get information from the following 
sources since my diagnosis (Check all that apply): 
sendothdoc  Other doctors or health professionals  
sendfam  Family members, friends, coworkers 
sendspat  Other cancer patients 
sendfacegp  Face-to-face support groups 
sendonlinegp  On-line support groups 
sendtvrad  Telephone hotlines (e.g. from the American Cancer Society) 
sendhotline  Television or radio 
sendbook  Books, brochures or pamphlets  
sendnews  Newspapers or magazines 
sendinternet  Internet  (other than personal email and on-line support groups) 
sendoth  Other 
 
Variable 
name 
  
 
 Where have you actively looked for information about quality of 
life issues since your diagnosis? Check all that apply: 
 
Noqual  I did not actively look for information about quality of life after 
cancer since my diagnosis 
181 
 
 
 I have actively looked for this quality of life information since 
my diagnosis from the following sources (Check all that apply): 
Qualtreatdoc  My treating doctors  
Qualothdoc  Other doctors or health professionals  
Qualfam  Family members, friends, coworkers 
Qualpat  Other cancer patients 
Qualfacegp  Face-to-face support groups 
Qualonlinegp  On-line support groups 
Qualtvrad  Telephone hotlines (e.g. from the American Cancer Society) 
Qualhotline  Television or radio 
Qualbook  Books, brochures or pamphlets  
Qualnews  Newspapers or magazines 
Qualinternet  Internet  (other than personal email and on-line support groups) 
Qualoth  Other 
 
Variable name   
 
 Sometimes people find out things about their disease or 
its treatment even though they are not looking for 
information about their cancer at all.  This might happen 
because they were having a conversation or watching 
television or using the Internet and just happened to 
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come across it. What information have you come across 
about your cancer from media sources (television, radio, 
newspapers, magazines, Internet) when you were not 
looking for it since your diagnosis?  
 
Noscanmedia  I have not come across anything from media sources except 
when I was looking for it since my diagnosis. 
 
 I have come across information from media sources about 
the following topics since my diagnosis (Check all that 
apply): 
Scanmediatreat  What treatments were the best for my cancer 
Scanmediadochosp  Which doctors or hospitals would be the best for me 
Scanmediasideeff  How to manage side effects of treatments 
Scanmediaoth  Other: Specify _______________________________ 
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PART II ITEMS (4 QUESTIONS - FOR RANDOM HALF OF PARTICIPANTS 
ONLY) 
[Instructions for participants: The following questions ask about advertisements that you 
may or may not have come across in the mass media (e.g. television, radio, newspapers, 
magazines, billboards, or the internet.] 
 
[Programming instruction: Randomize the order of presenting each set of questions 
within PART II.] 
 
[Instructions for participants: Sometimes hospitals or doctors advertise their services 
(radiation therapy, chemotherapy, or comprehensive treatment) for treating patients with 
cancer. These advertisements may appear in the mass media (e.g., television, radio, 
newspapers, magazines, billboards, or the internet).  
Please view the following two examples of advertisements concerning hospitals or 
doctors offering services for cancer.] 
 
[Programming instruction: Show two randomly selected ads (one print ad and one video) 
of hospitals or doctors offering services for cancer from Pool A of ads] 
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Variable name  
viewad_hospdoc Were you able to view the two advertisements? 
 
 
No 0      [Programming instruction: Route to end of survey, consider incomplete] 
Yes 1      [Programming instruction: Proceed to next item] 
 
Variable 
name 
 
ad_hospdoc Since your diagnosis, how often have you seen or heard advertisements 
concerning hospitals or doctors offering services for cancer? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
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[Instructions for participants: Sometimes advertisements about dealing with side effects 
of cancer treatment appear in the mass media (e.g., television, radio, newspapers, 
magazines, billboards, or the internet). Please view the following two examples of 
advertisements concerning dealing with side effects of treatment.] 
 
[Programming instruction: Show two randomly selected ads (one print ad and one video) 
about dealing with side effects of treatment from Pool B of ads] 
 
Variable 
name 
 
viewad_sideeff Were you able to view the two advertisements? 
 
 
No 0      [Programming instruction: Route to end of survey, consider incomplete] 
Yes 1      [Programming instruction: Proceed to next item] 
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Variable 
name 
 
ad_sideeff Since your diagnosis, how often have you seen or heard advertisements 
concerning dealing with treatment side effects? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
 
[Instructions for participants: Sometimes advertisements about treatment alternatives for 
your cancer appear in the mass media (e.g., television, radio, newspapers, magazines, 
billboards, or the internet).  
Please view the following two examples of advertisements concerning treatment 
alternatives for your cancer.] 
 
[Programming instruction: Show two randomly selected ads (one print ad and one video) 
of advanced technology or alternatives for cancer treatment from Pool C of ads] 
 
 
 
187 
 
Variable name  
viewad_treatalt Were you able to view the two advertisements? 
 
 
No 0      [Programming instruction: Route to end of survey, consider incomplete] 
Yes 1      [Programming instruction: Proceed to next item] 
 
Variable 
name 
 
ad_treatalt Since your diagnosis, how often have you seen or heard advertisements 
concerning treatment alternatives for your cancer? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
 
[Instructions for participants: Sometimes advertisements about treatment for chronic 
diseases that are not related to cancer appear in the mass media (e.g., television, radio, 
newspapers, magazines, billboards, or the internet). Please view the following two 
examples of advertisements concerning treatment for chronic diseases.] 
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[Programming instruction: Show two randomly selected ads (one print ad and one video) 
for the treatment of non-cancer related conditions from Pool D of ads] 
 
Variable name  
viewad_chronicdis Were you able to view the two advertisements? 
 
 
No 0      [Programming instruction: Route to end of survey, consider incomplete] 
Yes 1      [Programming instruction: Proceed to next item] 
 
 
Variable 
name 
 
ad_chronicdis Since your diagnosis, how often have you seen or heard advertisements 
concerning treatment for chronic diseases? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
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PART III ITEMS (4 QUESTIONS - FOR RANDOM HALF OF PARTICIPANTS 
ONLY) 
 
[Programming instructions: Randomize the order of presenting each set of questions 
within PART III.] 
 
Variable 
name 
 
noad_hospdoc Sometimes hospitals or doctors advertise their services (radiation 
therapy, chemotherapy, or comprehensive treatment) for treating 
patients with cancer. These advertisements may appear in the mass 
media (e.g., television, radio, newspapers, magazines, billboards, or the 
internet).  
 
Since your diagnosis, how often have you seen or heard advertisements 
concerning hospitals or doctors offering services for cancer? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
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Variable 
name 
 
noad_sideeff Sometimes advertisements about dealing with side effects of cancer 
treatment appear in the mass media (e.g., television, radio, newspapers, 
magazines, billboards, or the internet).  
 
Since your diagnosis, how often have you seen or heard advertisements 
concerning dealing with treatment side effects? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
 
Variable 
name 
 
noad_treatalt Sometimes advertisements about treatment alternatives for your cancer 
appear in the mass media (e.g., television, radio, newspapers, 
magazines, billboards, or the internet). 
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Since your diagnosis, how often have you seen or heard advertisements 
concerning treatment alternatives for your cancer? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
 
Variable name  
noad_chronicdis Sometimes advertisements about treatment for chronic diseases that 
are not related to cancer appear in the mass media (e.g., television, 
radio, newspapers, magazines, billboards, or the internet). 
 
Since your diagnosis, how often have you seen or heard 
advertisements concerning treatment for chronic diseases? 
 
 
Never Less than every 
month 
About twice a 
month 
About once a 
week 
Almost every 
day 
0 1 2 3 4 
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PART IV ITEMS [Programming instructions: Ask the following questions to ALL 
participants] 
 
This series of questions asks about how often you use several media channels. 
 
Variable 
name 
In the past seven days, on how many days 
did you… 
Days (0 to 7 
days) 
Newspaper Read a newspaper? ___ 
Magazine Read a magazine? ___ 
Natnewstv Watch the national news on television? ___ 
Localnewstv Watch the local news on television? ___ 
TVprograms Watch television programs other than news? ___ 
Radio Listen to radio talk shows or news? ___ 
Email Use the Internet for email? ___ 
Internet Use the Internet, other than for email? ___ 
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People find out about health and medical issues from a variety of sources. Please indicate 
how often you have done each of the following in the past 30 days: 
Variable name  Not at 
all 
Less 
than 
once per 
week 
Once 
per 
week 
Two 
or 
more 
times 
per 
week 
Gennewsmag Read about health issues 
in newspapers or general 
magazines 
1 2 3 4 
Hlthnewsmag Read special health or 
medical magazines or 
newsletters 
1 2 3 4 
Hlthtvnews Watched special health 
segments of television 
newscasts 
1 2 3 4 
Hlthtvprogs Watched television 
programs (other than 
news) which address 
health issues or focus on 
1 2 3 4 
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doctors or hospitals 
Hlthinternet Read health information 
on the internet 
1 2 3 4 
Hlthfamfriend Talked with family or 
friends about health 
issues 
1 2 3 4 
 
The next series of statements ask about what you know now, rather than what you knew 
when your original treatment choices were made. Indicate whether you agree or disagree. 
 
Variable 
name 
 Strongly 
disagree 
Disagree Neither 
agree 
nor 
disagree 
Agree Strongly 
agree 
Knowtreat I know about 
possible 
future 
treatments 
for my 
cancer. 
1 2 3 4 5 
Knowriskrec I know about 1 2 3 4 5 
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the long term 
risk of my 
cancer 
coming back. 
Knowprob  I know about 
future health 
problems I 
might face 
because of 
my cancer. 
1 2 3 4 5 
 
This series of statements asks about whether you are confident or not about dealing with 
anything that might happen in the future. I am confident in my ability to… 
 
Variable name  Strongly 
disagree 
Disagree Neither 
agree 
nor 
disagree 
Agree Strongly 
Agree 
Effdecide Actively 
participate 
in decisions 
1 2 3 4 5 
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related to 
my cancer. 
Effgethelp Get help if I 
don’t 
understand 
something 
about my 
cancer. 
1 2 3 4 5 
Effaskquestion Ask my 
doctors or 
nurses 
questions 
about my 
cancer. 
1 2 3 4 5 
Effunexp Manage any 
unexpected 
problems 
related to 
my cancer. 
1 2 3 4 5 
Effemotprob Deal with 
any 
1 2 3 4 5 
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emotional 
problems 
related to 
my cancer. 
 
Variable name  
Cancertype Which of the following cancer types were you 
diagnosed with? 
 
1 Colon  
2 Lung 
3 Prostate  
4 Breast  
5 Others: Specify ____________________ 
 
Variable 
name 
 
Gender Please indicate your gender. 
1 Male  
2 Female 
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Variable name  
Hisp Do you consider yourself to be Hispanic or 
Latino? 
 
 
0 Yes  
1 No 
 
Variable name  
Race What is your race? Check all that apply: 
 
 
 
White  
Black 1.  
Asian  
American Indian or Alaska Native  
Native Hawaiian or other Pacific Islander  
Other  
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Variable name  
Educ What is the highest grade or level of school 
you completed?  
 
 
1 8th grade or less 
2 Some high school, but did not graduate 
3 High school graduate or GED 
4 Some college or 2-year degree 
5 4-year college graduate 
6 More than 4-year college degree 
 
[Instructions for participants: Thank you for your participation.] 
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Appendix B Panel of Video and Print Ads Displayed for Measure II Items (Study 
1B) 
1. Print ads for hospitals or doctors offering services 
Print ad 1 Print ad 2 Print ad 3 Print ad 4 
 
 
  
 
Note. All four print ads are from U Miami Sylvester Comprehensive Cancer Center 
 
2. Video ads for hospitals or doctors offering services 
Video ad 1 Video ad 2 Video ad 3 Video ad 4 
 
UNC Cancer Care  
 
Carle Cancer Center 
 
Hudson Valley 
Hospital Center 
 
Terrebonne General 
Medical Center – 
Mary Bird Perkins 
Cancer Center 
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3. Print ads for treatment side effects 
Print ad 1 Print ad 2 Print ad 3 Print ad 4 
 
Zuplenz (anti-
nausea) 
 
Aloxi (anti-nausea) 
 
Zuplenz (anti-
nausea) 
 
Zometa (prevent 
skeletal 
complications) 
 
4. Video ads for treatment side effects 
Video ad 1 Video ad 2 Video ad 3 Video ad 4 
 
 
Neulasta (increase 
immune cell count) 
 
 
Procrit (increase red 
blood cells) 
 
 
Procrit 
 
 
Procrit 
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5. Print ads for treatment alternatives 
Print ad 1 Print ad 2 Print ad 3 Print ad 4 
 
Altoona Regional 
Radiosurgery 
  
Altoona Regional 
Radiosurgery 
  
Las Vegas 
Cyberknife at 
Summerlin 
  
 
St. Peter’s 
University Hospital 
Cyberknife 
 
6. Video ads for treatment alternatives 
Video ad 1 Video ad 2 Video ad 3 Video ad 4 
 
 
Memorial Cancer 
Institute Cyberknife 
 
 
Fox Chase Cancer 
Center Minimally 
Invasive Surgery 
 
 
Novalis TX at St 
Vincent’s Medical 
Center 
 
 
Phoenix Cyberknife 
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Appendix C Key Survey Measures for Study 3 
1. Active information seeking behaviors 
 
The questions in the next pages explore different situations.  
 Sometimes you might have been actively looking for information about a specific 
cancer topic (e.g., treatment).  
 Other times you might not have been looking for cancer information at all, but 
just came across it.   
Please note what each question asks about. 
When we ask what “you” did, this includes you and any family members or friends who 
may have helped you look for information. 
  
 Did you actively look for information about your cancer (about treatments but 
also about other topics) from any sources in the past 12 months?  
 I did not actively look for information about my cancer in the past 12 months. 
 I did actively look for information about my cancer in the past 12 months from 
the following sources (Check all that apply): 
 My treating doctors  
 Other doctors or health professionals  
 Family members, friends, coworkers 
 Other cancer patients 
 Face-to-face support groups 
204 
 
 On-line support groups 
 Telephone hotlines (e.g. from the American Cancer Society) 
 Television or radio 
 Books, brochures or pamphlets  
 Newspapers or magazines 
 Internet  (other than personal email and on-line support groups) 
 Other 
 
  
 Sometimes people get information from other sources and discuss it with their 
doctors.  Where have you gotten information that you discussed with your 
doctors in the past 12 months?  
 I have not discussed information from another source with my doctors in the 
past 12 months. 
 I have discussed information with my doctors in the past 12 months that I got 
from the following sources (Check all that apply):  
 Other doctors or health professionals  
 Family members, friends, coworkers 
 Other cancer patients 
 Face-to-face support groups 
 On-line support groups 
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 Telephone hotlines (e.g. from the American Cancer Society) 
 Television or radio 
 Books, brochures or pamphlets  
 Newspapers or magazines 
 Internet  (other than personal email and on-line support groups) 
 Other 
 
  
 Sometimes doctors suggest that their patients go to other sources to find out 
more information. Where have your doctors suggested you go in the past 12 
months?  
 My doctors have not suggested I get information from other sources in the past 
12 months. 
 My doctors have suggested I get information from the following sources in the 
past 12 months (Check all that apply): 
 Other doctors or health professionals  
 Family members, friends, coworkers 
 Other cancer patients 
 Face-to-face support groups 
 On-line support groups 
 Telephone hotlines (e.g. from the American Cancer Society) 
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 Television or radio 
 Books, brochures or pamphlets  
 Newspapers or magazines 
 Internet  (other than personal email and on-line support groups) 
 Other 
 
  
 Where have you actively looked for information about quality of life issues like 
those mentioned in questions 21 and 22 in the past 12 months? Check all that 
apply: 
 
 I did not actively look for information about quality of life after cancer in the 
past 12 months. 
 I have actively looked for this quality of life in the past 12 months from (Check 
all that apply): 
 My treating doctors  
 Other doctors or health professionals  
 Family members, friends, coworkers 
 Other cancer patients 
 Face-to-face support groups 
 On-line support groups 
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 Telephone hotlines (e.g. from the American Cancer Society) 
 Television or radio 
 Books, brochures or pamphlets  
 Newspapers or magazines 
 Internet  (other than personal email and on-line support groups) 
 Other 
 
2. Integrative Model of Behavioral Prediction measures 
How likely is it that you will actively seek information about issues related to your 
cancer from a source other than your doctor in the next 12 months. Please circle the 
number that best reflects your response. 
UNLIKELY 1 2 3 4 5 6 7 LIKELY 
 
My actively seek information about issues related to my cancer from a source other than 
your doctor in the next 12 months would be. Circle one number in each row. 
USELESS 1 2 3 4 5 6 7 USEFUL 
UNENJOYABLE 1 2 3 4 5 6 7 ENJOYABLE 
FOOLISH 1 2 3 4 5 6 7 WISE 
NOT UP TO ME 1 2 3 4 5 6 7 UP TO ME 
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Most people who are important to me think I should actively seek information about 
issues related to my cancer from a source other than your doctor in the next 12 months.  
DISAGREE 1 2 3 4 5 6 7 AGREE 
 
Most people like me (e.g., other cancer patients) actively seek information about issues 
related to their cancer from a source other than their doctors.  
DISAGREE 1 2 3 4 5 6 7 AGREE 
 
If I really wanted to, I could actively seek information about issues related to my cancer 
from a source other than your doctor in the next 12 months. 
DISAGREE 1 2 3 4 5 6 7 AGREE 
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